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ABSTRACT 
 
The field of genetics is rapidly expanding and evolving. As more and more is understood on the 
genetics of complex human traits, a natural question arises as to how these findings can be translated 
to the everyday medical practice. While a little more than a decade ago sequencing the entire human 
genome was achieved by the largest international scientific collaboration ever undertaken in biology, 
today it is not farfetched to expect that in the near future obtaining the genetic profile of each patient 
may become routine medical practice. Pharmacogenomics, a blend of pharmacology and genomics, 
aims to determine the most suitable treatment for each patient as a function of his or her genetic 
makeup. Pharmacogenomic studies have increasingly provided evidence that there are gains to be 
achieved by incorporating genetic information when determining the optimal treatment choice for a 
patient. The case of warfarin, an anticoagulant, has often been considered as one of the most 
motivating success stories to pursue such type of studies. The success as well as the need of such 
studies, however, depend on a multitude of factors and vary greatly across traits. 
 
The objective of this thesis is to evaluate the current state of the art for Multiple Sclerosis (MS), a 
debilitating neurological disorder affecting primarily young adults. To date, no cure exists for MS but 
a number of disease-modifying therapies have been approved with varying degree of efficacy and 
toxicity. So far, little is known on the genetic factors that influence response to treatment in MS 
patients. Moreover, even if such factors are known apriori, evaluating and proving their utility at the 
clinical level is not as straightforward as one may be inclined to think. In this thesis, we highlight why 
the road to translate such findings to medical practice remains rough and challenging. 
 
In particular, relying on the association and prediction studies that we have conducted, we expose the 
design and limitations of each and discuss model choice in each context. Specifically, we conducted 
single-marker association analysis of response to interferon-β in MS patients. We compared single-
marker to multi-marker models in the context of association and also in that of prediction using both 
real and simulated datasets. Different approaches to multi-marker modeling exist. We focused on 
polygenic score analyses and Bayesian estimation methods and evaluated several of the properties of 
these modeling approaches. 
 
Our findings showed that, in the context of association, the use of more complex and computationally 
heavy multi-marker models that has been recently advocated may lead to little, if any, benefit over the 
classical single-marker association analysis. On the other hand, multi-marker models that take into 
account the effect of many markers simultaneously clearly appear better suited to predict genetic risk. 
Nevertheless, focusing on polygenic score analyses, we demonstrated that many factors such as the 
study sample size and the heritability of the trait influence the predictive performance of a model. 
 
Pharmacogenomic studies may revolutionize patient care. However, in all the excitement of the 
promise that they hold, in the concluding part of this thesis we also address the social, ethical and 
economic issues that they raise. 
 
 
KEYWORDS: pharmacogenomics, multiple sclerosis, interferon-β, association study, prediction 
study, genetic markers, polygenic scores, Bayesian estimation methods, ethics 
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RESUME 
L’expansion ainsi que l’évolution du domaine de la génétique au cours de ces dernières années a été 
fulgurante. Cela s’accompagne par la génération d’une masse importante d’information génétique sur 
les traits complexes chez l’homme. Une question naturelle est de savoir comment utiliser cette 
information dans la pratique médicale quotidienne. Il y a dix ans à peine le séquençage du génome 
humain nécessitait une collaboration scientifique d’envergure internationale entre les différents acteurs 
de la recherche biomédicale. Aujourd’hui, il n'est pas exclu à ce que, dans un avenir proche, on puisse 
obtenir le profil génétique de chaque patient dans la pratique médicale courante. La 
pharmacogénomique, une fusion de la pharmacologie et de la génomique, vise à déterminer le 
traitement le plus approprié à chaque patient en fonction de son patrimoine génétique. En effet, 
plusieurs études pharmacogénomiques ont pu démontrer l’intérêt d’intégrer l'information génétique du 
patient pour déterminer son traitement optimal. Le cas de la warfarine, un anticoagulant, a souvent été 
considéré comme l'un des succès les plus motivants pour poursuivre ce type d'études. Cependant, le 
succès ainsi que le besoin de ces études dépendent de multiples facteurs et varient considérablement 
selon les traits étudiés. 
 
L'objectif de ce travail est d'évaluer l'état actuel des connaissances pour la sclérose en plaques (SEP), 
une maladie neurologique invalidante touchant principalement les jeunes adultes. À ce jour, il n'existe 
aucun remède à la SEP, mais il existe des traitements modificateurs de la maladie avec des degrés 
d'efficacité et de toxicité variable. Les facteurs génétiques qui influencent la réponse au traitement 
chez les patients atteints de SEP sont à ce jour mal connus. Même si ces facteurs peuvent être mis en 
évidence dans le futur, il n’en demeure pas moins que leur utilisation en routine clinique n’est pas 
aussi simple que supposée. Dans ce travail, nous avons essayé de mettre en évidence la complexité du 
passage de l’utilisation de données génétiques à grande échelle à la pratique médicale pour les traits 
complexes. 
 
Nous avons mené des études d’association et de prédiction. Tout d’abord, nous exposons leurs 
concepts et revisitons les différences dans leurs objectifs. Plus précisément, nous avons effectué une 
analyse d’association simple-marqueur de la réponse à l'interféron-β chez les patients atteint de SEP. 
Ensuite, nous avons comparé les modèles simple-marqueur et multi-marqueur dans le contexte de la 
recherche d’association puis dans celui de la prédiction en utilisant  des données réelles et des données 
simulées. Différentes approches de modélisation multi-marqueur existent. Nous nous sommes basés 
sur l'analyse des scores polygéniques et des méthodes d'estimation bayésienne en évaluant plusieurs 
des propriétés de ces approches de modélisation. 
 
Nos résultats montrent que, dans la cadre d’une étude d’association pangénomique, les modèles multi-
marqueurs, récemment préconisés, ne sont pas forcément plus puissants que les modèles classiques 
simple-marqueur. En revanche, les modèles multi-marqueurs qui prennent en compte l'effet de 
plusieurs marqueurs simultanément apparaissent clairement mieux adaptés pour prédire le risque 
génétique. Néanmoins, en se concentrant sur l'analyse des scores polygéniques, nous montrons que de 
nombreux facteurs comme la taille de l'échantillon de l'étude et l'héritabilité du trait influencent la 
performance prédictive d'un modèle. 
 
Les études pharmacogénomiques peuvent révolutionner les soins aux patients. Cependant, en dehors 
de l'enthousiasme qu’elles peuvent susciter, nous discutons dans la dernière partie de cette thèse les 
questions sociales, éthiques et économiques qu'elles soulèvent. 
 
 
MOTS-CLÉS: pharmacogénomique, sclérose en plaques, interféron-β, étude d’association, étude de 
prédiction, marqueurs génétiques, scores polygéniques, méthodes d'estimation bayésienne, éthique 
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1 INTRODUCTION 
1.1 The Genetic Material 
“We wish to suggest a structure for the salt of deoxyribose nucleic acid (D.N.A.). This structure has 
novel features which are of considerable biological interest.” (Watson and Crick, 1953) Such is the 
opening of the 1953 monumental paper by James Watson and Francis Crick postulating on the 
structure of the molecule of life carrying our genetic information, the DNA. 
The human body is composed of trillions of cells which store our genetic information. In 
particular, the nucleus of each cell contains two copies of 23 different chromosomes with one copy 
inherited from each of our parents. Of the 23 chromosomes, one is a sex chromosome (X or Y) 
determining the gender of an individual where females carry two copies of the X chromosome (XX) 
and males carry a copy of each (XY). The chromosomes comprise long strings of double-stranded 
DNA, made up of four nucleotide bases, namely, Cytosine (C), Adenine (A), Guanine (G), and 
Thymine (T). The two strands of the DNA are connected through hydrogen bonds between 
complementary base pairs where A always pairs with T and C always pairs with G. This is illustrated 
in Figure 1.1 below. 
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Figure 1.1: How genetic information is stored in our bodies. Adapted from (Mayo Clinic staff, 2011). 
 
The human genome consists of roughly 3 billion DNA base pairs. A specific sequence 
of these bases forms genes. It was long believed that genes coded for a single protein but this 
simplified assumption has been refuted. Specifically, the same gene can code for more than 
one protein or for none at all (directly transcribe to ribonucleic acid, or RNA, a single-
stranded molecule similar to the DNA with the nucleotide base Thymine (T) replaced by 
Uracil(U)). It is complicated to come up with a precise definition of a gene and as such the 
estimated number of genes in the human genome vary based on the definition used (Pennisi, 
2003). The most recent estimate lies somewhere around 20 500 genes. (Clamp et al., 2007) 
The regions of the DNA between genes are referred to as intergenic regions. The DNA 
comprises roughly 75% of intergenic regions. Of the remaining 25% of the DNA spanned by 
genes, only 1% are exons (coding for RNA or protein) while the remaining 24% are introns 
(non-coding sequences) (Venter et al., 2001). 
Individuals share more than 99% of their DNA sequence. The remaining 1% or so of our 
genetic variation influences disease susceptibility and other complex traits and has proven important in 
the study of human health. Most of the genetic variation occurs in intergenic regions but some occur in 
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genes and may thus directly impact their function. Nevertheless, even if the variations lie in intergenic 
regions, they may still be implicated in the susceptibility to diseases and in the phenotypic variation of 
other complex traits. 
1.2 Biomarkers 
The term biomarker is short for biological marker. In 1998, the National Institutes of Health 
Biomarkers Definitions Working Group defined a biomarker as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention”. (Biomarkers Definitions Working Group, 
2001) There are many different applications of biomarkers leading to three major categories of 
biomarkers: diagnostic, prognostic and predictive. A diagnostic biomarker is a diagnostic tool for the 
identification of a disease. A prognostic biomarker is an indicator for disease prognosis. Lastly, a 
predictive biomarker predicts response to an intervention or treatment. 
The  United States Food and Drug Administration (US FDA) industry guidelines, proposed in 
2008, narrow down the definition of a genomic biomarker as a “measurable DNA and/or RNA 
characteristic that is an indicator of normal biologic processes, pathogenic processes, and/or 
response to therapeutic or other interventions.” (FDA, 2008) DNA characteristics include but are not 
limited to variations in a single DNA base (a Single Nucleotide Polymorphism or SNP) and other 
more complex forms of genetic variations discussed by (Frazer et al., 2009). Alternatively, RNA 
characteristics can refer to RNA sequences, microRNA levels and others. Thus, a genomic biomarker 
may simply consist of a single SNP or of a more complex combination of several DNA and/or RNA 
characteristics. 
1.3 Pharmacogenetics and Pharmacogenomics 
The terms pharmacogenetics and pharmacogenomics are often used interchangeably. The US FDA 
proposed industry guidelines in 2008 define pharmacogenomics as “the study of variations of DNA 
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and RNA characteristics as related to drug response” and pharmacogenetics, as a subset of 
pharmacogenomics, and define it as “the study of variations in DNA sequence as related to drug 
response.” (FDA, 2008) Thus, pharmacogenetic studies, by definition, do not involve the study of 
variation in RNA characteristics. More recently, the terms are distinguished based on the scope of the 
study. A pharmacogenetic study focuses on variations related to drug response in a targeted gene. On 
the other hand, a pharmacogenomic study investigates the variations related to drug response across 
multiple genes or even at the genome-wide level (Ritchie, 2012). 
Such studies may be conducted at all stages of the drug development process from drug 
discovery to clinical practice. Further, drug response is a broad term encompassing drug disposition 
(that is, absorption, distribution, metabolism, and excretion, known by the acronym ADME) and drug 
effects (that is, efficacy and adverse effects). 
Presently, the US FDA website (FDA, 2013) lists roughly 120 drugs with pharmacogenomic 
information in their labels. For instance, the label of the drug carbamazepine (Tegretol®, Novartis), 
one of the most widely used and effective treatments of epilepsy, recommends against the treatment of 
patients carrying a specific variant in the human leukocyte antigen (HLA) region. This variant, found 
almost exclusively in patients of Asian ancestry, has been associated with serious side effects in these 
populations. (Novartis, 2007) Alternatively, the gene CYP2C19 is implicated in the metabolism of 
many drugs. The translation of CYP2C19 pharmacogenetics into clinical practice, however, is 
currently limited to a small number of functional variants although more than 2000 variants have 
already been discovered. (Lee, 2012) 
1.4 Study Designs 
Pharmacogenomic studies do not differ significantly from traditional epidemiological studies but 
important considerations specific to pharmacogenomic studies exist. Major epidemiological study 
designs are summarized in Figure 1.2 below. 
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Two main types exist, experimental and observational. In the former, the investigators aim to 
control for all main forms of bias. In the latter, the information is passively observed and collected by 
the investigator. The most common example of an experimental study design is a randomized 
controlled trial (RCT) where subjects are randomly assigned to one of several treatment groups. This 
type of study design most closely resembles a controlled experimental setting and typically leads to 
the most rigorous scientific results. 
 
 
Figure 1.2: Epidemiological study designs. Adapted from (London School of Hygiene and Tropical 
Medicine, 2013). 
 
However, oftentimes such studies are infeasible due to cost or ethical issues, so a large portion 
of the epidemiologic research is conducted using observational study designs the most common types 
being the case-control or cohort studies. In case-control studies, as their name suggests, subjects are 
classified into cases and controls and their risk exposure history is compared. In cohort studies, 
subjects are followed up examining multiple health effects of exposure. Other less common types of 
observational study designs include cross-sectional study designs where the relationship between 
exposure and disease is examined at a single point in time and ecological study designs where this 
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relationship is compared at group rather than individual level. Cohort studies are typically prospective 
where the information is yet to be collected to answer a specific research question in mind, while case-
control studies are typically retrospective where the information has already been collected not 
necessarily with the specific research question in mind. 
The main study designs among those described above used in pharmacogenomic studies are 
RCT and case-control studies. However, given the high-dimensional data context of genetic studies 
atypical to traditional epidemiological studies, a third important study design that has been emerging 
in the field of pharmacogenomics is a type of prospective observational study design where DNA 
biobanks are linked to electronic health records. Such a study design, for instance, has been 
successfully applied for determining the appropriate dose of warfarin (an anticoagulant) to administer 
to patients. (Ramirez et al., 2012) Pharmacogenomic studies have been carried out for a wide variety 
of diseases. The focus of this thesis is on Multiple Sclerosis. 
1.5 Multiple Sclerosis 
Multiple Sclerosis (MS) was first characterized in 1868 by a French neurologist, Jean-Martin Charcot. 
(Charcot, 1868) MS is a chronic inflammatory disease of the central nervous system (CNS). Healthy 
nerve fibers, or axons, are surrounded with a protective covering, the myelin sheath. Myelin is a 
material that is primarily comprised of protein and fat and is essential for the proper functioning of the 
nervous system. When a loss of myelin occurs, referred to as demyelination, the functions of the 
implicated nerve fiber are jeopardized. Often times, the damage to myelin is reversible. 
In MS, the body’s own immune system attacks the nervous system resulting in inflammation 
causing demyelination in many areas leaving scars (sclerosis). This may eventually result in 
deterioration to the nerves themselves which, however, is not reversible. Depending on the amount of 
damage and the nerves that are affected, the range of symptoms experienced by individuals varies 
from mild (sensory troubles) to severe (handicap). 
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MS affects two to three times more females than males and this trend is observed for other 
autoimmune diseases such as rheumatoid arthritis (RA). It is not clear what causes this gender 
difference. Most patients are diagnosed between the ages of 20 and 40 years with the peak disease 
onset occurring around the age of 30. MS is also diagnosed in children (younger than 18 years) and in 
seniors (more than 65 years). 
The diagnosis of MS is very difficult and misdiagnosis can be quite common. In 2001, an 
international panel of neurologists derived diagnostic criteria for MS (McDonald et al., 2001). These 
criteria were later revised in 2005 and again in 2010 (Polman et al., 2011; Polman et al., 2005) but, 
unfortunately, they remain imperfect. 
The criteria are primarily based, but not limited to, the clinical presentation of at least one 
attack. An, attack, also referred to as flair, relapse, or exacerbation, is defined as “patient-reported or 
objectively observed events typical of an acute inflammatory demyelinating event in the CNS, current 
or historical, with duration of at least 24 hours, in the absence of fever or infection.” (Polman et al., 
2011) Additional data needed for MS diagnosis include radiological measures such as the presence of 
magnetic resonance imaging (MRI) T2 and/or gadolinium-enhancing (GD+) lesions in MS-typical 
regions of the CNS. 
The clinical course of MS is highly heterogeneous. Many forms of the disease have been 
described but they can generally be grouped into four distinct types characterized by the disease 
progression. Figure 1.3 below illustrates these types: relapsing-remitting MS (RRMS, panel (A)), 
progressive-relapsing MS (PRMS, panel (B)), secondary-progressive MS (SPMS, panel (C)) and 
primary-progressive MS (PPMS, panel (D)). Each figure represents disability progression on the y-
axis versus time on the x-axis; each peak corresponds to an attack. 
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Figure 1.3: MS disease progression may be grouped into four major categories: relapsing-remitting 
MS (A), progressive-relapsing MS (B), secondary-progressive MS (C) and primary-progressive MS 
(D). Adapted from (MS Society of Western Australia, 2013). 
 
The most common type of MS is RRMS with roughly 85% of MS patients suffering from it. 
Patients alternate between periods of attacks (relapses) followed by periods of partial or full recovery 
(remission). As the disease progresses, the partial recovery accumulates into disability eventually 
leading to the SPMS form where the worsening of the disease course continues. About 10% of MS 
patients have the PPMS where, contrary to the SPMS form, there is a steady progression of disability 
right from disease onset without periods of full recovery. Finally, in the rare type of disease 
progression affecting roughly 5% of the patients, PRMS, patients experience recurring relapses 
(attacks) and steady worsening of symptoms. (Goldenberg, 2012) It is also possible, however, that for 
some patients the disease would not progress. 
To date, the cause of MS remains unknown but a number of environmental risk factors have 
been linked to MS. These include infectious factors such as Epstein-Barr virus infection and non-
infectious factors such as vitamin D deficiency (Ascherio and Munger, 2007a, b). None, however, 
provide a definite explanation and, in fact, the list of plausible causes continues to grow such as a 
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recent study using experimental animal models suggesting that high salt intake may, too, be linked to 
risk of MS. (Kleinewietfeld et al., 2013) 
The work by Kurtzke (2000) illustrated that there are also geographic clues to the cause of MS. 
Figure 1.4 shows the prevalence of MS around the world. The prevalence is highest in the USA, 
Canada and Northern Europe (more than 100 per 100 000), followed by Australia, New Zealand, 
Southern Europe, Russia and Latin America (between 5 and 100 per 100 000) and is rather low in Asia 
and Africa (less than 5 per 100 000). Variability within country exists as well. The prevalence in 
France ranges from 60 to 100 per 100 000 with higher prevalence in the north-eastern regions and 
lower in the Paris region and the south-western regions. (Fromont et al., 2010; Vukusic et al., 2007). 
 
 
Figure 1.4: World atlas of MS prevalence. Adapted from (World Health Organization, 2008). 
1.6 Multiple Sclerosis Genetics 
The prevalence among Native Indians in Canada as well as other ethnic communities across the world 
is lower than the corresponding national prevalence. This suggests that genetic risk factors also appear 
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to contribute to the risk of MS (Rosati, 2001). Moreover, familial studies have indicated that MS tends 
to aggregate in families and the risk tends to decrease with decreasing degree of relatedness. For 
instance, one study in a Northern European population (with MS prevalence > 0.1%, see Figure 1.4) 
estimated the age-adjusted lifetime risk at 38% for monozygotic (identical) twins and at 3-5% for 
dizygotic (fraternal) twins and first degree relatives such as a sibling or a child. Conversely, the risk 
for non-biological relatives such as adopted siblings was the same as the risk in the general population 
(that is, the prevalence) estimated at 0.2% in their study. (Sadovnick et al., 1999) 
Familial recurrence risk is often measured by the sibling recurrence-risk ratio, denoted   , 
which is the ratio of risk in siblings of affected individuals to the risk in the general population. In the 
study by Sadovnick et al. (1999) mentioned above,    (     ), that is, 3%/0.2% to 5%/0.2%. 
Overall, estimates of    in MS vary across studies and have tended to decline over time (Sawcer et al., 
2010) with some studies suggesting that       (Hemminki et al., 2009). 
Twin studies, aiming to evaluate the relative contribution of genetic and environmental risk 
factors, have also produced highly variable estimates of the genetic contribution to MS susceptibility 
ranging from 25% to 76%. (Hawkes and Macgregor, 2009) Therefore, while there is supporting 
evidence for a genetic component of the disease, the fine balance between the contributing genetic and 
environmental factors to the risk of MS is still unclear. 
Prior to the era of large scale genetic association studies (genome-wide association study, 
GWAS), the only recognized genetic association contributing to the risk of MS was mapped to the 
HLA region. The first GWAS of MS in 2007 in 931 family trios (discovery dataset) and 609 family 
trios as well as 2322 cases/789 controls (replication dataset) confirmed this association and identified 
two other genes, IL2RA and IL7RA at strict genome-wide significance criteria levels (< 10
-7
). (Hafler 
et al., 2007) In the four years that followed, six independent GWASs were conducted identifying over 
20 different loci outside the HLA region (most of them at genome-wide significance). ((Comabella et 
al., 2008); (Baranzini et al., 2009); (Australia and New Zealand Multiple Sclerosis Genetics 
Consortium (ANZgene), 2009); (Jakkula et al., 2010); (Sanna et al., 2010); (Nischwitz et al., 2010)) In 
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2011, the International Multiple Sclerosis Genetics Consortium in collaboration with the Wellcome 
Trust Case Control Consortium 2 completed the largest MS GWAS to date (roughly 9800 cases and 
17400 controls) replicating almost all of the previously identified associations and further identifying 
29 novel ones. (Sawcer et al., 2011) In 2012, another much smaller MS GWAS (296 cases and 801 
controls) was conducted replicating previously reported associations (Matesanz et al., 2012). Many of 
the genetic association findings were close to immunologically relevant genes thus providing basis to 
the belief that MS is an immunological disorder. Despite all the discovered variants, however, a large 
portion of the heritability of MS risk remains unexplained. In a dataset of roughly 2 000 MS cases and 
5 000 controls with close to 500 000 SNPs, Watson et al. (2012) found that approximately 30% of MS 
heritability was explained by the variants on current genome-wide SNP arrays, which includes the 
SNPs in the HLA region that alone account for  8%. 
1.7 Multiple Sclerosis Therapies 
There is no cure for MS but currently there are eight approved disease modifying therapies on the 
market. In France, the escalation approach to treatment of MS, illustrated in Figure 1.5, is used 
whereby therapies with increasing effectiveness but also more severe side effects are sequentially 
used. 
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Figure 1.5: Escalation approach to MS treatment. 
 
The first-line therapies include treatments based on interferon-β (Avonex®, Biogen Idec; 
Betaseron®, Bayer; Rebif®, Pfizer; Extavia®, Novartis) and glatiramer acetate (Copaxone®, Teva). 
Second-line therapies include natalizumab (Tysabri®, Biogen Idec), finglomod (Gilenya®; Novartis) 
and mitoxantrone (Novantrone®, EMD Serono). Interferon-β is the first ever therapy approved for MS 
dating back to the mid-90s. Fingolimod is the first oral treatment in MS and is the most recent drug 
approved by the European Medicines Agency. 
First line therapies cause relatively mild side effects but are also less effective. Approximately 
half of the patients fail to respond to interferon therapy. On the other hand, second-line therapies, as 
more aggressive treatments, have shown to be more effective in modifying the disease course for 
patients but can also lead to serious and sometimes fatal side effects. Natalizumab is arguably the most 
effective treatment of all but unfortunately it has been linked with potentially fatal brain infection 
known as progressive multifocal leukoencephalopathy (PML). In fact, during less than a decade of its 
existence, this treatment has undergone an exceptional course, being withdrawn months after being 
approved only to be put back on the market under unprecedented surveillance program (Steinman, 
2005). 
INTRODUCTION 
 
13 
The available variety of disease modifying therapies and the heterogeneous course of the 
disease progression pose challenges in determining the optimal treatment strategy for a MS patient. A 
number of treatment algorithms for MS have been proposed and have been reviewed by Rio (2011). 
The importance of treating MS as early in the disease onset as possible has long been recognized but 
the poor efficacy of the available drugs seems to be related to the fact that only the early stages of the 
disease are targeted (Lopez-Diego and Weiner, 2008). Effectively, treatments of MS may be 
considered for treating its clinical manifestations, managing its symptoms or preventing its 
progression. (Fox et al., 2006) 
There are currently at least seven medications in late phases of drug development primarily 
targeting the most common form of the disease, RRMS. (Ali et al., 2013) By 2020 the number of 
approved MS therapies is expected to rise significantly making the decision for the best course of 
treatment ever more challenging (Huynh, 2010). The increasing number of available therapies coupled 
with the potential risk of treatment failure and/or severe adverse reactions makes individualized 
therapy a necessity for MS. (Río et al., 2009) 
1.8 Response Definition to Multiple Sclerosis Therapies 
There is not a widely accepted definition of response to treatment in MS. The most common approach 
adopted in pharmacogenomic studies of MS has been to dichotomize the group of patients into 
Responders/Non-Responders by evaluating their response to treatment at a specific time point (for 
instance, one year after treatment onset) using a set of clinical and/or radiological variables. 
The criteria of grouping patients has widely differed across studies but typically a patient is 
classified as a Responder if all criteria are met and those patients not classified as Responders are 
classified as Non-Responders (at least one criterion is not met). Sometimes, however, the Non-
Responder group is as strictly defined (none of the criteria is met) as the Responder group (extreme 
phenotypes) leaving perhaps many patients classified as Intermediary (Suboptimal) Responders. 
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The number of relapses (see Section 1.5) experienced by the patient over the treatment period 
is commonly used to evaluate response. Another widely used clinical measure to evaluate treatment 
response in MS is the disability progression based on the change of the Expanded Disability Status 
Scale (EDSS) developed by Kurtzke (1983). It is a rating scale from 0.0 (normal neurological exam) to 
10.0 (death due to MS). Starting from 1.0, it goes in increments of 0.5. Despite its popularity, this 
measure is complicated to use and understand. While large discrepancies are unlikely, two physicians 
evaluating the same patient may assign different EDSS values. 
For the relapsing forms of MS, response has often been assessed over the treatment period by 
combining these two measures (relapses and EDSS) as illustrated in Figure 1.6 below. Sometimes one 
or both of these measures has been combined with radiological measures such as the presence/absence 
of MRI lesions to derive the response definition. 
 
 
Figure 1.6: Assessing treatment response in relapsing forms of MS based on EDSS progression and 
number of relapses experienced over the evaluation period. 
 
While the response classifications are usually based on the same clinical and/or radiological 
measures, response criteria across studies differ for the following reasons: (1) whether both clinical 
and radiological or only clinical measures are used to classify the patients; (2) for the same measure 
the threshold used to distinguish a Responder from a Non-Responder; (3) the duration of the period 
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over which the response is evaluated (six months, one year, two years, etc.). Moreover, even if the 
response classification is the same across studies, the evaluation of the measures on which it is based 
is physician-dependent and thus subjective. 
Alternatively, the response variable could be constructed as a composite score of the several 
variables used to classify the patients into Responders and Non-Responders. The challenges in 
deriving such definition of response are (1) how to build a composite score using variables measured 
on completely different scales (for example, EDSS versus MRI lesion load); (2) how to determine the 
weight that each of these variables carry in the score; and (3) the distribution of such a composite 
score is yet to be evaluated and its properties are yet to be established. 
For the second challenge, an added complexity to defining response of MS lies in the fact that 
the variables used to evaluate response vary by importance with the disease duration. For instance, in 
the beginning of the disease, radiological measures might be the best tool to evaluate disease activity 
as there may be no clinical manifestations of the disease. On the other hand, as time progresses, the 
role of the radiological measures reduces and the disease begins to manifest clinically. (Fox and 
Cohen, 2001) Thus, time-dependent weights may need to be assigned to reflect the increasing or 
diminishing role of each measure in determining response to treatment in MS. 
Yet another approach to defining response may rely on the principles of survival analysis. In 
this case, one can model the time to progression of the disease during treatment by defining 
progression based on one or several criteria (clinical and/or radiological). This approach is commonly 
used in randomized clinical trials, for example, modeling time to first relapse after treatment onset.  
Thus, response to MS therapies is a highly complex outcome to evaluate. As a contrasting 
example, to determine the warfarin dose, physicians use the international normalized ratio (INR), 
which is a standardized test result evaluating the clotting tendency of blood. It is an objective measure 
based on blood tests and is, therefore, directly comparable nationally and internationally. 
It is plausible that genetic factors play a role in determining response to MS therapies. 
Moreover, if such is the case, it is likely that multiple genes are involved. (Río et al., 2009) Therefore, 
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pharmacogenomic studies, investigating genes implicated in drug response, have the potential to 
identify key genetic biomarkers and facilitate the application of individualized therapy in MS. 
1.9 Pharmacogenomic Studies of Multiple Sclerosis To Date 
A handful of pharmacogenomic studies of MS have been carried out to date predominantly on 
interferon response (summarized in Table 1.1). Most of these studies have investigated the role of 
specific genes with only two studies (on interferon response) conducting genome-wide scans. Gene 
names are given in greater detail in Appendix I. 
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MS Therapy Study Scope Response Criteria/ 
Evaluation Period 
Study Sample Size 
(Responders / Non-Responders) 
Study Findings
1
 Reference 
Interferon-β 
HLA Class II Genes 
EDSS, Relapses / 2 years 134 Spanish patients No association (Villoslada et al., 2002) 
EDSS, Relapses / 1 year 96 Spanish patients No association (Fernández et al., 2005) 
IFNAR1, IFNAR2 
EDSS, Relapses / 2 years 147 Spanish patients No association (Sriram et al., 2003) 
EDSS, Relapses / 1 year 147 Spanish patients
2
 No association (Leyva et al., 2005) 
100 interferon-stimulated 
response element genes 
EDSS, Relapses / 6-9 months 162 Irish patients Associated with response: IFNAR1, CTSS, 
LMP7 and MxA 
(Cunningham et al., 2005) 
MxA EDSS, Relapses, MRI / 2 years 37 US patients No association (Weinstock-Guttman et al., 2007) 
IFNG Relapses / 2 years 110 Spanish patients Associated with response (Martínez et al., 2006) 
IL28B EDSS, Relapses / 2 years 588 patients from US, UK, France, 
Spain, Italy, Germany, Serbia) 
No association (Malhotra et al., 2011) 
TRAIL and TRAIL receptor 
genes (TRAIL, TRAILR-1, 
TRAILR-2, TRAILR-3 and 
TRAILR-4) 
EDSS, Relapses / 2 years 509 Spanish patients (discovery); 226 
Spanish patients (replication) 
Associated with response: TRAILR-1 (López-Gómez et al., 2013) 
GPC5 and HAPLN1 EDSS, Relapses / 2 years 199 Spanish patients Association with response: GPC5 (Cénit et al., 2009) 
Genome-wide scan 
(≈ 100 00 0 SNPs) 
EDSS, Relapses / 2 years 206 patients from Spain and France 
(discovery); 81new Spanish patients 
for combined analyses (validation) 
Associated with response: GPC5, COL25A1, 
HAPLN1, CAST and NPAS3 and several 
SNPs in intergenic regions 
(Byun et al., 2008) 
Genome-wide scan 
(≈ 430 000 SNPs) 
EDSS, Relapses / 2 years 106 Spanish patients (discovery); 94 
Spanish patients (validation) 
Association with response: GRIA3, CIT, 
ADAR, ZFAT, STARD13, ZFHX4, IFNAR2 
and for 11 SNPs in intergenic regions 
(Comabella et al., 2009) 
Glatiramer Acetate HLA Class II Genes EDSS, Relapses / 2 years 44 Italian patients Association with response (Fusco et al., 2001) 
27 genes EDSS, Relapses, MRI /  
9 months; 2 years 
101 patients from Europe, Canada and 
US (fractional cohorts from clinical 
trials) 
Association with response: CTSS (corrected 
for multiple testing); MBP, CD86, FAS, 
IL1R1 and IL12RB2 
(Grossman et al., 2007) 
Natalizumab N/A 
Fingolimod N/A 
Mitoxantrone ABC-transporter genes EDSS, Relapses, MRI /  
9-12 months 
309 Spanish and German patients Association with response (Cotte et al., 2009) 
1 Reported association findings at α=0.05 significance level. 2 Different from the study by (Sriram et al., 2003) 
Table 1.1: List of pharmacogenomic studies carried out to date. 
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First-Line Therapies. Given the long established link between the HLA locus and susceptibility to 
MS, studies have also investigated the role of this locus in interferon response. Villoslada et al. (2002) 
and Fernández et al.(2005) found no association with interferon response, while Cunningham et 
al.(2005) identified an association with LMP7, a gene located within the HLA region. 
Several studies investigated the role of interferon-α/β receptor genes, IFNAR1 and IFNAR2 
and found no association with response. ((Sriram et al., 2003); (Leyva et al., 2005); (Cunningham et 
al., 2005)) A role for the IFNAR1 gene was suggested by the study of Sriram et al. (2003) when 
response was evaluated based only on the number of relapses and by the study of Cunningham et al. 
(2005) studying a different polymorphism in that gene. The IFNAR genes are located in the vicinity of 
interferon-γ receptor genes (IFNGR). Martínez et al. (2006) found a polymorphism in the interferon-γ 
gene, IFNG, to be associated with interferon response. 
All in all, Cunningham et al. (2005) investigated 100 interferon-stimulated response element 
genes. Apart from the genes already mentioned, that is, LMP7 and IFNAR1, two more were found to 
be associated with response to interferon, CTSS and MxA. Weinstock-Guttman et al. (2007) evaluated 
the association of two SNPs from the MxA gene and found no relation. 
Malhotra et al. (2011) investigated the role of two polymorphisms in the IL28B gene in 
interferon response but did not find an association. One of the 100 genes included in the study by 
Cunningham et al. (2005) was the TRAIL gene (with which no association was found). A recent study 
focused on TRAIL and TRAIL receptor genes (TRAIL, TRAILR-1, TRAILR-2, TRAILR-3 and TRAILR-
4) was reported suggesting a role for the TRAILR-1 gene in interferon response. (López-Gómez et al., 
2013) 
In 2008, Byun et al. (2008) reported the first GWAS of response to interferon in a small cohort 
of 206 MS patients. Their study did not identify any of the previously reported associations (IFNAR1, 
LMP7, CTSS, MxA, IFNG). However, their study found significant (at nominal level) associations for 
SNPs in or close to several novel genes including GPC5, COL25A1, HAPLN1, CAST and NPAS3 and 
several SNPs in intergenic regions. A study by Cénit et al. (2009) aimed to replicate the association 
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findings for the two most strongly implicated genes, GPC5 and HAPLN1, and was able to confirm the 
association only with the GPC5 gene. A second GWAS followed in 2009 reporting significant 
associations for SNPs in or close to seven genes, GRIA3, CIT, ADAR, ZFAT, STARD13, ZFHX4, 
IFNAR2 and for 11 SNPs in intergenic regions. (Comabella et al., 2009) 
For glatiramer acetate, only two candidate gene studies have been conducted. Fusco et al. 
(2001) assessed the relationship between HLA and response to glatiramer acetate and, contrary to 
interferon therapy, results suggested that it was implicated in response to glatiramer acetate. Grossman 
et al. (2007) studied 27 candidate genes and found significant association with the CTSS gene after 
correcting for multiple testing. Nominally significant associations were reported with the following 
five other genes, MBP, CD86, FAS, IL1R1 and IL12RB2. 
Second-Line Therapies. To our knowledge, no genetic association study has been conducted to 
evaluate natalizumab or fingolimod response in MS patients. One study suggested a role for ABC-
transporter genes in mitoxantrone response. (Cotte et al., 2009) 
In summary, the study sample sizes were small and the response definitions differed across 
studies. Most of the reported association findings were weak and have not been validated in 
independent datasets. Therefore, these studies do not provide a clear indication of whether genetic 
factors influence response in MS for the investigated therapies, namely, interferon, glatiramer acetate 
and mitoxantrone, while this possibility is yet to be explored for natalizumab and fingolimod. 
1.10 Thesis Objective 
A pharmacogenomic study design needs to include two essential phases: identification and validation. 
In the first phase of identification, the association between genes and drug response is initially 
assessed. In other words, a genetic association study is conducted. If one or more genes are found to 
be associated with drug response, these findings then need to be validated in an independent dataset 
and their clinical utility in actually predicting drug response needs to be evaluated. In other words, a 
genetic prediction study is conducted. 
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In this dissertation work, we review the basic methodological aspects behind genetic 
association and genetic prediction studies. To begin, we give a brief account of the multinational effort 
that laid the foundations to (large-scale) genetic association studies. Next, we describe these studies 
and present our findings from the studies we conducted. Specifically, we investigated the role of the 
OAS1 gene in response to interferon-β in a multinational MS patient cohort and the role of the ITGA4 
gene in response to natalizumab in a subset of French MS patients from the BIONAT cohort. 
(Outteryck et al., 2013) 
We next describe genetic prediction studies and also present findings from the prediction 
studies we conducted. Here, we focused on investigating the role of non-genetic factors in predicting 
response to natalizumab in a subset of patients from the BIONAT cohort. We note that genetic data for 
these patients are being generated at the time of writing this manuscript and will soon be available for 
analysis. Further, using a simulated dataset provided by the Genetic Analysis Workshop 18 (GAW18) 
on a continuous trait (diastolic blood pressure) we compared two alternative methods for detecting 
genetic associations and evaluated the predictive performance of each. 
We conclude by contrasting genetic studies of MS susceptibility to those of response to 
therapy in MS with the aim of providing a perspective on the feasibility of pharmacogenomics of MS. 
We also briefly discuss important economic, social, legal and ethical considerations that we believe 
concern us all as long as genetic testing has been, is or will be used to guide clinical decision making. 
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2 LAYING THE FOUNDATIONS 
 
The “central dogma of molecular biology”, an (incorrect) term coined in 1956 by Francis Crick (Crick, 
1956), describes the flow of genetic information in a living organism (see Figure 2.1). 
 
 
Figure 2.1: The flow of genetic information as described by Francis Crick taken from an early draft of 
the original article published in 1958 ((Crick, 1956); (Crick, 1958)). 
 
Principally, it is a unidirectional flow of information where DNA is transcribed to RNA which 
is then translated into a protein of a specific function. In some special cases, information can flow in 
the reverse direction from RNA to DNA but never from protein to RNA or from protein to DNA. 
Crick’s representation of the flow of genetic information has been contradicted by experimental work 
over the years (Shapiro, 2009). While Crick had later acknowledged that the use of the term “dogma” 
(referring to a belief that cannot be doubted) was incorrect and he had meant it more as a “hypothesis” 
(Crick, 1990), it is without question that the concept he put forward remains of fundamental 
importance in molecular biology. 
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Adopting this simplistic flow of genetic information for illustrative purposes, in Figure 2.2 we 
present the type of analytical approaches performed depending on the unit of analysis at each level. In 
particular, genomics studies the structure and the function of the DNA. In turn, transcriptomics 
measures the expression level of RNA in a given cell population. Lastly, proteomics studies the 
functions and the structures of proteins. 
 
 
Figure 2.2: The flow of genetic information and the type of analytical approaches performed 
depending on the unit of analysis at each level. 
 
Additional “-omics” terms can be added to the list depending on the unit of analysis such as 
metabolomics, epigenomics, glycomics, lipidomics and others. In the era of this omics data revolution, 
it is an increasing challenge to adopt an integrative approach to analyzing this omics information that 
may ultimately lead us toward personalized medicine. For instance, Chen et al. (2012) conducted the 
first-ever integrative personal omics profile analysis of a healthy individual revealing the subject’s risk 
for various diseases such as Type 2 diabetes. 
Of the omics terms, our focus in this thesis is on genomics and, specifically, on the human 
genome. 
2.1 Understanding the Human Genome 
The main goals of the Human Genome Project (HGP) were to determine the sequence of the 3 billion 
DNA base pairs that make up the human genome and to identify and map all of the estimated 20 500 
genes. It was the largest international collaborative effort ever undertaken in biomedical research 
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coordinated by the US Department of Energy with participants from all over the world including 
United Kingdom, Japan, France, Germany and China. An initial draft of the genome was reported in 
2001 (Lander et al., 2001) and the final sequence completed in 2003 (International Human Genome 
Sequencing Consortium, 2004), 13 years after the project’s initiation at a cost of more than 3 billion 
US dollars. Many believe that the private quest by former National Institutes of Health (NIH) scientist 
J. Craig Venter and his company, Celera Genomics®, to sequence the human genome challenged and 
accelerated the work. In 2001, only three years after commencing on his project, Venter also reported 
an initial draft of the human genome using samples from geographically diverse individuals as well as 
his, and employing a different sequencing technique at a fraction of the cost of the publicly funded 
project (Venter et al., 2001). 
A large number of donors contributed blood and sperm samples to HGP only few of which 
were processed for DNA sequencing. Neither the researches nor the donors knew whose DNA was 
sequenced. In fact, the derived reference sequence did not represent a specific individual’s genome but 
was rather based on a composite of DNA from several donors. This “representative” sequence of the 
human genome is freely available in public databases. 
Many genetic variations were also identified during the HGP and, in October 2002, another 
international collaboration gave birth to the International HapMap Project (International HapMap 
Consortium, 2003). Its primary objective was to develop a haplotype map of the human genome 
describing the most common patterns of human DNA sequence variation with the minimum number of 
SNPs. By definition, a haplotype is a combination of alleles at nearby SNPs. 
The project has had so far three phases. In Phase I, the haplotype map of the human genome 
was derived from 270 individuals from Africa, Europe, China and Japan consisting of approximately 
1.3 million SNPs (International HapMap Consortium, 2005). In Phase II, over 3.1 million SNPs were 
genotyped in the same individuals (Frazer et al., 2007). In Phase III, the number of DNA samples was 
increased from 270 to 1301 obtained from more geographically diverse human populations (Altshuler 
et al., 2010). 
The first complete genome sequence of a single individual (J. Craig Venter’s) was published 
in 2007 (Levy et al., 2007) followed by that of James D. Watson (Wheeler et al., 2008) in 2008. That 
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year, the genome sequences of two anonymous individuals from Asian and African descent were also 
published ((Wang et al., 2008); (Bentley et al., 2008)). Early 2008, yet another large international 
effort was put forth and the 1000 Genomes Project was launched the goal of which was to sequence 
the genomes of at least 1000 individuals from genetically diverse backgrounds. The pilot phase of the 
project was completed in 2010 (Abecasis et al., 2010) and the sequence of the genomes of 1092 
anonymous individuals was published in late 2012 (Abecasis et al., 2012). Both the HapMap and the 
1000 Genomes project databases are continuously used. 
All these large-scale collaborative efforts certainly fostered biomedical research but, most 
importantly, built the foundation for investigating the role of genetic variants in human health and 
disease at the genome-wide level. 
2.2 Genetic Variations 
Types of genetic variants include SNPs and structural variants such as insertions-deletions, block 
substitutions, etc., as illustrated in Figure 2.3 below. 
 
 
Figure 2.3: Types of human genetic variations. Adapted from (Frazer et al., 2009). 
 
We focus here on the most common and simplest form of genetic variation, the SNP. The 
Single Nucleotide Polymorphism Database, dbSNP, is a central public repository for genetic variation 
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(not only of SNPs unlike its name is suggesting) in humans and other species created and maintained 
by the US National Center for Biotechnology Information (NCBI) since 1998 (Sherry et al., 2001). 
A SNP represents a difference in a single nucleotide base. SNPs occur on average every 300 
bases giving rise to roughly 10 million SNPs in the human genome. A SNP can have up to four 
possible alleles (A, C, G or T) but most SNPs are bi-allelic (only two alleles are present in the 
population). Each individual carries two SNP alleles one for each copy of the chromosome forming 
the genotype at that single position. For instance, if the two SNP alleles are A and T, then the 
genotypes would be A/A, A/T and T/T. When the alleles on both chromosome copies are identical 
(that is, genotypes A/A or T/T), the individual is said to be homozygous at that locus; otherwise the 
individual is said to be heterozygous (that is, genotype A/T). The allele with the lower frequency in the 
population is referred to as the minor allele. So far, mostly common or low-frequency SNPs have been 
catalogued, with minor allele frequency (MAF) of at least 1%. Recent advances in sequencing 
technologies enable the analysis of rare variants with MAF < 1% (Cirulli and Goldstein, 2010). 
2.3 Linkage Equilibrium/Disequilibrium 
Obtaining fine maps of the genetic variations have not only allowed the determination of the patterns 
of common variation and their frequencies but have also made possible the determination of the 
complex correlation structures that exists between SNPs. This concept, first introduced in 1960 by 
Lewontin and Kojima (Lewontin and Kojima, 1960) and unfortunately termed Linkage Disequilibrium 
(LD), simply reflects the nonrandom association of alleles at two or more loci. It is a misleading term 
because loci that are in disequilibrium may not necessarily be linked (that is, physically close) and also 
loci that are linked may not necessarily be in disequilibrium. The original definition of LD referred to 
the non-random association between two or more loci from possibly different chromosomes but lately 
the term has been used to refer to the non-random association between two or more loci on the same 
chromosome (Slatkin, 2008). 
Several metrics exist to measure LD. We briefly discuss the most commonly used ones here. 
Suppose, without loss of generality, that there are two bi-allelic SNPs with alleles A/a and B/b, 
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respectively, resulting in the following four haplotypes: AB, Ab, aB, ab. Let f(x) be the frequency of x 
where x can refer to an allele or a haplotype. This is summarized in Table 2.1 below. 
 
 
Table 2.1: Table of allele and haplotype frequencies for two bi-allelic SNPs, SNP1 and SNP2. 
 
Then, the basic measure of LD for the pair of alleles A and B,    , is given by 
       (  )    ( ) ( ) (2.1) 
where     is essentially the difference between the observed and the expected frequency (under the 
assumption of independence of alleles) of the haplotype AB. Since the allele frequencies at both loci 
have to add up to 1 and the haplotype frequencies have to add up to 1, the range of LD values is 
constrained. That is, 
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Similar derivations can be obtained for     and    . In fact, the measures of LD for all pairs of alleles 
are related as follows  
                      . (2.3) 
If    , the loci are said to be in Linkage Equilibrium (LE). 
B b
A f(AB) f(Ab) f(A)
a f(aB) f(ab) f(a)
f(B) f(b) 1
SNP2 alleles
SNP1 alleles
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While all additional metrics that have been proposed to measure LD relate to D, they aim to 
circumvent some of its limitations. For instance, when the goal is to compare the LD between different 
pairs of SNPs, D is not a good measure since its range of possible values is constrained by the specific 
allele frequencies. Hence, Lewontin (1964) defined an alternative normalized measure,   , as 
    
 
    
  
(2.4) 
where 
       {
    ( ( ) ( )  ( ) ( ))      
    ( ( ) ( )  ( ) ( ))      
  
(2.5) 
That is,      is the maximum D which can be achieved given the specific allele frequencies. As such, 
    [    ]  When |  |   , it is indicative of the absence of at least one of the haplotypes and the 
case is known as complete LD. 
Another measure of LD is the correlation coefficient,   , between the two loci defined as 
follows 
    
  
 ( ) ( ) ( ) ( )
  
(2.6) 
When     , exactly two of the four possible haplotypes are observed. This is known as perfect LD. 
In this case, knowing the genotypes at one SNP completely determines the genotypes at the other SNP. 
A typical LD plot with    as the measure of LD is illustrated in Figure 2.4 below. SNPs 1 and 2 are in 
weak LD with         while SNPs 5 and 6 are in strong LD with        . The shading of each 
diamond is proportional to the    value ranging from white for      to black for       . (Note 
that a plot with    as the measure of LD can be obtained analogously.) 
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Figure 2.4: A typical LD plot with    as the measure of LD. SNPs 1 and 2 are in weak LD with 
        while SNPs 5 and 6 are in strong LD with        . The shading of each diamond is 
proportional to the    value ranging from white for      to black for       . Adapted from 
(Lessard et al., 2012). 
 
LD can range over as little as few kilobases (kb, 1 kb = 1000 base pairs) to as much as 100 kb 
or more. (Reich et al., 2001) Studies on the pattern of LD have shown that it varies across the genome 
and across populations of different ancestry. For example, a particularly long range LD is observed at 
the major histocompatibility complex (MHC) on chromosome 6 over several megabases (Mb, 1Mb = 
1 000 000 base pairs). Further, the LD in African populations is weaker on average than that in 
European or Asian populations as, for example, illustrated in Figure 2.5 below for a region on 
chromosome 9. 
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Figure 2.5: LD plots based on    as the measure of LD for a region on chromosome 9 and for three 
HapMap populations: CEU (European), CHB+JPT (Asian) and YRI (African). The shading of each 
diamond is proportional to the    value ranging from white for      to red for     . Adapted 
from (Frazer et al., 2009). 
 
The breakdown of LD is primarily driven by recombination but evolutionary forces such as 
mutation, genetic drift, natural selection and migration, can also influence LD. 
2.3.1 Recombination 
Recombination occurs during meiosis, a special type of cell division producing gametes (reproductive 
cells) that are genetically different from their parental types. This is illustrated in Figure 2.6 below. 
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Figure 2.6: During meiosis, homologous chromosomes undergo crossing-over producing 
chromosomes containing genetically heterogeneous regions. Adapted from (GeneticsSuite, 2013). 
 
The recombination frequency is given by the total number of recombinant gametes divided by 
the total number of all transmitted gametes. (Note that in Figure 2.6, the recombination frequency is 
0.5.) Loci that are located close to each other tend to be inherited together (that is, they are less likely 
to be separated during chromosomal crossing-over). Such loci are said to be genetically linked. The 
unit of measure of genetic linkage between any two loci is the centimorgan (cM) and represents the 
genetic distance between the two loci. The unit, named after the Nobel laureate geneticist Thomas 
Hunt Morgan, refers to the distance between the two loci determined by the frequency with which 
recombination occurs between them. By definition, 1cM is equivalent to a recombination frequency of 
1%. Note that two loci that are genetically the same distance apart may not be so physically (in terms 
of base pairs). In humans, 1cM corresponds, on average, to 1 million base pairs but this number varies 
widely across the genome. 
Recombination breaks up the genomic regions over generations. Thus, the strength of LD 
tends to decrease with distance as well as time and this relationship is represented through the 
following formula 
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     (   )    (2.7) 
where   is the recombination frequency and   is time in generations. The recombination frequency is 
      for unlinked loci and       for linked loci with     the more linked the loci. Also,   is 
not uniform across the genome with some regions having a higher recombination frequency 
(recombination hotspots) than others. Equation (2.7) generalizes to 
     (   )
    (2.8) 
where    is the LD at generation 0 and      is the LD   generations after. From Equation (2.8) and as 
illustrated in Figure 2.7, it is easy to see that LD at closely linked loci decays at a slower rate than at 
loci that are far apart. 
 
Figure 2.7: LD decay as a function of generation   and recombination frequency  . 
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2.3.2 Mutation, Genetic Drift, Natural Selection and Migration 
The four basic mechanisms of evolutionary change are mutation, genetic drift, natural selection and 
migration. They lead to changes in allele and haplotype frequencies in a population and as such can 
influence LD. 
Mutation is a change in the DNA sequence occurring in one generation and passed on to future 
generations. When a mutation first occurs, it creates LD with neighboring loci. Recurrent mutations, 
which are rare for SNPs, reduce LD. 
Genetic drift is a change in allele frequencies due to random sampling of gametes in a finite 
population over generations. Genetic drift may lead to an eventual loss of haplotypes especially if the 
population is small and the haplotype is rare thus leading to increased LD. 
Individuals with certain genotypes may be more likely to survive and reproduce and, thus, 
pass on their alleles to the next generation than individuals with other genotypes. Natural selection is 
the process by which allele frequencies in a population change due to these differences in survivorship 
and/or reproduction among individuals (genotypes). Natural selection can lead to increased or 
decreased LD. 
Migration (or gene flow) is the transfer of alleles from one population to another. Initially, the 
extent of LD is proportional to the allele frequencies in each population. The larger the differences of 
allele frequencies between populations, the more significant the impact of migration will be on LD. 
2.4 Tag SNPs 
In genomic regions with high LD, the variation can be described without capturing all SNPs in the 
region but instead focusing on a minimal set of most informative SNPs, so called tag SNPs. This is the 
primary objective of the International HapMap Project that we referred to earlier in this chapter. The 
principle is illustrated in Figure 2.8 below. Specifically, the panel (a) of the graph illustrates the DNA 
sequence of the same chromosomal region in four different individuals. These individuals differ in 
three nucleotide bases as shown by the colored SNPs. Panel (b) shows the haplotype for each of the 
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four individuals composed of alleles of 20 SNPs including the three SNPs from panel (a). Panel (c) in 
turn shows the three SNPs that uniquely identify each of the four haplotypes. 
 
 
Figure 2.8: Describing common patterns of human genetic variation. (a) DNA sequences of four 
individuals including three SNPs. (b) Haplotypes formed by nearby SNPs including the three SNPs 
from panel (a). (c) The three SNPs which uniquely identify the four haplotypes. Adapted from 
(International HapMap Consortium, 2003). 
2.5 SNP Genotyping 
SNP genotyping refers to the process of determining the SNP genotypes. Several genotyping platforms 
exist based on different technologies. The choice of platform depends on the number of SNPs to be 
genotyped. Microtiter (well) plates (for example, Taqman®) are typically used for small scale projects 
limited to few SNPs. The work by the International HapMap Project coupled with novel technological 
advances led to the development of microarrays or SNP chips (for example, Affimetrix® or 
Illumina®) enabling large-scale, whole-genome, genotyping. 
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2.6 SNP Chips 
A common criterion to assess the quality of a SNP chip involves the evaluation of its global coverage 
of the genome. Li et al. (2008) evaluated this criterion for several commercial SNP chips available at 
the time for the CEU (European), CHB+JPT (Asian) and YRI (African) HapMap populations. The 
percentage of the genome covered by each evaluated SNP chip and for each population is given in 
Table 2.2 below. 
 
Company SNP Chip Number of SNPs CEU (%) CHB+JPT (%) YRI (%) 
Affimetrix® 
SNP Array 5.0 500 568 64 66 41 
SNP Array 6.0 934 968 83 84 62 
Illumina® 
HumanHap300 317 511 77 66 29 
HumanHap550 555 352 87 83 50 
HumanHap650Y 660 917 87 84 60 
Human1M 1 072 820 93 92 68 
Table 2.2: Global coverage of the genome for several commercial SNP chips for the CEU (European), 
CHB+JPT (Asian) and YRI (African) HapMap populations. Adapted from (Li et al., 2008). 
 
Thus, from Table 2.2 above, it can be seen that the global coverage of the genome depends on 
the number of SNPs on the chip and on the extent of LD in the population. As expected, a higher 
number of SNPs leads to higher coverage and fewer SNPs are needed to achieve the same coverage in 
populations with higher LD (for instance, CEU versus YRI, see Figure 2.5). 
2.7 Testing for Hardy-Weinberg Equilibrium 
Genotyping errors may be detected by Hardy-Weinberg Equilibrium (HWE) testing. It is an essential 
quality control step in genetic association studies. 
The HWE states that allele and genotype frequencies in a population will remain constant 
from generation to generation under the assumption of random mating and in the absence of 
evolutionary forces (mutation, genetic drift, natural selection and migration). This principle is named 
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after Godfrey Harold Hardy and Wilhelm Weinberg who developed it independently in 1908. (Hardy, 
1908;Weinberg, 1908) 
If the allele frequencies in one generation are given by  ( )    and  ( )   , then the 
expected genotype frequencies in the next generation are  (  )      for the A/A homozygote, 
 (  )      for the A/a heterozygote and  (  )     for the a/a homozygote as illustrated in Table 
2.3 below. 
 
 Paternal 
A (p) a (q) 
Maternal 
A (p) AA (  ) Aa (  ) 
a (q) Aa (  ) aa (  ) 
Table 2.3: Punnet square giving the probabilities of an offspring having a particular genotype at a bi-
allelic locus in a population in Hardy-Weinberg Equilibrium. 
 
Thus, the HWE principle relates the allelic and genotypic frequencies. The principle is 
presented here on a single bi-allelic locus but may be extended to loci with multiple alleles and also to 
multiple loci (Hastings, 2001). 
The principle provides theoretical genotype frequencies against which the observed 
frequencies in a population can be compared. Table 2.4 below summarizes the observed and the 
expected genotype counts under HWE in a population of size   for a single bi-allelic locus. 
 
Genotype AA Aa aa 
Observed Counts             
Expected Counts              
Table 2.4: Observed and expected (under HWE) genotype counts at a single bi-allelic locus in a 
population of size  . 
 
We test for deviations from HWE in a population though the    goodness-of-fit statistic,     
 , 
given by 
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(      
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(2.9) 
Under the null hypothesis of HWE,     
      
 .  
Genotyping errors may impact the genotype frequencies. Thus, in large enough, randomly 
mating populations, where HWE is assumed to hold, significant deviations from HWE may be 
indicative of genotyping errors. 
2.8 Where Are We Now? 
Genetic variants associated with or explaining complex traits may be identified using hypothesis-
driven or hypothesis-free study designs. The former incorporates prior knowledge of the potentially 
causal SNPs or genes focusing analyses on one candidate SNP or several of them typically lying 
within a specific candidate gene. 
However, the obvious disadvantage that prior information may not always be available 
coupled with the rapid advances in technology leading to sharply falling genotyping costs, have 
caused a shift in the popularity of candidate SNP or gene studies to genome-wide association studies 
(GWASs). Nowadays, GWAS is the most widely used approach to detect genetic association with 
complex human traits. In a GWAS, no prior hypothesis on the potential causal SNP or gene is made 
(hypothesis-free) and, instead, the whole genome is scanned one SNP at a time. 
The first successful GWAS was conducted in 2005 in age-related macular degeneration, a 
serious condition affecting old adults leading to loss of vision (Klein et al., 2005). Only three years 
after that, several hundred GWASs had been conducted identifying hundreds of association in over 80 
distinct traits and diseases (Hindorff et al., 2009). Figure 2.9 below illustrates identified associations 
as of December 2012 at stringent criteria levels for 17 trait categories (represented by different colors) 
locating the different findings across the genome. 
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Figure 2.9: Published genome-wide associations at stringent significance criteria as of December 
2012. Adapted from www.genomes.gov. Last accessed August 2013. 
 
Basically, these findings indicate that there is a correlation between a specific genomic region 
and a trait. However, correlation does not imply causation which is of higher importance clinically. 
Thus, while our understanding of the genetic component of complex traits has deepened significantly, 
little benefit of that has been seen at the clinical level. Not surprisingly, skepticism on the usefulness 
of these studies has been on the rise. The review by Manolio (2013) addresses precisely this issue and 
suggests at least four areas where GWAS findings can be readily translated into clinical care, namely, 
disease prediction, disease classification, drug development and drug toxicity. 
In Chapter 3, we describe the genetic association studies, while in Chapter 4, we discuss 
genetic prediction studies and highlight why the road to translate genetic association findings to 
medical practice remains rough and challenging.  
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3 GENETIC ASSOCIATION STUDIES 
 
In a GWAS, the association between the SNP and the trait of interest is tested one SNP at a time. In 
this chapter, we describe single SNP-trait association analysis and present several limitations of 
GWAS. 
3.1 Traits 
Genetic association studies aim to relate genetic information to a clinical outcome or phenotype. The 
outcome can be quantitative, binary, survival, count, etc. In this thesis, we focus on quantitative and 
binary outcomes. 
3.1.1 Quantitative Traits 
A quantitative outcome is a continuous trait such as blood pressure or height. In epidemiology, 
assuming a linear relationship between a risk factor,  , and a continuous trait,  , measuring its effect 
on the trait involves the calculation of the correlation coefficient,     , between   and   given by 
       
   (   )
    
  
 [(     )(    )]
    
  
(3.1) 
where    and    are the mean values, and    and    are the standard deviations of   and  , 
respectively. 
In the case when only a single risk factor is evaluated, the coefficient of determination,   , is 
given by the square of the correlation coefficient, that is, 
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  (3.2) 
3.1.2 Binary Traits 
A binary or dichotomous outcome can take on one of two possible values typically referring to disease 
status, (disease versus healthy) or, in the case of response to treatment, responders versus non-
responders, for example. 
In epidemiology, measuring the effect of a risk factor on a dichotomous trait involves a 
comparison of risks or odds between the exposed (cases) and the unexposed (controls) groups. The 
risk is defined simply as the probability that the disease will occur, that is 
      (       ) (3.3) 
and is constrained between 0 and 1. The odds is defined as the ratio of probabilities of the disease 
occurring versus not occurring, that is 
     
 (       )
 (          )
 
(3.4) 
and can take any value between 0 and infinity. The two measures are related as follows 
      
    
      
  
(3.5) 
For example, suppose that 1 in 1 000 individuals acquires a certain disease. Then,       
 
    ⁄
   
    ⁄
  
 
 
   
         and, using Equation (3.5),      
     
        
                . On the other hand, 
suppose for another disease, that 1 in 4 acquires it. Then,       
 
 ⁄
 
 ⁄
   
 
 
       and      
 
    
      
     . 
The above examples illustrate that, in the case of rare outcomes (diseases), the probability of 
disease is closely approximated by the odds of disease (that is,           ). Alternatively, for more 
common outcomes, important differences between the two measures arise and this approximation 
loses validity. 
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In epidemiological studies, associations between disease and risk factors are typically 
expressed in terms of relative risk (RR) which is the ratio of risks in the exposed versus the unexposed 
group, that is 
   
 (       |       )
 (       |         )
  
(3.6) 
In case-control studies, the odds ratio (OR) is often used as a surrogate for RR. Similarly to RR, the 
OR is the ratio of odds in the exposed versus the unexposed group, that is 
   
 
 (       |       )
 (          |       )⁄
 (       |         )
 (          |         )⁄
  
(3.7) 
Since the assumption that       may not always hold, however, one must be cautious when 
interpreting study findings. 
3.2 Heritability of Traits 
3.2.1 Quantitative Traits 
Variation in complex traits can be due to genetic and environmental factors and can be decomposed as 
follows 
                (   )  (3.8) 
where    is the phenotypic variance,    and    are the variance components attributable to genetic 
and environmental factors, respectively, and    (   ) is the covariance between the genetic and 
environmental factors. Most of the times,   and   are assumed to be independent simplifying 
Equation (3.8) to 
            (3.9) 
The effects of   can be further decomposed into additive,   , dominant,  , and epistatic (interaction) 
effects,  , leading Equation (3.9) to become 
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                    (3.10) 
The most widely used formulation assumes that there are no dominance and interaction effects and 
models only additive genetic effects. As such, Equation (3.10) reduces to 
            (3.11) 
The broad-sense heritability,   , is defined as the ratio of total genetic variance to total phenotypic 
variance and is given by 
    
  
  
  
(3.12) 
while the narrow-sense heritability,   , is defined as the ratio of total additive genetic variance to total 
phenotypic variance and is given by 
    
  
  
  
(3.13) 
3.2.2 Binary Traits 
For binary traits (such as disease traits) the observed scale is 0/1 (control/case). It is assumed that such 
traits can be represented by an underlying normally distributed liability trait. If an individual’s value 
exceeds a specific threshold on the liability scale, then this individual is assigned a phenotypic value 
of 1, otherwise he is assigned a phenotypic value of 0. The relationship between the heritability at the 
observed scale,     
 ,  and the narrow-sense heritability on the continuous liability scale,   , (Equation 
(3.13)) is given by 
    
  
    
 
 (   )
   
(3.14) 
where   is the prevalence of disease in the population,    (   ) and    is the standard normal 
quantile such that  (     )   . (Dempster and Lerner, 1950) The maximum value of     
  = 0.64 
when       and     . (Visscher et al., 2008) 
 
GENETIC ASSOCIATION STUDIES 
43 
As in classical epidemiology, the choice of analytical method depends on the study design 
which is further dictated by the study subjects (related or unrelated) and by the type of trait under 
investigation (dichotomous, quantitative, survival, etc.). From here onwards, we focus on the most 
widely used case-control study design for a dichotomous trait in unrelated individuals. Most of the 
discussion applies also to quantitative traits. 
3.3 Penetrance (Genetic Effect) 
Heritable traits are carried forth over generations through the transmission of DNA. Penetrance is 
defined as the probability that an individual will express the trait given the he or she carries the 
implicated gene (or genotype). 
A Mendelian or monogenic trait is controlled by a single gene. A mutation in that gene can 
cause disease. For example, Huntington’s disease and cystic fibrosis are monogenic diseases. 
Mutations in the HTT gene (Huntington’s disease) or in the CFTR gene (cystic fibrosis) cause the 
respective disease. In other words, the probability that an individual will develop the disease given that 
he or she carries the mutations in the respective gene is 1. In this particular case, the gene is said to 
have complete penetrance. 
Monogenic disorders are relatively rare. Most traits are complex, arising as a result of a 
complex interplay between genetic and environmental factors. For these traits, we study the penetrance 
or the effect of variants in genes that may be associated with the trait. 
The penetrance of a gene (or genotype) may be influenced by other genes (gene-gene 
interactions) or by environmental factors (gene-environment interactions). For the discussion that 
follows, we have adopted a simplified view and assumed that no such interactions are present. 
Further, penetrance may be age-related or gender-related. For instance, penetrance for cystic 
fibrosis is 1 at birth and for Huntington’s disease is 1 by the age of 70 years. Different penetrance 
estimates exist for mutations for breast cancer in females and males. 
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Suppose, without loss of generality, that there is a single bi-allelic SNP with alleles a and A, 
where allele A is associated with the risk of developing a disease. An individual can carry one of three 
genotypes a/a, A/a and A/A with penetrance         and    , respectively, given by 
      (        |    )  
      (        |    )  
      (        |    )  
(3.15) 
constrained as follows 
                      (3.16) 
Under the dominant genetic model, 
             . (3.17) 
Under the recessive genetic model, 
               (3.18) 
Under the additive genetic model 
      
 
 
(        )  
(3.19) 
The relative risk of genotype A/a to genotype a/a is then given by 
       
   
   
 
(3.20) 
and, similarly, the relative risk of genotype A/A to genotype a/a is given by 
       
   
   
  
(3.21) 
We mentioned in Section 3.1.2 that, in case-control studies, the    is often used as a surrogate for   . 
The corresponding ORs are then given by 
      
      
      
 
   
(      )
⁄
   
(      )
⁄
 
(3.22) 
and 
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(      )
⁄
   
(      )
⁄
  
(3.23) 
Under the dominant model,          , under the recessive model,           and under the 
additive genetic model,      (    )
 . 
In the following section we describe the methods for estimating the genetic effect under the 
different genetic models, a summary of which is presented in Table 3.5. 
3.4 Methods 
In a case-control study, the allele or genotype frequencies are compared between disease individuals 
and healthy controls. Assume, for illustrative purposes, that we are analyzing the effect of the SNP in a 
case-control sample of   individuals. The arising contingency table of genotypic counts is illustrated 
in Table 3.1 below. 
 
 Genotype Counts 
Total 
a/a A/a A/A 
Cases                 
Controls                 
Total               
Table 3.1: The contingency table of disease status by genotype counts for a single bi-allelic SNP with 
alleles a and A and for   individuals. 
 
When the effect of a single SNP is being investigated, the analyses may also be conducted at 
the allelic level. The arising contingency table of allele counts is derived based on the genotypic 
counts in Table 3.1 and is given in Table 3.2 below. 
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 Allele Counts 
a A Total 
Cases             
Controls             
Total            
Table 3.2: The contingency table of disease status by allele counts for a single bi-allelic SNP with 
alleles a and A and for   individuals with the allelic counts related to the genotype counts in Table 3.1 
as follows:                 and                for      . 
3.4.1 Allelic Tests 
Assuming, without loss of generality, that A is the risk allele, the estimated allelic     based on the 
counts in Table 3.2,    ̂, is given by 
   ̂   
      
      
  (3.24) 
The most popular method to estimate the precision of this estimate has been proposed by (Woolf, 
1955). Asymptotically, the distribution of     on the natural logarithm scale is approximately 
normally distributed. The    (   )  confidence interval can thus be derived as 
   (   (   ̂)      ⁄        (   ̂)
)  (3.25) 
where   
 ⁄  
 denotes the (    ⁄ ) standard normal quantile and       (   ̂) is the standard error of 
   (   ̂) given by       (   ̂)   √
 
   
  
 
   
  
 
   
  
 
   
. 
If there is no association between the SNP and the disease status, the     = 1. Based on our 
definition (allele A is associated with risk of disease), an       would indicate that the allele A is a 
risk allele (     , allele A increases the risk) or a protective allele (     , allele A decreases the 
risk). Therefore, we could test the following hypothesis 
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(3.26) 
If the    (   )  confidence interval obtained by Equation (3.25) above contains the value of 1, 
then the null hypothesis cannot be rejected at the   level of significance. The hypothesis can be tested 
using the    test for independence of rows and columns. The test statistic,         
 , is given by 
        
   ∑∑
(     [   ])
 
 [   ]
 
   
 
   
   
(3.27) 
where  [   ]   
     
  
            . Under the null hypothesis of no association,         
     
 . 
In case any                  , the  
  approximation is not valid and the Fisher’s exact 
test is used. In this test, the exact probability of observing these cell counts is computed based on the 
hypergeometric distribution  (               ) such that 
  (   )    (               )
(
   
   
) (
   
   
)
(
  
   
)
  
(3.28) 
Next, the probability for each possible arrangement of the cell counts conditional on the marginal 
counts (that is,          ) is computed. The two-sided p-value is given by 
         ∑   ( )  such that   ( )     (   ). (3.29) 
The effect of the SNP on the disease status may be different according to gender. Therefore, 
we may want to conduct stratified association analysis where we built a series of allelic contingency 
tables, one for each stratum (for example, females and males) as illustrated in Table 3.3 below (a 
subscript   for stratum is added to the counts from Table 3.2). 
 
Stratum s 
Allele Counts 
a A Total 
Cases                
Controls                
Total               
Table 3.3: Allelic contingency table per stratum           with    individuals in each stratum. 
GENETIC ASSOCIATION STUDIES 
48 
 
The Cochran-Mantel-Haenszel (CMH) estimate of the OR adjusted for stratum is then given by the 
weighted OR across all strata  . 
     ̂   
∑
        
   
 
   
∑
        
   
 
   
   
(3.30) 
Let     denote the OR for stratum          . The hypothesis being tested is 
                    
                                   
(3.31) 
The CMH test statistic is given by 
    
[∑ (      (    ))
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(3.32) 
where  (    )   
        
   
 and    (    )   
                
   
 (     )
. Under the null hypothesis of no 
association,      
 . 
The CMH test assumes homogeneous association across strata (Agresti, 2007). That is, it 
assumes that 
                   (3.33) 
A    test, named the Breslow-Day (BD) test, can be used to test the homogeneity of odds ratios. The 
test statistic,    
 , is given by 
   
   ∑∑∑
(       (    ))
 
 (    )
   
   
(3.34) 
where  (    ) is the expected cell count for cell    in stratum  , respectively. Under the null 
hypothesis of homogeneous odds ratios,    
       
 . 
It is straightforward to carry out stratified analyses controlling for one categorical variable. 
However, controlling for several covariates simultaneously (for example, gender, smoking status and 
geographic origin) leads to numerous contingency tables reducing the sample size per table (and per 
cell) as more covariates are added. Moreover, the covariates need to be categorical or forcibly 
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categorized. Therefore, to adjust for several risk factors and/or for continuous factors, regression 
methods are used.  
Lastly, the allelic test (Equation (3.27)) is valid when the true model of association is 
multiplicative (additive on the logarithmic scale) (Sasieni, 1997). The Cochran-Armitage trend test 
(see Equation (3.38)) is a genotype-based test that is asymptotically equivalent to the allelic test and is 
more robust to deviations from HWE. (Guedj et al., 2008) 
3.4.2 Genotypic Tests 
The estimated genotypic odds ratio based on the counts in Table 3.1 for genotype A/A relative to 
genotype a/a,      ̂ , is given by 
    ̂   
      
      
 
(3.35) 
and for genotype A/a relative to genotype a/a,     ̂, is given by 
    ̂   
      
      
  (3.36) 
The confidence intervals are computed in much the same way as for the allelic contingency table. For 
the hypothesis test, the test statistic in Equation (3.27) becomes 
          
   ∑∑
(     [   ])
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(3.37) 
where  [   ]   
     
  
              . Under the null hypothesis of no association, 
          
     
 . 
The tests discussed so far refer to the general model without any assumption on the underlying 
genetic model. Based on the counts in Table 3.1, Table 3.4 provides the contingency tables that arise 
under the dominant (A) and recessive (B) models. In those cases, the usual    test for independence of 
rows and columns for a     contingency table applies as the one described for the allelic contingency 
table (Equation (3.27)). 
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(A) 
Dominant   
(B) 
Recessive 
a/a A/a + A/A   a/a + A/a A/A 
Cases                Cases              
Controls                Controls              
Total                Total              
Table 3.4: Contingency tables arising under the dominant (A) and recessive (B) models derived based 
on the genotype counts in Table 3.1. 
 
Alternatively, the Cochran-Armitage trend test (CATT - Cochran, 1954; Armitage, 1955) 
modifies the genotypic    test (Equation (3.37)) to incorporate a particular order of the genotypes. The 
test statistic is given by 
   
[∑   (              )
 
   ]
 
      
 
[∑   
    (      )   ∑ ∑           
 
     
 
   
 
   ]
  
(3.38) 
where            are the weights assigned to genotypes a/a, A/a and A/A, respectively. The weights 
are assigned according to the assumed genetic model setting   (     ) for a dominant effect of 
allele A and   (     ) for a recessive effect of allele A. Most of the times, the underlying genetic 
model is unknown and in most genetic association studies the general additive model is used where 
  (     ). CATT with   (     ) is asymptotically equivalent to the allelic test described earlier 
(Equation (3.27), (Sasieni, 1997)). Under the null hypothesis of no association,      
 . 
3.4.2.1 Regression Framework 
All the association tests discussed so far were based on contingency table analyses. Tests based on 
genotype counts can also be formulated in a logistic regression framework. In logistic regression, the 
odds of disease is assumed to be a linear function of the intercept and   explanatory variables (for 
example, genotype variables) on the log scale, that is, 
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   (    )      ∑    
 
   
  
(3.39) 
where   is the intercept and    is the coefficient for the    variable,        . The corresponding 
parameterization for the different genetic models is given in Table 3.5. 
Using this formulation, it is possible to construct association tests based on the likelihood of 
the model. There are three main testing approaches, namely, the likelihood ratio test (LRT), the Wald 
test and the score test. 
For the LRT, we fit two models, the null model,   , under which the risk of disease is not 
affected by the genotype, that is               and the alternative model,  , under which the risk 
of disease is affected by the genotype, that is,         and then compare the fits. The LRT statistic, 
 , is given by 
       (
            
            
)  
(3.40) 
Note that    is a special case of    and, in fact, the LRT requires nested models. Under the null 
hypothesis of no association,       
 , where    is the difference between the degrees of freedom of 
the null and the alternative model. 
The Wald test is asymptotically equivalent to the LRT and has the advantage that it requires 
the estimation of only one model. For a model with one explanatory variable (for instance, additive, 
dominant and recessive models, see Table 3.5 below), the Wald statistic, , is given by 
   (
 ̂
  ( ̂)
)
 
  
(3.41) 
where  ̂ is the maximum likelihood estimate of   and   ( ̂) is the standard error of  ̂. Under the null 
hypothesis of no association,      
 . If many variables need to be tested simultaneously (such as for 
the genotypic model, see Table 3.5 below), using matrix notation, the Wald statistic, , is given by 
    ̂     ̂  (3.42) 
where  ̂ is the vector of maximum likelihood estimates of   and   is the variance matrix. Under the 
null hypothesis of no association,       
 , where    is the number of variables being tested 
simultaneously. 
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Lastly, the score test (often known as the Lagrange multiplier test) also requires the estimation 
of only one model. Contrary to the Wald test, however, the estimated model does not include the 
parameter(s) of interest. Let  ( | ) be the likelihood function depending on one parameter,  , given 
the data  . The score,  ( ), is given by 
 ( )   
      ( ( | ))
  
 
(3.43) 
and corresponds to the slope of the log likelihood with respect to  . The variance of the score,  ( ), is 
known as the Fisher’s information and is given by 
 ( )   {[
      ( ( | ))
  
]
 
}  
(3.44) 
The score test statistic,  ( ̂), is given by 
 ( ̂)   
( ( ̂))
 
 ( ̂)
 
(3.45) 
where  ( ̂) and  ( ̂) are the score and its variance evaluated at  ̂, the maximum likelihood estimate 
of  . Under the null hypothesis of no association,  ( ̂)    
 . As for the Wald test, the multivariate 
version of the test statistic exists and is given by 
 ( ̂)    ( ̂)   ( ̂) ( ̂)  (3.46) 
where  ( ̂) is a vector of scores and    ( ̂) is the inverse of the variance matrix. Under the null 
hypothesis of no association,  ( ̂)     
 , where    is the number of variables tested by the null 
hypothesis. Throughout this thesis, we have used the LRT or the Wald test. 
3.4.3 A Note on Quantitative Traits 
Genetic associations with quantitative traits are typically conducted in a simple linear regression 
framework. All likelihood-based tests described so far for the binary traits are applicable to continuous 
traits as well. For the underlying genetic model, the same parameterization described in Table 3.5 
applies except that the linear relationship modeled is between the mean trait value and the SNP as 
opposed to between the logarithm of the odds of disease and the SNP. 
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Table 3.5: Parameterization of genetic models in a logistic regression framework and the corresponding contingency table analyses described in the text. 
 
 Genetic Model 
 Genotypic (General) Dominant Recessive Multiplicative (log-additive) 
    (    )                    (    )             (    )             (    )           
       OR    OR    OR    OR 
Genotype 
a/a 0 0 1 0 1 0 1 0 1 
A/a 1 0    (  ) 1    ( ) 0 1 1    ( ) 
A/A 0 1    (  ) 1    ( ) 1    ( ) 2    (  )    (    ( ))
  
Corresponding 
Contingency Table 
Analysis 
Table 3.1  
(   test on 2df) 
Table 3.4 (A)  
(   test on 1df) 
Table 3.4 (B)  
(   test on 1df) 
At the allelic level, Table 3.2  
(   test on 1df) 
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3.4.4 The Power of    Tests for Contingency Tables 
For a contingency table with   rows and   columns, the test statistic,   , under the null hypothesis of 
independence between the rows and the columns follows a    distribution with (   )(   ) 
degrees of freedom, that is 
     (   )(   )
   (3.47) 
Let   be the probability of falsely rejecting the null hypothesis, that is, of committing a Type I Error, 
given by     (         |           ). The value of α is called the significance level of the test. The 
null hypothesis of independence is rejected if 
    (   )(   ) 
   (3.48) 
where  (   )(   ) 
  is the critical value of the    distribution with (   )(   ) degrees of freedom 
at the α level of significance, that is,   (     (   )(   ) 
 )    . 
Next, let   be the probability of failing to reject the null hypothesis when it is false, that is of 
committing a Type II Error, given by     (                |            ). We do not reject the null 
hypothesis of independence if 
    (   )(   )  
   (3.49) 
The test statistic under the alternative hypothesis of association,   
 , follows a non-central    
distribution with non-centrality parameter   and (   )(   ) degrees of freedom such that 
  
   (   )(   )
 ( )  (3.50) 
and, hence, 
    (                |           )    (  
   (   )(   )  
 )  (3.51) 
The power of the test at the α level of significance is then given by the probability of correctly 
rejecting the null hypothesis, that is, 
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        (         |             ) 
     (                |           ) 
      
      (  
   (   )(   )  
 ) 
   (  
   (   )(   )  
 )  
(3.52) 
Following these principles, the power can be estimated for the allelic or the genotypic    tests that we 
described in Sections 3.4.1 and 3.4.2. This can be achieved by deriving the non-centrality parameter, 
 . We provide here the expression for   for the most general genotypic test (Equation (3.37)). 
For simplicity, we express the genotype counts in Table 3.1 as frequencies for     cases and 
    controls in Table 3.6 below. 
 Genotype Frequencies 
a/a A/a A/A 
Cases      
   
   
      
   
   
     
   
   
  
Controls     
   
   
     
   
   
     
   
   
 
Table 3.6: Genotype frequencies in cases and controls derived from the genotype counts in Table 3.1. 
 
Then, Gordon et al. (2002) derive the non-centrality parameter,           , as 
                  [
(       )
 
              
  
(       )
 
              
  
(       )
 
              
] 
(3.53) 
Therefore, the power of the    tests on contingency tables at a given level of significance,  , depends 
on the degrees of freedom and on the non-centrality parameter  . Through the latter, it also depends on 
number of cases and controls, on the genotype (allele) frequencies and on the effect size (the 
difference between cases and controls based on genotype). 
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3.5 Pitfalls and Limitations of Genome-Wide Association Studies 
We discuss next several of the pitfalls and limitations of genetic association studies specifically in the 
context of GWASs by drawing examples from the literature as well as from our own work. 
3.5.1 Multiple Testing 
In a GWAS, hundreds of thousands to millions of null hypotheses of no association are being tested, 
one for each SNP. If we carry out one million association tests at the 0.05 significance level, we would 
expect approximately 50 000 (1E+6 * 0.05) false positives. Therefore, if we wish to maintain an 
overall Type I Error of 0.05, we need to reduce the significance level of the test. 
One of the most commonly used approach to correct for multiple tests is the Bonferroni 
correction method whereby the pre-specified significance level,  , is adjusted to reflect the number of 
tests,  , that were carried out such that the new significance level,   , is given by        . For a 
typical GWAS,    is set at 1E-7 or stricter. This approach, while simple to apply, is conservative since 
it assumes that all   tests are independent which is not correct as SNPs are correlated due to LD. 
In the previous section (Section 3.4.4), we pointed out that the power to detect association is 
obtained at a given significance level,  . Therefore, if the adjusted significance level is too 
conservative, the power is compromised. 
Alternative methods exist that are less conservative such as the false discovery rate (FDR), 
where the proportion of rejected null hypotheses that were falsely rejected is specified instead 
(Benjamini and Hochberg, 1995). 
3.5.2 Direct, Indirect and Confounded Associations 
A statistically significant difference in the allele or genotype frequencies between cases and controls 
may be indicative of evidence that the SNP is associated with the disease. Moreover, even if the 
detected association is not spurious, it is rarely the case that the SNP’s influence on the trait is direct. 
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For certain traits, prior investigative work has identified potentially causal SNPs. Direct 
association studies target these SNPs. These are powerful studies as prior knowledge is incorporated. 
However, most of the times, little is known on the underlying genetic mechanism of complex traits 
and causal SNPs are rarely directly analyzed. 
In indirect association studies, the SNPs surrounding the causal SNP are analyzed. Since those 
SNPs are likely correlated with the causal SNP (due to LD, see Section 2.3), the association may be 
picked up. The concepts of direct and indirect associations are illustrated in Figure 3.1 below. 
 
 
Figure 3.1: Direct (a) and indirect (b) association studies. In direct association studies, only one SNP, 
the causal (in red), is analyzed. In indirect association studies, several SNPs (in red) that are correlated 
with the causal SNP (in blue) are analyzed. Adapted from (Hirschhorn and Daly, 2005). 
 
A significant SNP association from a GWAS may only be hinting to the location of the causal SNP 
and, therefore, should not be interpreted as the causal SNP. 
Further, the power to detect association with a SNP nearby the causal SNP depends on the LD 
between the two SNPs. The stronger the LD between the genotyped SNP and the causal SNP is, the 
higher the power is to detect the association. Alternatively, Pritchard and Przeworski (2001) 
compared the sample sizes needed to achieve the same power, holding all else fixed, when the causal 
SNP and a SNP in LD with the causal is tested. Let   be the sample size when the causal SNP is tested 
and let    be the sample size when the SNP in LD with the causal is tested. They showed that    
    ⁄ , where  
  is the measure of LD as defined in Equation (2.6). Hence, to achieve roughly the same 
power, a much larger sample size (in the order of    ⁄ ) is necessary when the SNP in LD with the 
causal SNP is tested. 
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Lastly, if the cases and controls are not properly matched, the association may be confounded. 
Large study sample sizes are required for conducting GWASs (see Section 3.5.4). Major international 
collaborations over the years have made that possible. However, with such collaborative efforts 
combining samples of different ethnic origins and from different research centers may lead to biased 
results if not appropriately accounted for. Population stratification (also referred to as population 
structure) arises when the study population is non-homogeneous as, for example, when subjects from 
different ethnic backgrounds having different allele frequencies are included in the study and 
disproportionately represent the cases and controls. However, if population stratification is detected, 
methods exist to appropriately account for it. 
3.5.3 Effect Size and Allelic Frequency 
The dominating hypothesis of the GWAS era was that the genetic variability of common diseases (and 
traits) could be explained by few common genetic variants (with minor allele frequency, MAF ≥ 5%) 
exerting a small to moderate effect on the trait. This is known as the common disease-common variant 
hypothesis (CDCV). Figure 3.2 below shows that the CDCV hypothesis provides a limited view of 
the genetic architecture of complex traits and diseases. 
 
 
Figure 3.2: Effect size (OR) plotted against risk allele frequency. Adapted from (Manolio, 2013). 
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Alternatives to the CDCV hypothesis have since been proposed such as the common disease-
rare variant (CDRV) hypothesis where it is assumed that genetic variation of common diseases may be 
explained by a large number of low frequency or rare variants (MAF < 5%) having large effect sizes 
(Cirulli and Goldstein, 2010). As we saw in Chapter 2, genotyping chips were designed to capture 
only common variation and, hence, rare variants are not tagged by the existing SNPs on the chips. 
Therefore, the GWAS was not designed to detect associations under the CDRV hypothesis. Currently, 
methodological focus has turned to analyzing whole-genome sequence data that would allow 
uncovering the role of rare variants in complex traits. As we saw in Section 3.4.4, for the association 
tests that we have discussed, the power depends on the effect size and on the allele frequency. Holding 
everything else fixed, the power increases with larger effect size and decreases with lower allele 
frequency. 
3.5.4 Study Sample Size 
Figure 3.3 below illustrates the results of a simulation study estimating the required sample size to 
detect associations for given effect sizes and disease-allele frequencies in order to achieve power of 
80% at genome-wide significance threshold (p-value < 10
-6
) under the multiplicative genetic model. 
 
GENETIC ASSOCIATION STUDIES 
60 
 
Figure 3.3: Required number of cases and controls to achieve 80% power at p-value < 10
-6 
to detect 
associations for given allelic frequencies and effect sizes (OR, shown near each corresponding curve). 
Perfect linkage disequilibrium between the test markers and the disease variants and the multiplicative 
genetic model is assumed. Adapted from (Wang et al., 2005). 
 
Figure 3.3 above illustrates that extremely large sample sizes are required to detect variants of weaker 
effects and/or low allelic frequency. This provided an impetus for the formation of large international 
consortia to combine samples and collaborative efforts for better powered studies. 
The landmark GWAS of age-related macular degeneration in 2005 was conducted on 146 
subjects (96 cases and 50 controls) with roughly 120 000 genotyped SNPs (Klein et al., 2005). Lately, 
GWAS sample sizes have reached the vicinity of tens of thousands of individuals. A GWAS on blood 
pressure and cardiovascular disease risk reported in 2011, for example, evaluated associations between 
roughly 2.5 million SNPs on approximately 70 000 subjects in their discovery dataset and used a 
sample size of roughly 200 000 individuals for their combined discovery and replication datasets 
(Ehret et al., 2011). 
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3.5.5 Missing Heritability 
In their study, Ehret et al. (2011) estimated that around 120 genetic variants contribute to blood 
pressure explaining 2.2% of the phenotypic variation while the 29 independent variants that they 
identified in their study explained only about 0.9% of the variation. Thus, despite the large sample size 
and large SNP map, more than half of the heritability still remained unexplained. 
In fact, while GWAS have provided significant insights into the genetics of common complex 
traits and diseases, it is important to note that much of the genetic variance of the studied  phenotypes 
has remained largely unexplained – the so called missing heritability problem (Maher, 2008). 
Plausible explanations for the missing heritability problem include overestimation of heritability from 
twin and family studies but mostly surround the limitations of GWAS. 
3.5.6 Underlying Genetic Model 
The power of the genetic association studies depends on the underlying genetic model. Most of the 
times, the underlying genetic model is unknown and typically, in GWASs, the multiplicative (additive 
on the log scale) genetic model is assumed. This can lead to loss of power if the underlying genetic 
model is not the assumed one. It is possible, of course, to use the general model but testing for it 
requires two degrees of freedom instead of one. We saw from Section 3.4.4 that the power depends on 
the number of degrees of freedom and, holding everything else constant, it decreases as the number of 
degrees of freedom increases. 
3.5.7 Modeling Strategies 
We saw in Section 3.5.4 that much larger sample sizes are needed to detect associations with rare 
variants and/or variants with weaker effects and, even then, the GWAS is not well powered. 
Alternative methods need to be considered that may improve the power in these contexts. 
Although this was not the primary focus of my thesis, for the analyses of rare variants, I 
contributed to a comparative study evaluating the power and Type I Error of several novel statistical 
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methods that have been proposed for the analyses of rare variants in simulated data provided by the 
Genetic Analysis Workshop 17 (GAW17) (Saad et al., 2011b). 
Analogously, for the analyses of common SNPs with weak effects (where my focus lies) 
alternative modeling strategies to the somewhat simplistic SNP-by-SNP approach adopted in GWAS 
have been proposed. It has been suggested that estimating SNP effects individually is not optimal and 
does not lead to consistent effect estimates due to LD (see, for example, (de los Campos et al., 2010)). 
Therefore, approaches modeling the effect of all SNPs simultaneously may be better powered at 
identifying the set of SNPs that are associated with the trait or disease of interest. In Sections 3.6.3 and 
3.6.4, we describe two different multi-marker association analyses that we conducted and how they 
compare to the classical single-marker approach. Briefly, though, the results of these studies did not 
convince us of the superiority of these more complex approaches over the classical single-marker 
approach to detect associations. 
 
The remainder of this chapter describes the various genetic association studies that we have 
conducted. 
3.6 Applications 
3.6.1 Role of the 2'-5'-oligoadenylate synthetase 1 (OAS1) gene in interferon 
response in MS patients 
3.6.1.1 Objective 
The objective of this study was to investigate whether the SNP rs2660 in the 2'-5'-oligoadenylate 
synthetase 1 (OAS1) gene was associated with response to interferon treatment in MS patients. OAS1, 
an essential protein involved in the innate immune response to viral infection, is upregulated by 
interferons. Since viral infection is a potential causative factor in MS and established causative factor 
in relapses, OAS1 may be playing a vital role in interferon response in MS patients. A recent study, for 
instance, has found a gender-related immunological action of interferon therapy in MS (Contasta et 
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al., 2012). Therefore, we were also interested in investigating if there was a gender-related genetic 
action. 
3.6.1.2 Dataset 
The dataset consisted of 1162 unrelated MS patients from France, Germany, Italy and Spain. Patients 
with missing response status (1), genotypes (22), gender (22) and non-RRMS patients (3) defined as 
having EDSS at treatment onset > 6 were excluded from the analyses. The final study dataset 
consisted of 1115 patients. All patients were genotyped for the SNP rs2660 (A/G) in the OAS1 gene. 
3.6.1.3 Response Definition 
Response was determined based on the EDSS progression and the number of relapses over two years 
of treatment (see Figure 1.6). Let    be the time at treatment onset and let    be the time at which 
response is evaluated. Here,           . Let       be the EDSS progression since    evaluated at 
time   and let     be the number of relapses experienced up to time   since   . Then, Responders 
were defined as 
            {
               
       
 
(3.54) 
All patients not classified as Responders were classified as Non-Responders. Clinical characteristics 
by response status and cohort are provided in Appendix II (Table II.1-Table II.4). 
3.6.1.4 Methods 
Prior all analyses, we tested the SNP rs2660 for deviations from HWE using the HWE exact test. We 
first conducted a stratified analysis by cohort using the CMH test (Equation (3.32)). We computed 
ORs and 95% confidence intervals (CI) with allele A as the reference allele. We tested for 
homogeneity of ORs using the BD test (Equation (3.34)). Pooling cohorts with homogeneous effects, 
we then used logistic regression to test for association including cohort as a covariate and modeling 
different genetic models. All genetic models we considered are described in Table 3.5 except for the 
overdominant model under which both homozygous genotypes (A/A and G/G) are baseline (    
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  ). The LRT (Equation (3.40)) was used to evaluate the significance of these findings. Lastly, we also 
explored whether there was heterogeneity of genetic effects according to gender by conducting logistic 
regression analyses in female and male patients separately. 
Analyses were carried out using PLINK (Purcell et al., 2007) and the R statistical software (R 
Core Team, 2013) and, specifically, the SNPassoc package (González et al., 2007). 
3.6.1.5 Results 
The SNP rs2660 is an A/G polymorphism with the minor allele G having a frequency of 0.36 in the 
European population (HapMap Release #28). The genotype distributions by response status and by 
cohort are given in Table 3.7 below. No deviations from HWE were observed (HWE exact test, all p-
values > 0.05). 
 
 
Table 3.7: Allele and genotype frequencies by response status and cohort for the MS patients included 
in the study. The p-value for the HWE exact test is given as well. 
 
The ORs and the 95% confidence intervals per cohort and for all patients adjusted for cohort are 
presented in a forest plot in Figure 3.4 below. 
HWE Exact Test
A G AA AG GG p-value
France
Responders 164 66% 34% 43% 45% 12% 1.00
Non-Responders 168 61% 39% 38% 46% 16% 0.75
Overall 332 (49%) 63% 37% 40% 46% 14% 0.81
Germany
Responders 123 62% 38% 39% 46% 15% 0.70
Non-Responders 83 72% 28% 47% 49% 4% 0.06
Overall 206 (60%) 66% 34% 42% 47% 11% 0.64
Italy
Responders 252 62% 38% 39% 45% 16% 0.43
Non-Responders 68 66% 34% 47% 38% 15% 0.28
Overall 320 (79%) 63% 37% 41% 43% 16% 0.19
Spain
Responders 144 60% 40% 35% 51% 14% 0.49
Non-Responders 113 71% 29% 53% 36% 11% 0.25
Overall 257 (56%) 65% 35% 43% 45% 12% 0.89
All Patients
Responders 683 62% 38% 39% 46% 14% 0.81
Non-Responders 432 66% 34% 45% 43% 12% 0.52
Overall 1115 (61%) 64% 36% 41% 45% 13% 0.48
Cell counts < 5
ALL PATIENTS
Number of Patients 
(% Responders)
Allele Genotype
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Figure 3.4: Forest plot of the stratified analyses by cohort evaluating the association between the 
OAS1 SNP rs2660 and response to interferon-β. 
 
Overall, there was no evidence that the G allele was associated with response after adjusting for cohort 
(CMH test, p-value = 0.0651). However, there was statistical evidence of non-homogeneous effects 
across cohorts (BD test, p-value = 0.016), with opposite direction of the effect in France and in the 
remaining cohorts. 
To investigate whether the heterogeneity of effects was arising due to one of the cohorts, we 
repeated the analyses four times, each time excluding one of the four cohorts. These analyses revealed 
that the genetic effects in the French cohort were significantly different from those in the remaining 
cohorts (BD test, p-value = 0.53810 when France was excluded from the analyses but p-value < 0.05 
when France was included, see Table 3.8). 
 
 
Table 3.8: CMH and BD test results after excluding one cohort at a time. 
 
We pooled the German, Italian and Spanish cohorts into one as Non-France. From here 
onwards, unless otherwise indicated, by “cohort” we refer to the France/Non-France grouping of the 
patients. 
Breslow-Day
OR 95% CI P-value P-value
France (n=332) 1.46 (1.16, 1.83) 0.0012 0.53810
Germany (n=206) 1.11 (0.91, 1.37) 0.30 0.01581
Italy (n=320) 1.18 (0.96, 1.46) 0.11 0.00579
Spain (n=257) 1.07 (0.87, 1.33) 0.51 0.03491
Excluded Cohort
Cochran-Mantel-Haenszel
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Table 3.9 below provides the association results from the logistic regression analyses. We 
observe weak evidence of association under the dominant and the log-additive models (LRT, p-values 
0.049 and 0.046, respectively). 
 
 
Table 3.9: Association results for logistic regression analysis including cohort as a covariate and 
modeling different genetic models. Statistically significant results from the LRT (uncorrected p-value 
< 0.05) are highlighted in red. AIC: Akaike Information Criterion; R: Responders; NR: Non-
Responders. 
 
Gender was not associated with response (   test on 1 df, p-value=0.26), with cohort (   test 
on 1 df, p-value=0.13) and with the SNP (   test on 1 df, p-value=0.59). Deviations from HWE were 
observed in the male cohort for all patients combined (HWE exact test, p-value = 0.026). 
The results from the logistic regression analyses in females (793 patients) and males (322 
patients) separately are given in Table 3.10 (A) and Table 3.10 (B), respectively. The association was 
significant under the overdominant model in male patients (LRT, p-value = 0.013) but not in female 
patients (LRT, p-value = 0.79). Conversely, the association was borderline significant under the 
recessive model in female patients (LRT, p-value = 0.048) but not in the male patients (LRT, p-value 
= 0.32). 
  
NR % R % OR lower upper p-value
1
AIC Log-Likelihood df
Codominant
A/A 194 44.9 268 39.2 1 0.12397 1465 -728.4573 (df=4)
A/G 186 43.1 317 46.4 1.25 0.96 1.63
G/G 52 12 98 14.3 1.39 0.94 2.05
Dominant
A/A 194 44.9 268 39.2 1 0.04879 1463 -728.6037 (df=3)
A/G-G/G 238 55.1 415 60.8 1.28 1 1.64
Recessive
A/A-A/G 380 88 585 85.7 1 0.24445 1466 -729.8676 (df=3)
G/G 52 12 98 14.3 1.24 0.86 1.79
Overdominant
A/A-G/G 246 56.9 366 53.6 1 0.24627 1466 -729.8728 (df=3)
A/G 186 43.1 317 46.4 1.16 0.9 1.48
log-Additive
0,1,2 432 38.7 683 61.3 1.2 1 1.44 0.04581 1463 -728.5508 (df=3)
1 p-value for the likelihood ratio test with respect to the model without the SNP.
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(A) 
 
(B) 
 
Table 3.10: Association results for logistic regression analysis in female (A) and male patients (B) 
including cohort as a covariate and modeling different genetic models. Statistically significant results 
from the LRT (uncorrected p-value < 0.05) are highlighted in red. AIC: Akaike Information Criterion; 
R: Responders; NR: Non-Responders. 
 
NR % R % OR lower upper p-value
1
AIC Log-Likelihood df
Codominant
A/A 142 44.9 197 41.3 1 0.12726 1059 -525.4895 (df=4)
A/G 139 44 204 42.8 1.07 0.79 1.46
G/G 35 11.1 76 15.9 1.59 1.01 2.51
Dominant
A/A 142 44.9 197 41.3 1 0.26836 1060 -526.9385  (df=3)
A/G-G/G 174 55.1 280 58.7 1.18 0.88 1.57
Recessive
A/A-A/G 281 88.9 401 84.1 1 0.04777 1057 -525.592  (df=3)
G/G 35 11.1 76 15.9 1.53 1 2.36
Overdominant
A/A-G/G 177 56 273 57.2 1 0.79172 1061 -527.5162  (df=3)
A/G 139 44 204 42.8 0.96 0.72 1.28
log-Additive
0,1,2 316 39.8 477 60.2 1.21 0.98 1.48 0.07733 1058 -525.991  (df=3)
1 p-value for the likelihood ratio test with respect to the model without the SNP.
NR % R % OR lower upper p-value
1
AIC Log-Likelihood df
Codominant
A/A 52 44.8 71 34.5 1 0.0461 402.4 -197.1777 (df=4)
A/G 47 40.5 113 54.9 1.8 1.08 3.01
G/G 17 14.7 22 10.7 0.96 0.45 2.04
Dominant
A/A 52 44.8 71 34.5 1 0.06326 403.1 -198.5297 (df=3)
A/G-G/G 64 55.2 135 65.5 1.58 0.98 2.56
Recessive
A/A-A/G 99 85.3 184 89.3 1 0.31633 405.5 -199.7526 (df=3)
G/G 17 14.7 22 10.7 0.7 0.35 1.41
Overdominant
A/A-G/G 69 59.5 93 45.1 1 0.01319 400.4 -197.1832 (df=3)
A/G 47 40.5 113 54.9 1.82 1.13 2.94
log-Additive
0,1,2 116 36 206 64 1.17 0.82 1.68 0.38307 405.7 -199.8742 (df=3)
1 p-value for the likelihood ratio test with respect to the model without the SNP.
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3.6.1.6 Concluding Remarks 
In the combined sample, the association of OAS1 SNP with interferon response was borderline 
significant under the dominant and the log-additive models (LRT, p-values < 0.05). Using the Quanto 
software (Gauderman and Morrison, 2009), we calculated the power to detect association when the 
true model is log-additive or dominant in the female and male patients at the        level of 
significance. We assumed homogeneous effects of 1.28 (dominant) and 1.20 (log-additive) for females 
and males. In the female patients, assuming a sample size of 793 individuals, the power was less than 
40% under both the genetic models. In the male patients, assuming a sample size of 322 individuals, 
the power was less than 20% under both genetic models. That is, if an association exists under the 
dominant or the log-additive model, we have very low power to detect it. Therefore, although the 
separate analyses by gender appeared to suggest possible difference in the effects of OAS1 (rs2660) in 
interferon response according to gender, the possibility that the underlying genetic model in both 
genders is the same (dominant or log-additive) cannot be excluded. At present, this study awaits 
finalization as an additional cohort from Italy will be added to the analyses. 
 
A puzzling result is the evidence of heterogeneity between the French and the remaining cohorts. 
Indeed, OAS1 SNP genetic effects on response to interferon were found heterogeneous with opposite 
direction in the France and Non-France cohorts. We performed additional analyses attempting to 
delineate the source of this heterogeneity. 
We first investigated the epidemiological and/or clinical characteristics of the French and the 
non-French patients. In fact, and as shown in Table II.5 (Appendix II), several of the tested variables 
significantly differ between the two cohorts. Specifically, the variables are: age at disease onset, 
disease severity (both EDSS at treatment onset and number of relapses 2-year prior treatment onset) 
and type of interferon, with French patients having an older age at disease onset, a more severe MS 
(higher EDSS and number of relapses) and about half of them have been treated with Avonex® (less 
than a third of the non-French patients received the same type of interferon). Therefore, we repeated 
our association analysis adjusting for clinical and epidemiological variables with and without a 
France/Non-France cohort variable to identify the variables that contribute the most to the evidence of 
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heterogeneity. We excluded age at disease onset and number of relapses because of a high rate of 
missing data. Note that age at disease onset is, nonetheless, highly correlated with age at treatment 
onset in both cohorts (correlation > 0.80). Adjusting for interferon type does not improve the model 
containing only the SNP (LRT, p-value = 0.055) but adjusting for age at treatment onset or for EDSS 
at treatment onset does (LRT, p-values = 5.9E-04 and 1.7E-05, respectively). However, the models 
including one of these two covariates have a worse fit than the model including both of them (LRT, p-
value = 2.3E-05 and = 6.9E-07 for age at treatment onset and EDSS, respectively). Yet, the 
France/Non-France cohort variable remains highly significant (LRT, p-value=1.1E-06) thus 
suggesting that factors other than age and EDSS at treatment onset underlie the genetic heterogeneity 
at OAS1. 
Table 3.11 shows the estimated ORs under the different investigated models. Under all but 
one (including age at treatment onset) multivariate models the SNP effect was more significant. 
In summary, despite adjusting for clinical/epidemiological characteristics, the genetic effects of OAS1 
on response to treatment remain heterogeneous between the France and the Non-France cohorts. From 
our data, we have been unable to isolate the underlying reason for this heterogeneity. 
 
Model Including 
SNP Effect 
OR (95% CI) 
P-value 
(Wald test) 
SNP 1.20 (1.01, 1.44) 0.045 
Age at treatment onset + SNP 1.19 (1.00, 1.43) 0.053 
EDSS at treatment onset + SNP 1.22 (1.02, 1.47) 0.031 
Age at treatment onset + EDSS at treatment onset + SNP 1.22 (1.01, 1.46) 0.036 
Cohort + Age at treatment onset + EDSS at treatment onset + SNP 1.22 (1.02, 1.47) 0.033 
Table 3.11: The estimated SNP effect and its significance after adjusting for various covariates. 
 
 
Finally, we evaluated the sensitivity of our association results to the response definition. Various 
response definitions can be found in the literature. Here, we used the same definition as used by 
O’Brien et al. (2010), Couturier et al. (2011) and Malhotra et al. (2011). They are summarized as 
Alternative Definitions 1, 2 and 3, respectively, in Table 3.12 below. These definitions apply 
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increasingly stricter threshold criteria on        and/or       as compared to our threshold criteria. 
Consequently, under these alternative response definitions, a larger fraction of patients are classified 
as “unknown” with respect to the phenotype status. For instance, over 40% of our patients are 
unclassified under Alternative Definition 3, thus far reducing the effective sample size of subsequent 
association analyses. 
 
 
Responders Non-Responders 
Unclassified 
Patients 
n (%) 
Definition 
Number 
of 
Patients 
Definition 
Number 
of 
Patients 
Study Definition 
               
       
 683 
              
       
 432 0 (0%) 
Alternative 
Definitions 
1 
             
       
 604         332 179 (16%) 
2 
             
       
 439 
              
       
 432 244 (22%) 
3 
             
       
 439 
               
       
 220 456 (41%) 
Table 3.12: Alternative response definitions and how they compare to the definition we adopted for 
this study. 
 
The statistical significance of OAS1 SNP association with interferon response decreased (p-values = 
0.09, 0.07 and 0.11 under definition 1, 2 and 3, respectively). This decrease is likely explained by the 
reduction of the effective sample size. Indeed, the SNP effect estimates remain similar (OR = 1.19, 
1.20 and 1.22 under definition 1, 2 and 3, respectively) and close to the value (OR = 1.19) obtained 
under our response definition. These results suggest that our association finding is robust to the 
threshold criteria used to define response to interferon. 
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3.6.2 Role of the integrin alpha 4 subunit (ITGA4) gene in natalizumab response 
in MS patients 
3.6.2.1 Objective 
Migration of blood into tissues is facilitated by receptors such as the Very Late Antigen-4 (VLA4, α4 
β1 integrin, integrin α/β complex). Natalizumab binds to VLA4 and prevents the migration of immune 
cells into the central nervous system. Thus, because of its mechanism, the ITGA/ITGB complex has 
been proposed as a reasonable candidate region to investigate the role of genetic variants in 
natalizumab response in MS patients. (Pappas and Oksenberg, 2010) The objective of this study was 
to investigate whether the integrin alpha 4 (ITGA4) gene is implicated in response to natalizumab. 
3.6.2.2 Dataset 
A total of 904 French RRMS patients from the BIONAT cohort (Outteryck et al., 2013) were 
genotyped for 94 SNPs in the ITGA4 gene. During quality control (QC) analyses, noninformative 
SNPs, SNPs which failed the HWE or had high missing genotype rates were removed. Similarly, 
individuals with high missing genotype rates were removed. A total of 894 individuals genotyped at 
60 SNPs were included in the study, post-QC. 
3.6.2.3 Response Definition 
The response definition for natalizumab-treated patients is much more complex than for interferon-
treated patients. It relies on clinical as well as radiological measures. Let             and     be as 
defined before (see Section 3.6.1.3). Further, let        be the new T2 lesions observed at time    
with respect to    and let        indicate the presence/absence of gadolinium enhancing (GD
+
) 
lesions at time  . In this study, response was evaluated at one year after treatment onset (         ). 
Responders, Non-Responders and Intermediary Responders were defined as described in Table 3.13 
below. 
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Responders Non-Responders Intermediary Responders 
                                           
                                                                     
                       - 
                                 - 
Table 3.13: Response classification for natalizumab-treated patients. 
 
Note that Intermediary Responders include patients who experienced relapses within the first 
three months of treatment. Natalizumab is administered through intravenous infusions on a monthly 
basis and a period of three months, that is, three infusions, could be allowed before evaluating 
treatment effectiveness. 
 
Inclusion Criteria I. Intermediary Responders were excluded from this study. Only patients who 
received treatment for at least one year were included in the study. Thus, of the 894 patients, only 734 
(431 Responders, 303 Non-Responders) met the inclusion criteria for the study. 
 
Inclusion Criteria II. Over time patients may develop antibodies against natalizumab thus reducing 
treatment efficacy. Thus, in addition to Inclusion Criteria I, we imposed an additional inclusion 
criterion including only patients who had negative antibody status, that is, they had not develop 
antibodies against natalizumab. This reduced further the study sample size to 579 patients (324 
Responders, 255 Non-Responders). Our conclusions were unchanged and we only report our findings 
under Inclusion Criteria I. 
3.6.2.4 Methods 
We conducted logistic regression analyses under the dominant and recessive models and also without 
assuming any underlying genetic model (genotypic coding, Table 3.5). Significance of the SNP-
response association results was evaluated using the LRT (Equation (3.40)). All QC and association 
analyses were carried out with PLINK (Purcell et al., 2007). We also studied the LD structure of the 
investigated region based on the    measure (Equation (2.6)) using Haploview (Barrett et al., 2005). 
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3.6.2.5 Results 
We found that only one of all 60 tested SNPs, rs155106, was associated with natalizumab response at 
the nominal significance level (uncorrected p-values of 0.045 and 0.032 under the dominant and 
genotypic coding, respectively, and 0.34 under the recessive coding). The results under the dominant 
genetic model are illustrated in Figure 3.5 below. 
 
 
Figure 3.5: Association test results under the dominant genetic model from the ITGA4 candidate gene 
study on response to natalizumab. Results are expressed as the negative logarithm of the p-value of the 
association test for all 60 SNPs tested. The most significant finding is indicated at the top center of the 
graph, the SNP rs155106. Graph generated with LocusZoom (Pruim et al., 2010). 
 
The LD structure of the investigated region is presented in Figure 3.6. The SNP rs155106 is 
circled in blue on the graph. A preliminary scan on fewer patients was carried out by former 
colleagues (Couturier, 2010) and two plausible SNPs had been identified. These two SNPs are also 
circled, in red, in the figure below. 
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Figure 3.6: LD plot (based on    , Equation (2.6)) for the ITGA4 gene. The SNP rs155106 from the 
candidate gene study (circled in blue) and two SNPs from the preliminary study conducted by 
(Couturier, 2010) (circled in red) are noted. Graph generated with Haploview (Barrett et al., 2005). 
 
From Figure 3.6, we can see that the most significantly associated SNP from this study, 
rs155106 (circled in blue), is located in a block of weak LD. Note that this was also apparent from 
Figure 3.5. It can also be seen from Figure 3.6 that the two previously suggested SNPs (circled in red 
on the graph) from the preliminary analyses appear to be independent of rs155106. 
3.6.2.6 Concluding Remarks 
Overall, given the large number of tests carried out (multiple SNPs and two different inclusion criteria 
scenarios), we concluded that this study failed to provide evidence that the ITGA4 gene was implicated 
in response to natalizumab in our cohort of French MS patients. 
We note that, contrary to the study on interferon response, here we evaluated only one 
response definition which also included radiological measures. While no consensus on the actual 
response definition exists, it is believed that combining radiological measures (when available) with 
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clinical measures can lead to more precise evaluation of treatment response. (Río et al., 2009) This is 
because the disease may be active even if there are no clinical manifestations of it. 
Dropping the radiological criteria from our response definition may reclassify Non-
Responders into Responders but never the other way around. Using both clinical and radiological 
criteria, there were 431 Responders and 303 Non-Responders (under Inclusion Criteria I). Without the 
radiological criteria, 41 Non-Responders would be reclassified or, even worse, “misclassified” as 
Responders. 
 
Genome-wide data for all patients from the BIONAT cohort (Outteryck et al., 2013) are being 
generated at the time of writing this manuscript and a GWAS of natalizumab response is planned 
ahead. We describe this upcoming work in greater detail in the concluding chapter of this thesis. 
3.6.3 Multi-Marker Modeling of GWAS Data on Parkinson’s Disease 
3.6.3.1 Background 
Hundreds of thousands to millions of SNPs nowadays are tested in a sample of tens of thousands of 
individuals (ideally). The sample sizes are unlikely to ever reach the number of SNPs tested. Thus, in 
order to carry out simultaneous analyses of all SNPs, we run into the high dimensionality,     , 
problem where   represents the number of SNPs and   the number of individuals. In a multivariate 
framework, when     or    , classical regression methods fail and alternative modeling 
approaches reducing the dimension of the parameter space need to be used. Two main classes of such 
approaches are penalized estimation methods and Bayesian estimation methods. 
In penalized estimation methods, a penalty function is applied to shrink the marker effect 
estimates towards zero relative to their maximum likelihood estimates. Some methods apply the same 
large penalty to all estimates whereas others apply large penalties to some estimates and small 
penalties to the remaining estimates. Thus, the defining factor for these methods is the choice of the 
penalty function. 
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Bayesian estimation methods, on the other hand, require the specification of a prior 
distribution on the marker effects. There is a close relationship between these two classes of 
approaches. In particular, certain penalty functions lead to empirically equivalent estimates under 
certain priors. 
We were thus interested in evaluating how the multi-marker approaches would fare compared 
to the single-marker approach. We note that all of these more sophisticated approaches have been 
primarily used for estimating breeding values in the animal and plant breeding literature and only 
recently their application to human genetics has been considered. 
3.6.3.2 Materials and Methods 
We compared several multi-marker approaches with a focus on Bayesian estimation methods using 
GWAS data on Parkinson’s disease (PD) of 3023 French subjects (1039 cases, 1984 controls) and 
almost 500 000 SNPs. A recent GWAS conducted by our colleagues on this dataset had confirmed the 
association of known PD genes such as SNCA and had identified novel ones such as BST1 in the 
European population (Saad et al., 2011a). 
We treated the disease status as a continuous outcome variable. The linear model is given by 
            (3.55) 
where   is     vector of phenotypes,   is the     incidence matrix,   is     vector of 
covariates,   is a     matrix of observed genotypes (typically coded under the additive genetic 
model),   is the     vector of SNP effects and   is the      vector of random residual effects 
where     (    
 ). 
In a Bayesian regression setting, a prior on            that depends on the SNP-specific 
variance,    
 , and on the proportion of SNPs, π, expected to be associated with the complex trait is 
specified. This prior function is given by 
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                  (   )
 (     
 )                   
  
(3.56) 
Depending on the choice of these two parameters, namely,    
  and  , different Bayesian models have 
been proposed and have sometimes been referred to under the umbrella term “The Bayesian Alphabet” 
coined by (Gianola et al., 2009). Such models include but are not limited to Bayes A and B 
(Meuwissen et al., 2001) and later extensions Bayes C/Cπ and D/Dπ (Habier et al., 2011). Table 3.14 
compares the parameterization of these four models for illustrative purposes. 
 
Model    
    
Bayes A 
SNP-specific variance,  
   
          
    
Bayes B 
SNP-specific variance,  
   
          
    
Bayes C   
common variance to all SNPs, 
   
     
          
         (   )  
(i.e., treated as unknown) 
Bayes D   
SNP-specific variance,  
   
          
         (   )  
(i.e., treated as unknown) 
Table 3.14: Comparing the parameterization of Bayes A, B, C   and D   models. 
 
The difference between the models lies in whether   is treated as fixed and known or as random and 
unknown and in whether the SNP effects follow a common or SNP-specific random distribution. 
Regardless, the variance in all four models is assumed to follow the scaled inverse    distribution with 
ν degrees of freedom. 
We compared three multi-marker models. The parameter specifications of the three models are 
given in Table 3.15 below. All models were fitted using the GS3 software (Legarra et al., 2011). 
 
 
 
 
 
GENETIC ASSOCIATION STUDIES 
78 
Model    
    Note 
I 
common variance to all SNPs, 
   
     
         , 
fixed, known 
    
Reduces to the popular 
Best Linear Unbiased 
Predictor (BLUP) 
(Henderson, 1975) 
II 
common variance to all SNPs, 
   
     
           
random, unknown 
         (   ) 
(i.e., treated as unknown) 
Bayes C   
III 
common variance to all SNPs, 
   
     
         , 
random, unknown 
         
fixed, known 
Bayes C 
Table 3.15: Multi-marker models we evaluated on the PD GWAS dataset. 
 
A numerical iterative method (Gauss-Siedel) was used to derive the estimates from Model I 
and a Markov Chain Monte Carlo algorithm (Gibbs sampler) was used for Models II and III (as 
implemented in the GS3 software). We used 100 000 iterations for Model II and 500 000 iterations for 
Model III after ignoring the first 5 000 iterations (burn-in). Convergence criteria (difference between 
solutions of successive iterations less than 10
-8
) were achieved within 100 iterations for Model I. 
Convergence for Models II and III was visually inspected using traceplots (plotting the sampled 
parameter value at each iteration against the iteration number). 
Lastly, to evaluate the evidence of association of the estimated effects by the multi-marker 
models, we ranked the SNPs by the absolute value of their effect estimates. 
3.6.3.3 Results 
Focusing on SNCA, BST1 as well as on two other known PD genes (MAPT and LRRK2), we compared 
the ranking of the SNPs in these genes obtained by the three methods and also compared them to the 
ranks obtained based on the p-values of the estimated effects by the GWAS. Based on the results 
illustrated in Table 3.16, the three multi-marker models appeared to detect the known PD genes. 
The ranks for all SNPs were relatively highly correlated between methods. For example, the 
correlation between Model I and GWAS ranks was 0.43. However, the best SNP rank within a gene 
was not found at the same SNP. Importantly, the SNP effect estimates were on a very different scale 
depending on the model as illustrated, for example, in Figure 3.7 comparing Models II and III. 
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Gene ± 1 Mb Number of SNPs Model I Model II Model III GWAS 
 ̂ Rank  ̂ Rank  ̂ Rank  ̂ P-value Rank 
SNCA 323 -1.8 E-04 1 -5.0 E-04 1 -0.0537 2 0.29 1.3 E-07 1 
BST1 455 1.4 E-04 4 3.6 E-04 8 0.0149 16 -0.27 2.1 E-06 6 
MAPT 330 1.3 E-04 8 3.4 E-04 18 0.0098 26 -0.29 7.30 E-06 8 
LRRK2 713 9.4 E-05 504 2.5 E-04 683 -0.0016 126 0.3535 0.000271 168 
Table 3.16: The SNP effect estimate and the corresponding SNP rank within known PD genes (± 1Mb) for the three multi-marker models, Models I, II, III 
and GWAS. 
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Figure 3.7: Absolute value of SNP effect estimates obtained by Model II (top) and Model III (bottom) 
plotted against the SNP position. The red dashed line on the graph of Model III corresponds to the 
maximum absolute SNP effect estimate under Model II. 
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It took a couple of minutes to run Model I, while it took at least 4 days per 100 000 iterations for 
Model II (used 100 000 iterations) and Model III (used 500 000 iterations). Running times were 
slower for Model II than for Model III due to the additional unknown parameter (the proportion of 
SNPs having an effect,  ). For Model III, the SNP effect estimates remained relatively unchanged 
beyond 300 000 iterations. For Model II, the proportion of SNPs having an effect,  , appeared to reach 
a plateau at just about 100 000 iterations (results not shown). 
3.6.3.4 Discussion and Conclusions 
In this study, we investigated three different multi-marker models (Models I, II and III) to detect SNP-
disease associations in a French Parkinson’s disease GWAS dataset. Focusing on known associated 
genes, we also compared the results from these models to the results from a recent GWAS conducted 
in this same dataset. 
In Model I, the SNP effect variance was treated as a known and fixed quantity and all SNPs 
were assumed apriori to exert an effect on the trait. In Models II and III, the SNP effect variance was 
unknown and estimated from the data. In Model II, the proportion of SNPs exerting an effect was 
treated as unknown while, in Model III, it was assumed to be 0.0001 (only about 50 SNPs influence 
the trait). 
Contrary to the single-marker approach, there is no formal statistical test to evaluate the 
significance of the SNP-specific effects in multi-marker models. To circumvent that, we ranked the 
SNPs by the absolute value of their effect estimate and compared the SNP ranks between the models. 
Our main observations were as follows. First, focusing on four known genes (SNCA, BST1, 
MAPT and LRRK2), we found that the SNP ranks from Model I were closest to the SNP ranks from 
the GWAS (obtained by ranking the p-value of the association test). However, the best rank was not 
observed at the same SNP. 
Second, the scale of the SNP effect estimates obtained by Model III was a couple of hundred 
times higher than that of the other two multi-marker models. This was not surprising since in Model I, 
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for instance, we assumed that all SNPs (approximately half a million) exert an effect, while in Model 
III we limited this number to only 50 SNPs. Thus, the overall additive genetic variance was spread 
over fewer SNPs in Model III. 
Third, the required number of iterations varied by model in the order of 100 for Model I and in 
the order of 100 000 for Models II and III. Consequently, the running times for Models II and III were 
longer, in the order of days, while Model I estimates were obtained within a couple of minutes. For 
Model III, 500 000 iterations appeared largely sufficient as no apparent difference in the SNP effect 
estimates were observed beyond 300 000 iterations. Compared to Model III, Model II had an 
additional unknown parameter, the proportion of SNPs exerting an effect. Although 100 000 iterations 
appeared to be sufficient for this model, it would have been interesting to carry out a higher number of 
iterations. 
Overall, our study suggests that the multi-marker models we evaluated may seem a promising 
tool to detect association of genetic variants with complex traits. However, important considerations 
include the fact that there is no formal statistical test evaluating significance of the SNP effects, 
complex parameterization and heavy computational burden. Therefore, the advantages of multi-marker 
models over the classical GWAS approach remain to be fully investigated. 
 
This work was presented as an oral communication at the European Mathematical Genetics 
Meeting in 2012 and as a poster at the 21
st
 Annual International Genetic Epidemiology Society 
Meeting in 2012. 
3.6.4 Polygenic Score Analyses of Simulated Diastolic Blood Pressure Data 
3.6.4.1 Background 
The one SNP at a time analytical approach adopted by GWASs does not have sufficient power to 
detect SNPs of weak effects at the imposed stringent genome-wide statistical significance levels. 
Therefore, it is possible that a substantial number of causal SNPs remain undetected by GWASs. A 
recent method that has drawn considerable attention so far proposes to account for SNPs having a 
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wide spectrum of effects by aggregating them into a polygenic score (PS) and testing the PS for 
association with the trait. (Purcell et al., 2009) 
Typically, the PS is constructed in two steps. First, the set of SNPs to be included in the score 
is selected. The criteria for SNP selection vary between studies but it is crucial that this set contains 
only independent SNPs to avoid the inclusion of non-independent association signals. Further, this set 
must exclude all established variants as they would drive the association of the PS with the trait 
masking the weaker effects that we are precisely looking to detect. Second, the reference alleles of 
these SNPs may be combined in an unweighted or weighted manner. The former approach assumes 
that all SNPs have the same effect size which oversimplifies the context we are trying to evaluate (that 
is, a mixture of different effect sizes). In the latter approach, on the other hand, each reference allele is 
weighted by its effect estimated in a discovery dataset. 
Based on this theoretical framework, we conducted a study as part of our participation in the 
Genetic Analysis Workshop 18 (GAW18), where we compared PS association analyses using sets of 
SNPs derived from a single-marker and a multi-marker approach. We were interested in evaluating the 
value of PS association analysis in shedding light on the true genetic architecture of complex traits. 
3.6.4.2 Materials and Methods 
Study Dataset. We used the pedigree dataset provided by GAW18 on simulated blood pressure data 
for roughly 900 individuals (from 20 families) genotyped at more than 8.3 million SNPs. A trait, Q1, 
was highly heritable (heritability of 0.68) but was uninfluenced by any of the SNPs and was provided 
to control for Type I Error. We adjusted the simulated traits for age and gender in a linear regression 
framework. A total of 200 replicate datasets were made available but the genotypes were the same 
across the replicates. 
We carried out all our analyses with knowledge of the underlying simulated model. There 
were 1 457 SNPs (in 288 genes) contributing to diastolic blood pressure (DBP) and/or systolic blood 
pressure (SBP) variability. The individual contribution of the genes ranged from as low as 0.001% for 
gene ZZEF1 to as high as 6.5% for gene MAP4 (for DBP). In addition, part of the total variability was 
due to 1 000 SNPs, randomly selected in each replicate. 
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Methods: Analyses Restricted to Associated SNPs/Genes. We first estimated the power to detect 
association with any of the contributing genes accounting for family relatedness using the Measured 
Genotype (MG) test (mixed-linear regression model) (Boerwinkle and Sing, 1987), as implemented in 
QTDT software (Abecasis et al., 2000a; Abecasis et al., 2000b). Single-marker MG test was 
conducted for each SNP using all 200 replicates. We found that MAP4 was the only gene detectable 
(power = 96%) at the genome-wide significance level (p-value < 1E-08), which accounts for the 
largest percentage of the variance of DBP and contains several SNPs three of which had very strong 
individual effects each contributing more than 1% to the trait variability. Any of the remaining SNPs 
or genes were unlikely to be detected at stringent significance criteria (power < 50%). 
We estimated that we would need approximately 40 days to carry out one genome-wide 
association study using the MG test in one replicate for one phenotype. We had 200 replicates and two 
phenotypes (DBP and Q1). Therefore, due to these computational constraints, we took an alternative 
strategy working on the traits adjusted for family relatedness. We derived these new traits using 
GRAMMAR (Aulchenko et al., 2007a) as implemented in the GenABEL add-on package (Aulchenko 
et al., 2007b) developed for the R statistical software (R Core Team, 2013). As such, the classical 
single-marker linear model could be used. 
Lastly, since our goal was to evaluate whether power to detect association with SNPs with 
weak effects could be enhanced by pooling their effects, we further adjusted the de-correlated trait 
DBP for the strong effects of MAP4 (SNPs 3_48040283 and 3_48064367). 
 
Methods: Whole-Genome Analyses. First, in a discovery dataset (in our case it was replicate 1), we 
identified the set of top SNPs,  , varying the size of  ,    {                            }. For 
each SNP we derived two effect estimates, one through a classical single-marker (SM) analysis 
whereby each effect was estimated one at a time and the other through a multi-marker (BLUP, see 
Model I in Table 3.15) analysis whereby all effects were estimated simultaneously. If the SM 
approach was used to obtain the SNP estimates, the SNPs were ranked by the p-value of their effect 
estimate. If BLUP was used, the SNP were ranked based on the absolute value of their effect estimate. 
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In order to ensure that   contained only independent SNPs, the best SNP over a window of 100kb was 
retained until the full SNP map had been covered. (We also considered larger window sizes of 1Mb 
and 5Mb but the results were similar and are not reported here.) 
Second, we constructed the PS as follows 
     ∑ ̂ 
 
   
     
(3.57) 
where     is the polygenic score for the  
th
 individual,   is the size of the set of SNPs to combine,  ̂  is 
the estimated effect of SNP   in the discovery dataset and     is the number of reference alleles of the 
SNP   for the  th individual in an independent dataset (in our case it was replicates 2 through 200). 
Third, we tested for association between PS and the analyzed trait in replicates 2 through 200 
and we calculated the percentage of replicates in which the association was significant at different 
nominal p-values. Figure 3.8 below provides a schematic representation of our study design. 
 
 
Figure 3.8: Schema of the study design for the GAW18 data. 
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Methods: Evaluating Empirical Type I Error Rates. To evaluate the significance of our findings, we 
carried out PS association analyses in three different scenarios. First, we evaluated the associations 
with the Q1 trait which, we recall, was uninfluenced by any of the genotyped SNPs. Second, we 
evaluated the associations after permuting the DBP trait within family once in each replicate (n=199 
permutations). However, since the number of replicates/permutations was restricted to 199, we could 
only estimate the replication rates at nominal p-value of 0.05.Therefore, to obtain estimates of the 
replication rates at more stringent criteria levels (nominal p-values < 1E-04), we further permuted 
DBP within families 1 000 times in 100 of the replicates thus obtaining 100 000 permutations in total.  
Third, we also conducted PS association analyses with DBP or Q1 using a set of randomly chosen 
SNPs rather than SNPs selected based on their evidence of association. To compute the PS, we used 
the SNP effect estimates derived by each approach (SM or BLUP). 
3.6.4.3 Results 
Replication Rates. Figure 3.9 below illustrates the replication rates we obtained for the DBP trait. For 
the SM strategy, we see that the replication rates tend to increase with the SNP set size until reaching a 
peak at        SNPs after which they begin to decline especially at stringent significance criteria 
levels (p-value ≤ 1E-05). For the BLUP strategy, the peak is reached at          SNPs after which 
the replication rates tend to remain stable. Irrespective of the strategy, however, the replication rates 
are rather high especially at less stringent criteria (1E-03 ≤ p-value ≤ 0.05) and for larger set sizes 
(         ) where they are nearly always at or close to 100%. For smaller set sizes, (       ), 
replication rates are greater under the SM than under the BLUP strategy. The opposite trend is 
observed for larger set sizes (       ). 
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Figure 3.9: Percentage of replicates (out of replicates 2 through 200) with significant evidence of 
association of PS with DBP at a given nominal p-value by SNP set   derived using either Single-
Marker or BLUP strategies in replicate 1. 
 
Empirical Type I Error Rates. The results for Q1, permuted DBP and random SNP set at nominal p-
value of 0.05 are presented in Table 3.17. The results for lower significance thresholds for the 
permuted DBP and the random SNP set are presented in Table 3.18 and Table 3.19, respectively. 
From Table 3.17, we see that, for Q1, the estimated replication rates did not differ 
significantly from their expected theoretical value of 0.05, whether the top SNPs were selected under 
the SM or BLUP and irrespective of the set size,  . In the case of permuted DBP, we obtained slightly 
inflated rates especially for larger set sizes   and under the BLUP strategy (ranging from 8% to 12% 
and from 6% to 17% under SM and BLUP strategies, respectively, or alternatively expressed as fold 
difference, ranging from 1.51 to 2.41 times higher than 0.05 under SM and from 1.21 to 3.42 times 
higher under BLUP). At lower significance thresholds (Table 3.18), except for      under the 
BLUP strategy, all replication rates were inflated and the inflation was a lot more pronounced under 
the SM than under the BLUP approach. For instance, at nominal p-value < 0.1%, the replication rates 
were between 5.55 and 12.56 times higher than expected under SM and between 0.91 and 5.48 times 
higher under BLUP. 
Lastly, for the association analyses with DBP using a random SNP set, the replication rates 
increased with the SNP set size for both approaches and the rates under the SM strategy were at least 
as high as those under BLUP. For larger SNP sets (       ) and irrespective of the significance 
threshold, the replication rates under both approaches were at or nearly 100%. However, for the 
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smaller SNP sets (       ), the stricter the imposed significance threshold, the larger the observed 
difference in the replication rates between SM and BLUP (Table 3.19). For instance, for        , 
the replication rate under BLUP was close to that under SM at nominal p-value of 0.05 but was almost 
half of that of SM at nominal p-value of 1E -04. In contrast, applying the random SNP set strategy on 
Q1, we obtained replication rates that were close to their theoretical values irrespective of the 
approach (results not shown). 
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n = 199 
EMPIRICAL TYPE I ERROR RATES AT α = 0.05 
S = 10 S = 50 S = 100 S = 1000 S = 5000 S = 10000 
Q1 Single-Marker Ratio
1
 1.11 1.41 1.21 0.90 0.90 1.31 
  
95% CI
2
 (0.0235, 0.0871) (0.0349, 0.1059) (0.0272, 0.0934) (0.0163, 0.0741) (0.0163, 0.0741) (0.031, 0.0996) 
 
BLUP Ratio 1.11 1.51 1.41 1.31 1.21 1.11 
  
95% CI (0.0235, 0.0871) (0.0387, 0.1121) (0.0349, 0.1059) (0.031, 0.0996) (0.0272, 0.0934) (0.0235, 0.0871) 
                  
Permuted DBP Single-Marker Ratio 2.41 2.11 2.21 2.21 1.51 1.51 
  
95% CI (0.0754, 0.1658) (0.0628, 0.1482) (0.067, 0.1542) (0.067, 0.1542) (0.0387, 0.1121) (0.0387, 0.1121) 
 
BLUP Ratio 1.21 2.11 1.51 2.91 3.42 2.91 
  
95% CI (0.0272, 0.0934) (0.0628, 0.1482) (0.0387, 0.1121) (0.0967, 0.1947) (0.1186, 0.2232) (0.0967, 0.1947) 
  
  
      
Random SNP Set Single-Marker Ratio 1.91 3.42 15.78 20.00 20.00 20.00 
  
95% CI (0.0547, 0.1363) (0.1186, 0.2232) (0.7322, 0.8456) - - - 
 
BLUP Ratio 0.70 2.31 4.72 19.60 20.00 20.00 
  
95% CI (0.0096, 0.0608) (0.0712, 0.16) (0.1772, 0.2952) (0.9604, 0.9994) - - 
                  
1
Ratio of empirical estimate to nominal value. 
      295% CI for empirical estimate. 
        
Table 3.17: Empirical Type I Error rates and 95% confidence intervals (CI) under three scenarios: (1) with trait Q1 uninfluenced by any of the SNPs, (2) with 
permuted DBP within family thus breaking the association between the SNPs and DBP, and (3) with DBP using a randomly chosen sets of top SNPs (the same 
sets were used for both Single-Marker and BLUP). Rates were estimated based on 199 replicates. Due to the small number of replicates, only estimates at 
nominal p-value = 5% are given. Cases where the empirical estimate significantly exceeds the nominal value are underlined. 
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Permuted DBP, n = 100 000 
EMPIRICAL TYPE I ERROR RATES AT A GIVEN THRESHOLD 
S = 10 S = 50 S = 100 S = 1000 S = 5000 S = 10000 
p-value < 0.05 Single-Marker Ratio
1
 2.53 2.74 3.37 4.04 3.51 2.93 
  
95% CI
2
 (0.1243, 0.1285) (0.1348, 0.139) (0.1664, 0.171) (0.1995, 0.2045) (0.1732, 0.178) (0.1441, 0.1485) 
 
BLUP Ratio 0.99 1.44 1.53 2.35 2.46 2.47 
  
95% CI (0.0481, 0.0507) (0.0704, 0.0736) (0.075, 0.0782) (0.1156, 0.1196) (0.1211, 0.1251) (0.1213, 0.1253) 
                  
p-value < 0.01 Single-Marker Ratio 3.67 3.91 5.14 6.80 5.65 4.72 
  
95% CI (0.0355, 0.0379) (0.0379, 0.0403) (0.05, 0.0528) (0.0664, 0.0696) (0.0551, 0.0579) (0.0459, 0.0485) 
 
BLUP Ratio 0.96 1.75 1.88 3.35 3.53 3.59 
  
95% CI (0.009, 0.0102) (0.0167, 0.0183) (0.018, 0.0196) (0.0324, 0.0346) (0.0342, 0.0364) (0.0347, 0.0371) 
                  
p-value < 0.001 Single-Marker Ratio 5.91 5.55 8.10 12.56 9.48 8.51 
  
95% CI (0.0054, 0.0064) (0.0051, 0.0061) (0.0075, 0.0087) (0.0119, 0.0133) (0.0089, 0.0101) (0.0079, 0.0091) 
 
BLUP Ratio 0.91 1.94 2.39 4.99 5.38 5.48 
  
95% CI (0.0007, 0.0011) (0.0016, 0.0022) (0.0021, 0.0027) (0.0046, 0.0054) (0.0049, 0.0059) (0.005, 0.006) 
  
  
      p-value < 0.0001 Single-Marker Ratio 7.80 7.70 9.80 21.00 15.00 17.00 
  
95% CI (0.0006, 0.001) (0.0006, 0.001) (0.0008, 0.0012) (0.0018, 0.0024) (0.0013, 0.0017) (0.0014, 0.002) 
 
BLUP Ratio 0.80 2.20 2.70 7.80 8.00 7.30 
  
95% CI (0, 0.0002) (0.0001, 0.0003) (0.0002, 0.0004) (0.0006, 0.001) (0.0006, 0.001) (0.0005, 0.0009) 
                  
1
Ratio of empirical estimate over nominal value. 
      2
95% CI for empirical estimate. 
       
Table 3.18: Empirical Type I Error rates and 95% confidence intervals (CI) for scenario (2) of Table 3.17 with the number of permutations increased from 
once in each replicate (n=199) to 1 000 times in 100 replicates (n=100 000). Cases where the empirical estimate significantly exceeds the nominal value are 
underlined.  
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Random SNP Set, n = 199 
EMPIRICAL TYPE I ERROR RATES AT A GIVEN THRESHOLD 
S = 10 S = 50 S = 100 S = 1000 S = 5000 S = 10000 
p-value < 0.05 Single-Marker Ratio
1
 1.91 3.42 15.78 20.00 20.00 20.00 
  
95% CI
2
 (0.0547, 0.1363) (0.1186, 0.2232) (0.7322, 0.8456) - - - 
 
BLUP Ratio 0.70 2.31 4.72 19.60 20.00 20.00 
  
95% CI (0.0096, 0.0608) (0.0712, 0.16) (0.1772, 0.2952) (0.9604, 0.9994) - - 
                  
p-value < 0.01 Single-Marker Ratio 1.01 4.02 51.76 100.00 100.00 100.00 
  
95% CI [0, 0.024) (0.0129, 0.0675) (0.4482, 0.587) - - - 
 
BLUP Ratio 0.50 1.01 5.03 91.46 100.00 100.00 
  
95% CI [0, 0.0148) [0, 0.024) (0.0199, 0.0807) (0.8758, 0.9534) - - 
                  
p-value < 0.001 Single-Marker Ratio 0.00 10.05 180.90 994.97 1000.00 1000.00 
  
95% CI - [0, 0.024) (0.1274, 0.2344) (0.9852, 1.00] - - 
 
BLUP Ratio 0.00 0.00 5.03 688.44 1000.00 1000.00 
  
95% CI - - [0, 0.0148) (0.624, 0.7528) - - 
  
  
      p-value < 0.0001 Single-Marker Ratio 0.00 0.00 502.51 9396.98 9949.75 10000.00 
  
95% CI - - (0.0199, 0.0807) (0.9066, 0.9728) (0.9852, 1.00] - 
 
BLUP Ratio 0.00 0.00 0.00 4120.60 9798.99 9748.74 
  
95% CI - - - (0.3437, 0.4805) (0.9604, 0.9994) (0.9532, 0.9966) 
                  
1
Ratio of empirical estimate over nominal value. 
      2
95% CI for empirical estimate. 
             
Table 3.19: Empirical Type I Error rates and 95% confidence intervals (CI) for scenario (3) of Table 3.17 for stricter significance thresholds. Cases where the 
empirical estimate significantly exceeds the nominal value are underlined. If the confidence limit exceeded 0 or 1, the interval was truncated (denoted by “[” 
or “]”). 
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We estimated the probability of choosing a SNP lying in a true gene (as given by the 
simulated model) to be around 0.02 given by the proportion of SNPs lying in true genes out of all 
SNPs. Next, the probability that, say, in a set of ten SNPs there is at least one SNP lying in a true gene 
is 1-(0.98)
10
 = 0.18. Obviously, this probability increases and approaches one as the SNP set size   
increases. We recall that we used windows of size 100kb to identify independent SNPs. Given the 
density of our SNP map, this produced roughly 13 000 windows and thus a set size of          
(that is, top 10 000 windows) approaches full genome coverage. 
Of course, not all genes exert the same influence on the trait and, among the genes implicated, 
not all SNPs within a gene carry the same weight (effect size). Thus, while the composition of the 
random SNP set might be representative of the number of SNPs that were simulated to have an effect 
on DBP, the association results were impacted by the strategy due to the effect estimates that these 
SNPs exert on the trait. The scale of the SNP weights in the PS (that is, the effect estimates) differ 
significantly across the two approaches. In fact, the effect estimates by SM are orders of magnitude 
larger than the BLUP estimates. As an example, the mean and standard deviation of the SNP effects in 
the set of top ten SNPs (    ) is -3.03±7.53 for SM and -7.3E-05±1.7E-04 for BLUP. 
Finally, we compared the replication rates under SM and BLUP between the two Type I Error 
evaluating scenarios: permuted DBP and random SNP set. In absolute terms, the replication rates were 
very different between the scenarios (Table 3.18 and Table 3.19). When using permuted DBP, the 
replication rates under SM increased with increasing SNP set size until         after which they 
began to decline while, when using a random SNP set, the rates continued to increase reaching 100% 
for large SNP sets (       ). For BLUP, the replication rates tended to increase with increasing 
SNP set size in both scenarios also reaching 100% for large SNP sets (       ) when using a 
random SNP set but not when using permuted DBP. 
Irrespective of the significance threshold, for large SNP sets (       ), the replication rates 
under SM and BLUP were higher when using a random SNP set than when using permuted DBP. 
Conversely, for very small SNP set sizes (    ), the replication rates under SM or BLUP were 
lower when using a random SNP set than when using permuted DBP. Thus, for      or S      , 
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SM and BLUP behaved similarly. However, for      or    , SM and BLUP behaved differently 
depending on the scenario. For these two SNP sets, the replication rates under SM tended to be higher 
when using a random SNP set than when using permuted DBP but, under BLUP, were lower (even 
zero at strict significance thresholds, p-values < 0.0001). 
In relative terms, we noted that the replication rates under SM were always at least as high as 
those under BLUP. To see this, we plotted the ratio of the replication rate in SM versus BLUP for each 
SNP set size and for each evaluated significance threshold in both scenarios. The results are given in 
Figure 3.10 below. At the 0.05 significance threshold, a similar trend was observed whether permuted 
DBP or random SNP set was used, that is, the ratio decreased with increasing set size from 2.56 
(      ) to 1.19 (        ) when using permuted DBP and from 2.71 (    ) to 1.00 (   
       ) when using a random SNP set. The same trend was also observed at stricter significance 
thresholds only when using permuted DBP. In contrast, when using a random SNP set, the ratio of 
replication rates in SM versus BLUP increased up until       and then dropped reaching one for 
larger SNP set sizes (       ). 
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Figure 3.10: Ratio of empirical Type I Error rates of Single-Marker to BLUP for permuted DBP (left) and for the random SNP set (right). A dash “-” in the 
table above the right graph indicates that the replication rate under BLUP was zero. 
 
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
0.05 0.01 0.001 0.0001
Permuted DBP
Empirical Type I Error Rates: 
RateSingle-Marker / RateBLUP
S = 10
S = 50
S = 100
S = 1000
S = 5000
S = 10000
0.0
5.0
10.0
15.0
20.0
25.0
30.0
35.0
40.0
0.05 0.01 0.001 0.0001
Random SNP Set
Empirical Type I Error Rates: 
RateSingle-Marker / RateBLUP
S = 10
S = 50
S = 100
S = 1000
S = 5000
S = 10000
p-value S = 10 S = 50 S = 100 S = 1000 S = 5000 S = 10000
0.05 2.71 1.48 3.34 1.02 1.00 1.00
0.01 2.00 4.00 10.30 1.09 1.00 1.00
0.001 - - 36.00 1.45 1.00 1.00
0.0001 - - - 2.28 1.02 1.03
Random SNP Set (RateSingle-Marker / RateBLUP)
p-value S = 10 S = 50 S = 100 S = 1000 S = 5000 S = 10000
0.05 2.56 1.90 2.20 1.72 1.43 1.19
0.01 3.83 2.23 2.73 2.03 1.60 1.31
0.001 6.49 2.86 3.39 2.52 1.76 1.55
0.0001 9.75 3.50 3.63 2.69 1.88 2.33
Permuted DBP (RateSingle-Marker / RateBLUP)
GENETIC ASSOCIATION STUDIES 
95 
3.6.4.4 Discussion and Conclusions 
Overall, using a classical single-marker approach accounting for family relatedness to detect 
association, we found that, with the exception of the SNPs in the MAP4 gene, there was no power to 
detect SNPs of weaker effect at the genome-wide significance level. Through PS association analyses, 
we achieved high replication rates whether SM or BLUP was used especially when large sets of SNPs 
(≥ 1 000) were considered. However, we noted that the replication rates under SM began to decline for 
larger SNP sets (       ) especially at stringent criteria levels. This may be happening due to much 
more noise being added with larger SNP set sizes. However, the empirical Type I Error rates were 
elevated and question whether the actual power of the PS approach is well estimated by these 
replication rates. 
When no SNPs influenced the trait (Q1), the replication rates for both approaches were close 
to their theoretical values. When SNPs influenced the trait but these relationships were broken by 
permuting the trait within family, the replication rates were inflated under both SM and BLUP. This 
trend was exacerbated at stringent significance criteria levels (p-value < 1E-04) and more so under SM 
than under BLUP. Further, when SNPs were chosen randomly versus based on evidence of 
association, we obtained high replication rates for larger SNP sets (≥ 5 000) irrespective of the strategy 
to derive the SNP effect estimates. This was because with this SNP set sizes, we approached full 
genome coverage thus likely including all causal variants. For smaller SNP sets, however, the 
replication raters were higher under SM than under BLUP and this difference became more profound 
the stricter the significance threshold. In fact, small SNP sets were likely to contain functional variants 
and yet the replication rates under BLUP were zero suggesting that BLUP is possibly conservative. 
We recall that the genotypes were the same across replicates making it challenging to ensure 
that we have arrived at evaluating correctly the Type I Error rates. While the error rates appeared well 
controlled for Q1 at the 0.05 significance threshold, we recall that this trait although heritable was 
uninfluenced by any of the SNPs. In contrast to Q1, DBP was influenced by roughly 1 500 functional 
SNPs and 1 000 randomly chosen SNPs in each replicate (polygenic component). 
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This dataset was a family dataset and we used a de-correlation technique by adjusting the trait 
for family relatedness to render the individuals “unrelated.” This is a required assumption for the 
single-marker analyses. However, in the BLUP model, the family structure can be recovered from the 
genome-based relationship matrix and thus adjusted for. (Goddard, 2009) One explanation for the 
particularly inflated rates we observed under SM, therefore, might be that linkage may have affected 
the PS association analyses. In the provided GAW18 pedigree dataset (approximately 900 related 
individuals from 20 pedigrees) there were roughly 150 unrelated individuals. Despite this small 
sample size, it could have been interesting to run our analyses on this set of individuals and evaluate 
whether we would observe the same trends, that is, higher replication rates under SM than under 
BLUP. 
We conclude that the SM approach to PS association analysis should not be used with large 
SNP sets (≥ 5 000) – for these set sizes it performed equally well as choosing SNPs at random. For 
smaller sets of top SNPs, however, it remains a preferable approach to BLUP. However, if we 
controlled well for Type I Error, we point out that the power remained low to detect SNPs of weaker 
effect through PS association analyses. 
Dudbridge (2013) derived a closed form expression of the power of the PS association method 
to detect variants of weak effect as a function of a number of parameters including the sample size for 
the discovery and replication datasets and the SNP weighting method used in the PS (weighted and 
unweighted). Using a simulation study, he found that power was high under both weight alternatives 
but was much higher when the SNPs were weighted by their effect estimates than when the SNPs were 
unweighted (that is, when each SNP carried an equal weight in the score). Also, he showed that low 
power could be due to small discovery sample size. 
We recall that the BLUP effect estimates, contrary to the SM estimates, had very low 
variability and, hence, PS constructed with BLUP estimates was similar with or without weights. 
Hence, this could also explain why the replication rates under BLUP were lower than under SM. 
Moreover, our discovery sample size was small (approximately 900 individuals). 
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This study was further extended to the context of prediction, the results of which are described 
in the next chapter (Section 4.3.2). 
 
Part of this work was presented to the genetic prediction group of GAW18 and is to appear in 
BMC Proceedings (Bohossian et al., 2013). I also contributed to the group summary paper submitted 
to Genetic Epidemiology (Ziegler et al., 2013). 
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4 GENETIC PREDICTION STUDIES 
 
“Prediction is very difficult, especially if it’s about the future” – is a famous quote attributed to the 
Danish physicist and Nobel laureate, Niels Bohr. We wish to make the best decision about the future 
with the best information available today. This is true in every aspect of our lives and especially so for 
health decisions - an emerging science known as evidence based medicine (EBM). EBM is “the 
conscientious, explicit and judicious use of current best evidence in making decisions about the care of 
individual patients.” (Sackett et al., 1996) A more precise definition has been proposed by Donald and 
Greenhalgh (2000) to emphasize the important role of mathematical approaches to achieve this 
objective stating that EBM is “the enhancement of a clinician’s traditional skills in diagnosis, 
treatment, prevention and related areas through the systematic framing of relevant and answerable 
questions and the use of mathematical estimates of probability and risk.” 
Sackett and Rosenberg (1995) summarized the five essential steps of EBM as the following: 
(1) to convert our information needs into answerable questions (to formulate the question); (2) to track 
down, with maximum efficiency, the best evidence with which to answer these questions; (3) to 
appraise the evidence critically to assess its validity (closeness to the truth) and usefulness (clinical 
applicability); (4) to implement the results of this appraisal in our clinical practice; (5) to evaluate our 
performance. Most of the research has been focused on the third step. The whole process, covering all 
five steps, may take years, even decades. 
Personalized medicine is a paradigm of EBM. Although the definition of EBM appears to 
have been formalized only in the mid-90s, EBM is not a new concept. Drug administration, for 
instance, has traditionally been tailored to patients’ characteristics such as age, gender and body size. 
Large amount of genetic information has overwhelmed the medical community in the last decade or so 
changing the scope of EBM. This wealth of new information offers tremendous power for 
revolutionizing diagnosis and treatment and is laying the foundations of genomic medicine (Kumar, 
2007). Understanding how our genomes affect our health may lead to more precise estimates of risk, 
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and thus better treatment. However, predicting risk based on the genetic information that we carry has 
not been met with much success for complex traits. In this chapter, we review the necessary steps 
required to build a clinical prediction model and describe the factors influencing prediction accuracy. 
4.1 Methods 
Steyerberg (2009) presents seven main steps to building valid clinical prediction models. These steps 
apply equally in a genetic and in a non-genetic context. However, one particularity of the genetic 
context may be the high dimensionality of the data (if carrying out whole genome predictions). We 
describe these steps briefly below focusing on the genetic context and MS where applicable. 
4.1.1 Careful Consideration of the Prediction Problem 
Perhaps the most defining aspect of a prediction study is the outcome of interest and the available 
knowledge about the factors which influence it. As we discussed in the introductory chapter of this 
thesis (see Section 1.8), response to treatment in MS is a highly complex outcome to evaluate. Further, 
there is no widely accepted definition of it. 
Additionally, the most commonly used treatment of MS, interferon-β, has been relatively well 
studied. However, to this day, limited prior knowledge exists on the factors (genetic and non-genetic) 
which influence interferon response in MS patients. 
In contrast, we bring back the case of warfarin. The phenotype is a quantitative trait, stable 
warfarin dose, objectively defined. Moreover, prior building a model to predict the correct dose to 
administer to each patient, numerous studies had been carried out evaluating the factors, genetic and 
non-genetic, potentially influencing the correct dose. Thus, a lot of prior knowledge was available at 
the time of building the prediction model for warfarin dose. Of course, we note that warfarin has been 
available as a treatment since the 1950s while interferon-β, the first ever approved treatment of MS, 
has only been available since the late 90s. 
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4.1.2 Coding the Predictors in the Model 
The way the predictors are coded can influence the results of the prediction model. Continuous 
variables could be categorized and categorical variables may be treated as continuous. For example, 
age of disease onset could be categorized into “early disease onset” and “late disease onset” based on a 
predefined threshold age value. Another example is the EDSS which we recall is an ordinal variable 
on a scale from 0.0 to 10.0 measuring disability in MS patients. In most studies, however, it is treated 
as continuous. 
Further, a categorical variable may remain categorical but with reduced number of categories. 
Combining categories which do not have many observations in them, for example, is a common 
practice. Alternatively, categories could be added. For instance, missing data may be treated as a 
separate category although variables with a lot of missing data may need to be imputed or excluded 
from the study altogether. It is necessary and important to evaluate the implications of such coding 
strategies on the predicted outcome. 
4.1.3 Specification of the Model 
This is the most difficult of all steps and typically many different models are specified and evaluated. 
The type of outcome variable usually dictates the type of model to use such as regression for 
continuous variables and classification for categorical variables. The relationship between the type of 
outcome and the predictors may be modeled as linear or non-linear (of which the linear is a special 
case). Further, one may choose to work in a frequentist or in a Bayesian setting, using parametric or 
non-parametric approaches. Lastly, modeling techniques are often borrowed from the data mining and 
machine learning domains especially in the context of high dimensionality arising with genetic 
predictors (thousands to millions of genetic variants). Thus, there is a vast number of modeling 
approaches to choose from. An illustrative example of this is given by one of the prediction algorithms 
for warfarin dose which evaluated all of the following models: ordinary linear and polynomial 
regression, artificial neural networks, support vector regression with polynomial (including linear) and 
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Gaussian kernels, regression trees, model trees, least angle regression, Lasso and multivariate adaptive 
regression splines. (Klein et al., 2009) Of all, ordinary linear regression – the simplest - performed best 
(based on MAE, see Equation (4.10) below). 
4.1.4 Estimation of the Model Parameters 
In a frequentist setting, when the parameter space is of low dimension (   ), the most commonly 
used estimation method is the method of maximum likelihood (ML). The maximum likelihood (ML) 
estimates correspond to the most likely values of the parameters given the observed data. In a high 
dimensional context (that is, when      or     ), penalized estimation methods need to be used 
shrinking the estimates of the parameters towards their ML estimates. 
In a Bayesian setting, the approach is quite different. Let   be the parameter we are interested 
in estimating. The prior distribution of  ,  ( ), is defined by the investigators and reflects any prior 
knowledge on the value of  , if available. Let   denote the observed data and let  ( | ) be the 
likelihood. Bayesian methods estimate the posterior distribution of  ,  ( | ), that is proportional to 
the product of the prior distribution and the likelihood such that  ( | )    ( | ) ( ). Point estimate 
of   may also be obtained using, for instance, the mode of the posterior distribution which, under 
certain priors, is equivalent to the ML estimate. Moreover, for most penalized estimates, there is an 
equivalent Bayesian prior (de los Campos et al., 2010). 
4.1.5 Evaluation of the Model Performance 
Evaluation of the model performance is determined by the type of outcome. Let   be the observed 
outcome and  ̂ be the outcome predicted by the model. We provide a brief review of the performance 
measures for quantitative and binary traits (or outcomes). 
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4.1.5.1 Continuous Outcomes 
For continuous outcomes, the correlation between   and  ̂ is often evaluated. The estimated 
correlation,  , is given by 
   
∑ (     ̅)(  ̂    ̅)
 
   
√∑ (     ̅) 
 
   ∑ (  ̂    ̅)
  
   
  
(4.1) 
where    and   ̂,         are the observed and predicted outcomes, respectively, and  ̅ is the mean 
of   ,        . 
The most commonly used measure, however, is the square of   , the coefficient of 
determination,   , defined as 
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(4.2) 
Under certain conditions (such as when the   ̂’s have been derived using linear regression), 
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(4.3) 
and, hence, Equation (4.2) above can be expressed as 
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(4.4) 
which is the proportion of explained variance by the predictors in the model. 
It has been shown that    is a biased estimate of the true coefficient of determination,   , 
given by 
      
  
 
  
   
(4.5) 
where   
  and   
  are the true variances of the residuals and the dependent variable, respectively. The 
maximum value of the bias is given by 
GENETIC PREDICTION STUDIES 
104 
   
 
  
(4.6) 
where   is the number of variables in the model including the intercept. Thus, an adjusted   ,      
 , is 
often reported as well and is given by 
    
    (     ) (
   
   
)  
(4.7) 
(This issue is discussed at length by Montgomery and Morrison (1973).) 
Recalling our definition of heritability from the previous chapter (Equation (3.13)), if the 
prediction model contains only genetic predictors with additive effects, then    can be interpreted as 
the proportion of the phenotypic variance attributable to additive genetic factors and its upper bound is 
given by the heritability (narrow-sense) of the trait,   , such that 
         (4.8) 
Finally, a loss function is often specified measuring the “loss” in precision between the real 
and the predicted value. Several popular loss functions include the mean squared error (MSE), the 
mean absolute error (MAE) and the mean relative error (MRE) and are described below. 
The MSE is defined as the mean of the squared differences between   and  ̂. It is given by 
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(4.9) 
Alternatively, the MAE is defined as the mean of the absolute differences between   and  ̂. It is given 
by 
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(4.10) 
If     ,        , the MRE can be defined as the mean of the relative differences between   and 
 ̂. It is given by 
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4.1.5.2 Binary Outcomes 
Suppose we are interested in predicting disease status (disease/healthy). Table 4.1 illustrates a two-by-
two table with predicted versus observed outcomes. 
 
 OBSERVED 
Disease Healthy 
PREDICTED 
Disease TP FP 
Healthy FN TN 
Table 4.1: Two-by-two table of predicted versus observed disease status. TP: true positive count, FP: 
false positive count, FN: false negative count, TN: true negative count. 
 
Five measures can be derived from Table 4.1: sensitivity, specificity, positive predictive 
value, negative predictive value and overall accuracy. 
The sensitivity is defined as the proportion of correctly classified disease individuals among all 
observed disease individuals and is given by 
             
  
     
  
(4.12) 
The specificity is defined as the proportion of correctly classified healthy individuals among all 
observed healthy individuals and is given by 
             
  
      
  
(4.13) 
The positive predictive value (PPV) is defined as the proportion of correctly classified disease 
individuals among all predicted disease individuals and is given by 
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(4.14) 
The negative predictive value (NPV) is defined as the proportion of correctly classified healthy 
individuals among all predicted healthy individuals and is given by 
     
  
     
  
(4.15) 
Lastly, the overall accuracy is defined as the proportion of correctly classified individuals (disease or 
healthy) among all individuals and is given by 
                  
     
           
  
(4.16) 
These measures are summarized in Table 4.2 below. 
 
 OBSERVED  
Disease Healthy 
PREDICTED 
Disease TP FP PPV = TP/(TP + FP) 
Healthy FN TN NPV = TN/(FN + TN) 
 Sensitivity = 
TP/(TP + FN) 
Specificity = 
TN/(FP + TN) 
Overall Accuracy =  
(TP + TN)/(TP +FP +TN+FN) 
Table 4.2: Summary of several performance measures for a binary outcome. 
 
The accuracy of a prediction model may be assessed in several ways the most common being 
evaluating its discriminatory ability between the two groups (disease and healthy). The most widely 
used measure for that is the area under the receiver operating characteristics (ROC) curve. The ROC 
curve is obtained by plotting sensitivity (true positive fraction) on the y-axis versus 1-specificity (false 
positive fraction) on the x-axis for varying thresholds used to discriminate between disease and 
healthy individuals (for example, consecutive cutoffs for the probability of outcome). 
Figure 4.1 below illustrates hypothetical ROC curves to demonstrate different classification 
accuracies as measured by the area under the curve (AUC). AUC varies between 0 and 1 but 
classifiers with AUC < 0.5 are typically reformulated such that AUC > 0.5 (that is if predicting disease 
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status gives an AUC < 0.5, predicting healthy status will give an AUC > 0.5 with the same model). 
Thus, the focus is on the upper left diagonal such that the AUC is between 0.5 and 1 (0.5 < AUC < 1). 
 
 
Figure 4.1: Hypothetical ROC curves. Adapted from (Zou et al., 2007). 
 
For the binary classifier C, the          (half the area of the unit square). This classifier 
performs as good as a random guess, in other words, it is perfectly useless. On the other extreme, the 
binary classifier A has an       (full unit area) and is a perfect classifier. In other words, the 
model discriminates perfectly between disease and healthy individuals. 
Wray et al. (2010) demonstrated that the maximum achievable AUC,       , when the 
classifier is a genetic predictor depends on the heritability at the liability scale,     and on the 
prevalence of disease,  . Their derived expression for        is given by 
        
(
 
(   )  
√  [(      (   ))   (      (   ))]
)
   
(4.17) 
where  
GENETIC PREDICTION STUDIES 
108 
  ( ) is the cumulative density function of the standard normal distribution such that if 
   (   ), ( )   (    ); 
    
 
 
 where   is the height of the standard normal curve and   is the prevalence; 
    
  
(   )
; and 
      (   ). 
Distinction should be made between discrimination and calibration, which is another 
component in assessing the accuracy of a prediction model. Discrimination refers to the ability of the 
model to distinguish between disease and healthy individuals while calibration refers to the agreement 
between the predicted and the observed values. For instance, for continuous outcomes, calibration can 
be evaluated graphically by plotting   ̂ versus   ,        . If the model is well calibrated, the 
scatter plot should fall closely along the diagonal. Analogous approaches have been developed for 
binary outcomes although they are rather imperfect. 
A model may be good at discriminating but poorly calibrated. In other words, a model may be 
predicting a higher risk for disease individuals than for healthy individuals but the actual predicted 
risks by the model may be in poor agreement with the true risks. Alternatively, if there is little 
difference in the true risks between disease and healthy individuals, that is, the risk distribution has 
narrow spread, a model may not be able to discriminate well even if the predicted risks are in good 
agreement with the true risks. In fact, there is typically a trade-off between discrimination and 
calibration and the only time a model may be perfect at both is when the true and the predicted risks 
are 0 or 100%, that is, the risk distribution is U-shaped. (Cook, 2007) 
Other performance metrics have been developed to circumvent the limitations of the AUC 
such as reclassification tables (Cook, 2007). The idea is to evaluate how many subjects are reclassified 
after including additional predictor(s) in the model. This metric can sometimes better illustrate the 
classification improvement which may be reflected with a small or insignificant change in the AUC. 
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All metrics discussed so far assume that false positives and false negatives carry equal weight 
and a theoretical framework to account for different weights has been developed by Vickers and Elkin 
(2006). Net benefit,   , is a measure that tries to accommodate different weights for each wrong 
decision. It is given by    (      )   where   is the weight derived from the ratio of harm to 
benefit. Of course, in this measure, the challenging part is to come up with the value of  . 
Several traditional and novel performance metrics have been reviewed by Steyerberg et al. 
(2010) who also address performance metrics for survival outcomes. We note that, for some 
investigators (for example, Pepe et al., 2007) sensitivity and specificity (and, hence, AUC) remain the 
classical and pertinent piece of metric to be supplied in a prediction study. 
4.1.6 Generalizability of the Model 
A central concern of predictive modeling is over-fitting which occurs when the model describes noise 
in the data rather than a true existing relationship between the predictor(s) and the outcome. In that 
case, the detected relationship will fail to be reproduced in an independent dataset. To guard against 
that, the performance metrics described in the previous step need to be evaluated in a new independent 
dataset. Ideally, three datasets are necessary: training sample, testing sample and a target population. 
The model is learned (built) on the training sample, its performance is evaluated in the testing sample 
and only then the model is applied in practice in a target population. In the training and testing 
samples, the outcome is known, while in the target population it is unknown. 
Obtaining samples is a costly and lengthy process if at all possible so clever statistical 
approaches have been developed to circumvent this limitation as much as possible when building 
prediction models without limiting too much their generalizability. These approaches rely on the 
concept of data splitting or sample reuse techniques. Cross validation (CV), initially introduced in the 
mid-70s, is one of the most widely used such approach (Stone, 1974; Geisser, 1975). We discuss it at 
length here. 
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The main objectives of CV are: (1) to evaluate the error of the model giving an idea of how it 
can be generalized; (2) to compare the performance between models; and (3) to tune model 
parameters. (Refaeilzadeh et al., 2009) To achieve these objectives, there are many alternative ways in 
which the data could be split. 
To illustrate the many alternative ways in which the data can be split, we generated a simple 
dataset with one dependent variable ( ) and one independent variable ( ) for 20 subjects given in 
Figure 4.2 below. 
 
 
Figure 4.2: A simple dataset generated with one dependent variable ( ) and one independent variable 
( ) for      subjects. 
 
In the worst case scenario, the model is both trained and tested on the same dataset as 
illustrated in Figure 4.3. The red line in the figure illustrates the model fit and the blue lines illustrate 
the difference between the simulated and the predicted values (the “loss”). 
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Figure 4.3: The fitted model (red line) to the dataset in Figure 4.2. The blue lines illustrate the 
difference between the simulated and the predicted values. 
 
This procedure leads to over-fitting, where the model fits the random error rather than the 
relationship being modeled. To avoid the problem of over-fitting, one alternative would be to 
randomly split the dataset into two parts, training and testing. The model is learned on the training set 
and its predictive performance is evaluated in the testing set (Figure 4.4). The limitation of this 
approach is that only part of the data is used for training and as such the results may be strongly 
impacted by a specific split of the data. It is possible to repeat this procedure several times but this 
may only partially avoid the problem as the full data may remain still unused for training. 
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Figure 4.4: Random split of the dataset in Figure 4.2 into training (red points) and testing (blue) 
points. The model is fitted (red line) on the training datasets and its loss function evaluated in the 
testing dataset. 
 
An alternative to that is to use the famous  -fold cross validation. In this setting, the data are 
split into   equal partitions. Of these,     partitions are used for training and the remaining partition 
is used for testing. This procedure is iterated   number of times (Figure 4.5). Then, the prediction 
error obtained in each iteration is averaged over all   iterations. The optimal value of   may be 
determined from the data or a commonly used value such as     or      may be chosen. 
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Figure 4.5: The  -fold cross validation illustrated on the dataset in Figure 4.2. That is, in each 
iteration, the model is trained on   
 
 
 observations (red) and tested on  
 
 
 observations (blue). This 
process is repeated until all observations in the dataset have been used for testing. Here,    . 
 
A special case of this is when     (where   is the number of subjects in the full sample). 
This is referred to as leave-one-out CV (Figure 4.6). This type of approach is often used when the 
sample size is very small (dozen or so subjects). 
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Figure 4.6: Leave-one-out cross validation illustrated on the dataset in Figure 4.2. In each iteration, 
the model is trained on     observations (red) and tested on one observation (blue). This process is 
repeated until all observations in the dataset have been used for testing. 
 
Lastly, an extension to the last method is sometimes used, where the  -fold CV is repeated   
number of times thus creating   different sets of   partitions (Figure 4.7). Therefore, whereas with  -
fold CV we would have   estimates of the prediction error, with   repeated  -fold CV we have     
estimates. In other words, this approach produces a greater number of estimates of the prediction error 
hopefully leading to more accurate error estimates. 
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Figure 4.7: Repeated k-fold cross validation illustrated on the dataset in Figure 4.2. The  -fold cross 
validation illustrated in Figure 4.5 is repeated three times (   ). 
 
Lastly, one alternative method to CV is bootstrapping where, in its simplest form, instead of 
repeatedly analyzing subsets of the data, one repeatedly draws subsamples with replacement, fits the 
model on the subsamples and evaluates the predictive performance in the remaining observations not 
included in these bootstrap samples. This approach was introduced by Efron (1983). There is typically 
a bias-variance trade-off between the two approaches with CV producing less biased but more variable 
estimates of the prediction error than those derived by the bootstrap approach. Kohavi (1995) 
compared CV and bootstrapping approaches and favored the stratified 10-fold CV. Since then 
alternatives have been developed such as the .632+ bootstrap method which appears to outperform 
CV. (Efron and Tibshirani, 1997) Nevertheless, in a high dimensional context, Binder and 
Schumacher (2008) recommend against approaches relying on sampling with replacement. 
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4.1.7 Presentation of the Model 
An important final step in prediction model building is facilitating its usability. For instance, Figure 
4.8 below illustrates a snapshot of a free website created to help physicians and health professionals 
assess the appropriate initial warfarin dose to administer to patients based on the prediction algorithms 
that have been built for that purpose. Using this website, a patient’s clinical and genetic information is 
entered and an estimate of the warfarin dose is then derived based on that information. 
 
 
Figure 4.8: Snapshot of the free website created to help physicians and health professionals assess the 
warfarin dose to administer to patients based on the predictive models that have been built for that 
purpose. Adapted from (The Warfarin Dose Refinement Collaboration and International Warfarin 
Pharmacogenetics Consortium, 2013). 
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Another example of prediction algorithms with facilitated implementation is the prediction of 
cardiovascular disease risk. Figure 4.9 below illustrates the risk assessment tool based on data from 
the Framingham Heart Study (Anderson et al., 1991) available freely for anyone wishing to assess 
their 10-year risk of heart attack. 
 
 
Figure 4.9: Snapshot of the free website created for anyone wishing to assess their 10-year risk of 
heart attack. Adapted from (National Heart Lung and Blood Institute, 2013). 
 
Both for warfarin dose and for cardiovascular risk prediction, several prediction algorithms 
exist and, in the case of cardiovascular risk, implementations of the different methods are also freely 
accessible (see for example the University of Edinburgh’s cardiovascular risk calculator which allows 
the estimation of risk based on different risk prediction models (The University of Edinburgh, 2010)). 
Despite their complexity and variety, however, it is clear that an indispensable component of the 
successful application of prediction algorithms in practice is their simplicity of use. 
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4.2 Pitfalls and Limitations of Genetic Prediction Studies 
Analogously to the previous chapter where we discussed the limitations of genetic association studies, 
we discuss next several of the limitations of genetic prediction studies by drawing examples from the 
literature as well as from our own work. 
4.2.1 Direct, Indirect and Confounded Associations: Implications on Prediction 
Accuracy 
In a training dataset, we may conduct a genetic association study to identify the genetic factors which 
contribute to the trait and evaluate the predictive performance of these factors in a testing dataset. For 
quantitative traits, Equation (4.8) illustrates that the explained variation by the model attributable to 
additive genetic factors is bounded by the heritability of the trait. Similarly, for binary (disease) traits, 
the AUC is bounded by the heritability of the trait (and the prevalence of the disease) (Equation 
(4.17)). This upper limit is achievable only if all causal variants contributing to the variability of the 
trait are known and if their effects are estimated without error (Wray et al., 2013). 
However, as we saw in the last chapter, first of all, most of the genetic association studies are 
indirect association studies, where the genetic variants (SNPs) being analyzed are typically not the 
causal variants but rather those surrounding and correlated to the causal variants. Since not all causal 
variants may be tagged by neighboring SNPs on the genotyping chips, it is unlikely that all causal 
variants are identified in the training dataset. Second, it is possible that the effect of the actual causal 
SNP is larger than that estimated for its neighboring SNPs (effect gets “diluted”). Therefore, the 
estimated effects are also not accurate (they are underestimated). 
Moreover, another factor impacting the prediction accuracy of the model is spurious 
associations due to population stratification and cryptic relatedness. The predictive accuracy might be 
inflated if the training and testing datasets arise from the same population (if, for example, using data 
splitting techniques to derive training and testing datasets) which is different from the target 
population for which the predictive model is aimed. A recent study has suggested for instance that 
population structure has confounded a genetic classifier for autism. (Belgard et al., 2013) 
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4.2.2 Hypothesis-Driven versus Hypothesis-Free 
Prediction models in human traits incorporating genetic information have been so far restricted to the 
inclusion of a handful of genes the choice of which has been driven by prior knowledge. On the other 
hand, in animal breeding, genetic risk prediction of complex (quantitative) traits such as milk yield 
based on the whole-genome has been common practice. Particularly, breeding programs rely heavily 
on estimates of genetic values in the parent generation to predict offspring traits. The breeding value of 
an animal is defined as the sum of genetic effects of a breeding animal as measured by the 
performance of its progeny. In the absence of dominance, the genetic effects correspond to the additive 
genetic effects. The breeding value is estimated by summing the additive effects of the alleles and is 
referred to as the estimated breeding value or EBV. 
The recent study by Vazquez et al.(2012) is one of the first to apply whole-genome prediction 
techniques used in animal breeding to predict risk for a complex disease phenotype in humans. The 
investigators compared four models to predict risk for skin cancer: (1) the baseline risk model 
including gender and cohort, (2) model 1 with family history added, (3) model 2 with geographic 
ancestry (based on genomic information) added and (4) model 1 with 41 000 SNPs across the genome. 
The AUCs for the four models were 0.53, 0.58, 0.62 and 0.64, respectively. That is, they found that 
the whole-genome prediction model outperformed all other models albeit not by much. 
4.2.3 Guarding Against False Predictions 
For quantitative traits, if the predictors in the model do not explain any of the phenotypic variation, 
then   
     
  and the population coefficient of determination (Equation (4.5)) is zero, that is,     . 
The estimated coefficient of determination,   , from the discovery (training) sample is biased with the 
expected value of the bias being 
   
 
 (Equation (4.6)), where   is the number of variables including the 
intercept. That is, if randomly chosen   predictors are included in the model, the expected explained 
variation would be     
   
 
 with      as     even if the predictors are not associated with the 
phenotype of interest. Therefore, if the number of predictors,  , is large relative to the sample size,  , 
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   may represent a significantly inflated estimate of the true explained variation to be expected in an 
independent (testing) dataset. This also illustrates why it is never a good idea to train a model and 
evaluate its predictive performance in the same dataset and that it is essential that the training and 
testing datasets be independent and drawn from the same target population. 
4.2.4 Genetic Architecture of Complex Traits and Diseases 
For monogenic (Mendelian) traits (see Section 3.3), genetic profiles provide 100% accurate 
predictions. Most traits, however, are not Mendelian and variants associated with these traits cover a 
wide spectrum of penetrance values. Common variants, such as those identified by GWASs, have 
typically low penetrance, while rare variants have high penetrance. 
Predicting non-Mendelian traits is therefore based on probabilistic modeling and certainly 
involves errors in prediction accuracy. The more frequent the genetic variant, the lower its penetrance. 
The lower the penetrance, the weaker its role and the stronger the role of environmental factors in 
predicting the trait. 
For example, the BRCA1 and BRCA2 mutations occur in less than 1% of the US population. 
Their penetrance for breast cancer at age 70 years was estimated at 0.57 and 0.49, respectively. (Chen 
and Parmigiani, 2007). Nevertheless, family history remains one of the strongest predictors of the 
disease. 
4.2.5 Study Sample Size and Marker Panel Coverage 
Since the SNPs included in genome-wide SNP chips are typically not the causal SNPs the variation 
they capture does not fully explain the phenotypic variation that is due to genetic factors. Let   
  
denote the genetic variation captured by the genotyped SNPs and let    be the heritability in the 
narrow-sense as defined before (Equation (3.13)). Then, typically,   
    . This is especially true if 
rare variants contribute to the phenotypic variation as current marker panels capture only common 
genetic variation. 
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4.2.5.1 Quantitative Traits 
For quantitative traits, we recall that the estimated proportion of phenotypic variation due to genetic 
factors is bounded by the heritability, that is,       (Equation (4.8)). It depends on the number of 
independently measured genetic variants, , the proportion of total variance that they explain,   
 , and 
the sample size in the training (discovery) dataset,   . It is given by (Wray et al., 2013; Daetwyler et 
al., 2008) 
    
  
 
   
 
    
 (   
 )
  
(4.18) 
Figure 4.10 below illustrates the variation of    as a function of   , the discovery sample size, for 
different proportions of total variance explained by the genotyped SNPs,   
 . We see that high marker 
panel coverage and very large sample sizes in the discovery set are needed to achieve high   . 
 
 
Figure 4.10: The explained variation,   , as a function of discovery sample size,   , for different 
proportions of total variance explained by the genotyped SNPs,   
 . Adapted from (Wray et al., 2013). 
 
In other words, Figure 4.10 above illustrates that unless the discovery sample sizes are very large 
(         ),  
    
    , that is,    underestimates the heritability. 
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4.2.5.2 Binary Traits 
For binary (disease) traits, we give some examples in Table 4.3 and Table 4.4 to illustrate the impact 
heritability, disease prevalence and discovery sample size have on the maximum achievable AUC. All 
results are taken from the analyses conducted on polygenic score studies by Dudbridge (2013). 
Table 4.3 illustrates the maximum achievable AUC for two similarly heritable diseases, 
coronary artery disease and Crohn’s disease but the former is roughly 50 times more prevalent than the 
latter. 
 
 Coronary Artery Disease Crohn’s Disease 
Prevalence,   0.056 0.001 
Heritability,    0.72 0.76 
Discovery Sample Size,    ~2000 cases / 1480 controls 
Variance explainable by markers,   
  
  
   
 
 
   0.547 (0.843) 0.620 (0.948) 
  
      0.592 (0.948) 0.727 (0.995) 
Table 4.3: Maximum achievable AUC (in italic) for two diseases, coronary artery disease (CAD) and 
Crohn’s disease, with similar heritability but with very different prevalence. The maximum achievable 
AUC is given under the current discovery sample sizes and for marker panels explaining half (  
  
 
 
 
  ) or full (  
    ) heritability. In parenthesis, the AUC achievable with infinite discovery sample 
sizes, that is, when     , is given. Values adapted from Table 2 in (Dudbridge, 2013). 
 
Alternatively, Table 4.4 illustrates the maximum achievable AUC for two diseases, 
schizophrenia and prostate cancer, with similar prevalence but the former being almost twice more 
heritable than the latter. 
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 Schizophrenia Prostate Cancer 
Prevalence,   0.01 0.024 
Heritability,    0.80 0.44 
Discovery Sample Size,    
3322 cases / 
3587 controls 
1164 cases / 
1113 controls 
Variance explainable by markers,   
  
  
   
 
 
   0.62 (0.91) 0.52 (0.80) 
  
      0.72 (0.99) 0.54 (0.90) 
Table 4.4: Maximum achievable AUC (in italic) for two diseases, schizophrenia and prostate cancer, 
with similar prevalence but with very different heritability. The maximum achievable AUC is given 
for the current discovery sample sizes and for marker panels explaining half (  
   
 
 
  ) or full 
(  
     ) heritability. In parenthesis, the AUC achievable with infinite discovery sample sizes, that 
is, when     , is given. Values adapted from Table 3 in (Dudbridge, 2013). 
 
We see from Table 4.3 and Table 4.4 that the maximum achievable AUC increases with 
higher marker coverage and that this increase is more significant for more heritable and/or diseases 
having a low prevalence. However, the sample size of the discovery dataset has by far the largest 
impact on the maximum achievable AUC where AUC levels deemed clinically useful (AUC > 0.75) 
are achieved only with infinite (hypothetical) sample sizes. 
In the extreme, if we compare a rare, highly heritable disorder such as Crohn’s disease 
(               ) with a common, modestly heritable disease such as breast cancer (  
             ), we see from Figure 4.11 that extremely large sample sizes are needed to achieve 
clinically useful AUC levels in the order of tens of thousands for the former disease and hundreds of 
thousands to a million for the latter. 
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Figure 4.11: Maximum achievable AUC as a function of sample size (number of cases and controls) 
for Crohn’s disease (rare, highly heritable) and for breast cancer (common, modestly heritable). 
Adapted from Figure 4 in (Dudbridge, 2013). 
4.2.6 Phenotype Issues 
It is clear that more precise measures of the phenotype can lead to improved prediction accuracy (due 
to reduced noise in the model). Nevertheless, we saw that the prediction performance of a model is 
positively correlated with the sample size of the discovery set and heritability and, in the case of 
binary traits, it is negatively correlated with the prevalence. While the sample size could be a 
component of the study design that can be controlled for, the properties of the studied phenotype such 
as its heritability and prevalence cannot be modified. It is, therefore, important to recognize the 
limitations of the study imposed by the phenotype being investigated and adjust performance 
expectations accordingly. 
4.2.7 Clinical Use of the Findings 
A final remark is needed on the correspondence between the OR of a binary predictor and its 
predictive accuracy. Figure 4.12 below illustrates hypothetical accuracy curves corresponding to 
different ORs for a binary marker. 
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Figure 4.12: Correspondence between the accuracy curves and the ORs for binary markers with ORs 
as indicated on the various curves. Adapted from (Pepe et al., 2004). 
 
Figure 4.12 illustrates that binary predictors with OR as high as 3 which is considered strong 
association in traditional epidemiological studies will be very poor classifiers. From the graph, it is 
apparent that very strong ORs (    ) are needed to achieve clinically meaningful classification 
performance. Most of the genetic variants that have been identified through GWASs exert a small to 
moderate effects (           ) on the traits. Moreover, as we mentioned in the previous chapter, 
the OR is an estimate of the true risk ratio,   , and       only if the disease under study is rare, 
otherwise it overestimates it. 
Based on family history alone, siblings would have the same risk estimate. Incorporating 
genetic information, therefore, may lead to differential risk estimates. Family history and genetic 
profiling have typically been regarded as competing sources of information (one or the other) in 
estimating risk but recent studies have shown that there are benefits to be gained by incorporating 
genetic information into risk prediction models that have already accounted for family history. (Do et 
al., 2012) In many cases, however, these improvements would be marginal and perhaps of limited 
clinical utility (Ware, 2006). 
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4.2.8 Modeling Strategies 
We mentioned earlier in Section 4.1.3, that the most difficult step in building a clinical prediction 
model lies in the specification of the model. Oftentimes, many different models need to be specified 
and evaluated. Typically, there is a trade-off to be made between model complexity and prediction 
accuracy. 
We conducted two studies to evaluate the prediction performance of different modeling 
approaches for a binary and a quantitative trait. We compared classical logistic regression with a data 
mining approach (binary tree with recursive partitioning) to predict natalizumab response one year 
after treatment onset in MS patients using non-genetic factors. Further, we extended our work on the 
simulated blood pressure data from GAW18 to the prediction context. We describe these two studies 
in Section 4.3.1 and Section 4.3.2, respectively. 
4.3 Applications 
4.3.1 Logistic Regression versus Binary Tree with Recursive Partitioning 
4.3.1.1 Objective 
A recent study on 48 MS patients investigated several potential clinical predictors of natalizumab 
response and found that the number of relapses one year prior treatment onset (alternatively expressed 
as the number of relapses per year and referred to as the annualized relapse rate) was the only good 
predictor of response. (Sargento-Freitas et al., 2013) So far, however, little is known on the non-
genetic factors that influence natalizumab response. The objective of this study was to compare the 
performance of two modeling approaches, logistic regression and a classification tree algorithm, to 
predict response to natalizumab one year after treatment onset based on clinical, biological and 
radiological measures in French MS patients. 
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4.3.1.2 Dataset 
A total of 531 patients from the BIONAT cohort (Outteryck et al., 2013) were included in our study. 
Detailed description of the clinical, biological and radiological characteristics by response status for 
these patients is provided in Appendix III (Table III.1-Table III.3). (The data shown in these tables 
are taken from the most recent version of the BIONAT database, frozen November 2013, and may not 
necessarily correspond to the data we had at hand at the time this study was started.) 
All clinical variables, namely, gender, EDSS at treatment onset, number of relapses one year 
prior treatment onset, disease duration at treatment onset, previous immuno-modulatory treatment use 
and previous immuno-suppressory treatment use, were included in the study. Additionally, select 
biological and radiological variables at treatment onset were also included, namely, specific types of 
white blood cell (CD4, CD8 and CD19) counts and gadolinium (MRI GD+) enhancing lesions. For the 
majority of these patients, genotype data (SNPs from the ITGA4 gene) were available. However, given 
the unconvincing role of the ITGA4 in natalizumab response that we observed in the genetic 
association study that we conducted (Section 3.6.2), we did not include any genetic variants from this 
gene in the prediction model. 
4.3.1.3 Response Definition 
In Table 3.13, we defined Responders, Non-Responders and Intermediary Responders for 
natalizumab-treated MS patients one year after treatment onset. In the ITGA4 candidate gene study, we 
excluded Intermediary Responders. In this study, Intermediary Responders were included along with 
the Responders group (that is, the Responder-classification criteria were relaxed). Any patient who had 
developed antibodies against natalizumab was excluded from the study. Moreover, only patients 
whose clinical, biological and radiological data had been validated by two independent neurologists 
were included in the study. 
4.3.1.4 Methods 
We compared the performance of two modeling techniques, a logistic regression (LR) model with 
stepwise backward selection and a binary tree with recursive partitioning (BT) algorithm to predict 
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natalizumab response based on the non-genetic factors that we included in the study. All analyses were 
carried out with the R statistical software package (R Core Team, 2013). 
We used the rpart R package (Therneau and Atkinson, 2012) for the implementation of the BT 
model. Specifically, the procedure involves splitting the dataset recursively until an optimal 
classification of the Responders/Non-Responders is achieved based on pre-defined parameters 
controlling the fit of the tree. 
A tree consists of linked nodes. Any node in a binary tree can have at most two child nodes 
and at most one parent node. The node without a parent node is called the root node (at the top of the 
tree) and the node without any child nodes is called a terminal node. The depth of a node is the 
number of nodes on the path to its root node. The root node has a depth of zero. The resulting model 
fit is represented as a tree where the terminal nodes indicate the predicted response status. 
At each node, except for terminal nodes, the algorithm identifies the best variable on which to 
split, that is, the variable that best classifies the patients compared to all other remaining variables. For 
each possible split variable, the algorithm computes an impurity measure. This measure is at a 
maximum when the split classifies an equal number of patients as Responders and Non-Responders 
and is at a minimum when the split results in only one class (either Responders or Non-Responders). 
The chosen split variable then is the one which has the minimum impurity. Various impurity measures 
are implemented in the rpart package. We used a measure based on the Gini index (  ) which is 
closely related to the AUC (discussed in Section 4.1.5.2) through the formula           . 
(Gail and Pfeiffer, 2005) 
The largest advantage of BT over LR is its treatment of missing data. As long as the response 
status and at least one predictor variable are not missing, the patient can be included in the study. This 
is achieved as follows. First, if a potential split variable has missing values, the impurity measure is 
computed only over the observations which are not missing. Next, if a chosen split variable has 
missing values, rpart “imputes” the missing values by applying the partitioning algorithm to predict 
the split outcome based on the remaining independent variables. This approach could be particularly 
advantageous in studies with clinical data where missing data are the norm rather than the exception 
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and our study is no different. Table 4.5 below lists all predictor variables in our study dataset as well 
as the number and proportion (out of 531 patients) of missing values for each variable. 
 
Predictors Missing n (%) 
CD19 count 124 (23) 
CD8 count 53 (10) 
CD4 count 51 (10) 
Disease Duration 0 (0) 
MRI GD
+
 lesions 0 (0) 
Relapses prior treatment 0 (0) 
EDSS 0 (0) 
Gender 0 (0) 
Previous immuno-modulatory treatment use 0 (0) 
Previous immuno-suppressory treatment use 0 (0) 
Table 4.5: The number and proportion (out of 531 patients) of missing values per predictor variable in 
our study dataset. 
 
Thus, in the BT analyses all 531 patients were included, while in the LR analyses only patients 
with non-missing data in all ten predictors were included. 
Several parameters can be specified which influence the resulting model fit. These include 
 the minimum number of observations in a node required to partition the data (defaults to 20); 
 a parameter to control the selection of surrogate variables. For instance, the default option is to 
select surrogate variables leading to the highest number of correct classifications. 
Alternatively, surrogates may be selected based on the highest proportion of correct 
classifications calculated after excluding the number of missing values of the specific 
surrogate variable; 
 the maximum depth of any node (defaults to 30).  
For this study, we restricted the node depth to 3, a somewhat arbitrary choice. We used the default 
settings for the remaining parameters. 
We used repeated two-fold cross validation with 100, 500 or 1 000 repetitions. In each 
repetition, we trained each of the two modeling techniques on one partition of the data and we 
evaluated its predictive performance in the other partition. We then evaluated the sensitivity, 
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specificity, PPV, NPV and overall accuracy (Equations (4.12) through (4.16)) for both approaches 
averaging them over each validation run and then over the repetitions. 
We also constructed ROC curves (using the ROCR R package, (Sing et al., 2009)) in one 
repetition chosen at random. The curves were constructed by varying the threshold of the predicted 
probabilities of being a Responder by each approach and evaluating the sensitivity and the specificity 
at each threshold. Lastly, we evaluated the number of times each predictor was chosen by the model 
(that is, selected by the backward selection algorithm for the LR approach or selected as a split 
variable for the BT approach) over the repetitions. We then ranked the predictors from most selected 
to least selected and compared the ranks across the approaches. 
4.3.1.5 Results 
The performance metrics obtained for each of the two modeling approaches are illustrated in Table 
4.6 below. The number of repetitions (100, 500 or 1 000) had little impact on the results and here we 
report only the results for 1000 repetitions. 
 
On 1000 Repetitions LR BT 
Sensitivity 0.92 0.83 
Specificity 0.07 0.17 
PPV 0.61 0.62 
NPV 0.23 0.36 
Accuracy 0.58 0.58 
Table 4.6: Sensitivity, specificity, PPV, NPV and overall accuracy for the logistic regression (LR) and 
the binary trees with recursive partitioning (BR) models averaged over 1000 repetitions of two-fold 
cross validation runs. 
 
From Table 4.6 we see that LR classifies better Responders (sensitivity is 0.92 for LR versus 
0.83 for BT), while BT classifies better Non-Responders (specificity is 0.07 for LR versus 0.17 for 
BT). Both approaches lead to similar PPVs while the BT predicts slightly better the Non-Responder 
status than LR (NPV is 0.36 for BT versus 0.23 for LR). Both approaches, however, have the same 
and quite poor overall accuracy of 0.58 (a random guess has an expected overall accuracy of 0.50). 
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The ROC curves generated from the predicted probabilities in a randomly chosen repetition 
are illustrated in Figure 4.13 below. The ROC curve was smoother under the LR approach than under 
the BT approach due to more variable predicted probabilities although the range for both approaches 
was similar (from 0.36 to 0.79 for LR and from 0.44 to 0.82 for BT – right vertical axis in Figure 
4.13). For both approaches, the curves were quite close to the diagonal line which, as we saw in 
Figure 4.1 with classifier C, is equivalent to a random guess (       ). 
 
 
Figure 4.13: ROC curves for the LR and the BT approaches for a randomly chosen repetition. 
 
Lastly, Table 4.7 below illustrates the ranking of the predictors selected by each approach 
from most often to least often over 1000 repetitions. 
 
 
 
 
 
 
 
GENETIC PREDICTION STUDIES 
132 
LR BT 
Top Predictor Selection Rate 
Over 1000 
Repetitions (%) 
Top Predictor Selection Rate 
Over 1000 
Repetitions (%) 
MRI GD
+
 lesions 32 CD8 count 67 
Relapses prior treatment 28 CD19 count 59 
Disease duration 20 CD4 count 39 
CD4 count 18 Disease duration 22 
CD19 count 17 MRI GD
+ 
lesions 21 
EDSS 12 Relapses prior treatment 18 
Previous immuno-
modulatory treatments 
12 EDSS 4 
CD8 count 8 Gender 4 
Gender 7 Previous immuno-
suppressory treatments 
3 
Previous immuno-
suppressory treatments 
6 Previous immuno-
modulatory treatments 
< 1 
Table 4.7: Predictors ranked by the percentage of times over the 1000 repetitions that they were 
selected when using the logistic regression with backward selection (LR) or the binary tree with 
recursive partitioning model (BT). 
 
As Table 4.7 illustrates, the order as well as the selection rate of top predictors varies by 
approach. Interestingly, the most selected predictor by the BT approach, the CD8 count selected 67% 
of the times, was among the least selected by the LR approach (8%). Disease duration, on the other 
hand, was the only predictor with comparable selection rates between the two approaches (selection 
rate of 20% by LR and of 22% by BT). Overall, CD4 count, CD19 count and disease duration were 
identified among the top five predictors by both approaches. We note that the correlation (estimated in 
the complete dataset) between the CD4 and CD19 counts was 0.35, between CD4 count and disease 
duration was 0.004 and between CD19 count and disease duration was -0.05. Additionally, CD4 and 
CD8 counts were correlated (correlation = 0.51) as well as disease duration and EDSS (correlation = 
0.33). 
4.3.1.6 Concluding Remarks 
In summary, from our study we were unable to identify any potential predictors of response of clinical 
usefulness irrespective of whether LR or BT was used. Nevertheless, from the variables included, both 
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approaches consistently selected the immune cell counts and disease duration suggesting perhaps that 
these variables may be playing an important role in determining response. Referring back to the study 
by Sargento-Freitas et al. (2013), we note that the number of relapses was more consistently selected 
by the LR approach than by the BT approach. Interestingly, Sargento-Freitas et al. (2013) also used 
logistic regression (with stepwise forward selection) to build their prediction model. 
Of the two methodologies we evaluated, we recommend always considering the BT approach 
due to its significant advantage of missing data treatment even if in this instance it did not bring much 
benefit over the classical logistic regression. We note, however, that BT consistently selected the 
variables with the highest missing rates as predictors. In fact, one of the flaws of BT in its way of 
treating missing data is that a potential split variable with only two observations (extreme scenario of 
missing data) would be assigned an impurity measure of zero guarantying its selection as a split 
variable. The authors of the package acknowledge this bias of the method towards selection of 
variables with missing data and mention that it is unclear how it carries through to less extreme cases 
of missing data. (Section 5.1 in Therneau and Atkinson (2012)) 
BT is more heavily parameterized than LR. Although we did not do it in this study, it is 
desirable to evaluate the impact on the results using several different parameterizations of BT. For 
instance, we could have evaluated whether increasing the depth of the tree from our arbitrarily set 
choice of 3 would have improved or worsened classification performance. Deeper trees may be 
expected to lead to improved performance but, of course, the deeper the tree, the larger the risk for 
over-fitting. Finally, we note that the BT approach can be easily applied to continuous and survival 
outcomes. 
The clinical, biological and radiological information for this cohort is being continuously 
revised and updated and missing information, where possible, filled in. A much more ambitious study 
incorporating also genomic data for each patient is planned in the near future (see Section 5.2). 
 
Part of this work was presented as a poster at the UEPHA*MS Final Network Conference 
“Multiple Sclerosis and the Omics Spring” in April 2012. 
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4.3.2 Single-Marker and Multi-Marker Models for Polygenic Score Analyses 
4.3.2.1 Background 
We are interested in building a genetic (based on SNPs) predictor of a trait. To achieve this we follow 
a typical two-step procedure. In the first step, the SNP effects are estimated and the SNPs that are 
associated with the trait are identified in a training set. In the second step, a model based on the SNPs 
identified in the first step is built and the model’s predictive performance is evaluated in an 
independent testing set. In both steps, it is necessary to make important decisions on the choice of 
modeling approach that might have important implications on the performance of the prediction 
model. 
Specifically, we discussed in the last chapter a recent trend to move away from the simplistic 
GWAS approach to estimating SNP effects individually to more complex whole-genome regression 
methods that allow the estimation of SNP effects simultaneously. Earlier in this chapter, we also 
discussed the fact that the accuracy of the SNP effect estimates has important implications on the 
prediction accuracy of the model (Section 4.2.1). Thus, any methodology that reduces the SNP effect 
estimation error in the first step of the procedure is likely to lead to improved predictive performance. 
In the second step, the issue is how to combine the different SNP effects. It has been argued 
that whole-genome prediction methods are expected to achieve better prediction accuracy than 
methods which impose significance thresholds (such as, polygenic scores) and as such fail to capture 
all the genetic variability. (Daetwyler et al., 2008) 
4.3.2.2 Material and Methods 
As an extension to our study described in the previous chapter (see Section 3.6.4), we evaluated the    
(Equation (4.2)) and the     (Equation (4.9)) in the simulated diastolic blood pressure (DBP) and Q1 
traits from the GAW18 dataset averaged over replicates 2 through 200.We recall that we constructed 
PS based on sets of varying number of top SNPs (10, 50, 100, 1 000, 5 000 and 10 000) with effect 
estimates derived by a single-marker (SM) approach and a multi-marker (BLUP) approach and 
evaluated the association of the PS with the respective trait of interest (DBP or Q1). 
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We also computed the average    and     values using top SNPs from the MAP4 gene 
alone. We recall that this gene contributed the most to DBP variation (6.5%). For SM, we used the two 
SNPs for which we adjusted the DBP trait for the effects of MAP4 (SNPs 3_48040283 and 
3_48064367 – SNP name refers to <chromosome>_<position>). For BLUP, we refitted the model but 
this time on chromosome 3 only (where the MAP4 gene is located) and identified the top two SNPs 
which happened to be from that gene (SNPs 3_48024629 and 3_48096735). 
Finally, for the BLUP approach only, we computed the average    and     values using the 
expected breeding value (EBV) (see Section 4.2.2) which is essentially a PS computed with all 8.3 
million SNPs (no selection of SNPs). 
4.3.2.3 Results 
Trait: DBP. Figure 4.14 (A) and (B) show, respectively, the estimated    and     for the DBP trait 
averaged over replicates 2 through 200 for each of the six different SNP set sizes that we evaluated. 
 
 
Figure 4.14: The mean explained variation,    (A), and MSE (B) averaged over replicates 2 through 
200 of the PS constructed using sets of top SNPs derived by the single-marker and the BLUP 
approaches for the DBP trait. Error bars indicate the standard deviations of the    and the     values 
in each set. 
We observed higher    under SM than BLUP for smaller SNP set sizes (     ) while the 
reverse was true for larger SNP sets (       ). The two approaches did not seem to differ on the 
    measure. Both approaches gave almost identical results for        , where          and 
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For the analyses including only the top two SNPs from the MAP4 gene, we obtained mean    
of 0.0586 (± 0.013 standard deviations) and of 0.0178 (± 0.007 standard deviations) for the SM and 
BLUP approaches, respectively. Similarly, the     was 99 (± 4.8 standard deviations) and 103 (± 4.9 
standard deviations) for the SM and BLUP approaches, respectively. These results are summarized in 
Table 4.8 below. 
 
DBP 
  (± standard deviations)     (± standard deviations) 
Single-Marker BLUP Single-Marker BLUP 
Top two SNPs from MAP4 gene 0.0586 (± 0.013) 0.0178 (± 0.007) 99 (± 4.8) 103 (± 4.9) 
EBV (full genome - > 8.3 million 
SNPs) 
N/A 0.0405 (± 0.009) N/A 92 (± 4.7) 
Table 4.8: Summary of mean    and    values for DBP under the single-marker and BLUP 
approaches when taking only top two independent SNPs from the MAP4 gene, and under BLUP when 
taking all SNPs. N/A: Not Applicable. 
 
On the other extreme, Table 4.8 also gives the average    and    values under BLUP when 
the EBV ( > 8.3 million SNPs) was used as a predictor. For DBP, the mean    was 0.0405 (± 0.009 
standard deviations) and the     was 92 (± 4.7 standard deviations). 
 
Trait: Q1. For the trait Q1, within each approach there was little difference across the various SNP set 
sizes in the mean    and the    . On average, the mean    was 0.001238 (± 0.002 standard 
deviations) and 0.001364 (± 0.002 standard deviations) for the SM and BLUP approaches, 
respectively. We evaluated the MSE at 114 (± 5.6 standard deviations) under both approaches. 
We recall that Q1 was highly heritable but was uninfluenced by any of the genotyped SNPs. 
Therefore, we obtained    values consistent with the expected bias in    (see Section 4.2.3). 
Specifically, the PS association analyses were conducted on roughly 900 individuals (857 precisely) 
for whom both phenotypic and genotypic data were available. The linear regression model included 
the intercept and the PS obtained either by SM or BLUP and thus there were     parameters. 
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Following Equation (4.6), the expected bias, therefore, was 
(   )
   
⁄          . Also, not 
surprisingly, the MSE values for Q1 were higher than those for DBP at 114 (± 5.6 standard deviations) 
under both approaches. 
4.3.2.4 Discussion and Conclusions 
For smaller SNP sets, (     ), higher    values were obtained under SM than under BLUP. The 
reverse was true for larger SNP sets (       ). Based on the     metric, there was no difference 
between SM and BLUP. When no SNPs were associated with the trait (Q1), the    and the     
values were similar between the two approaches and across the different SNP set sizes. Further, the 
observed    was close to its expected value and the     was higher than the     obtained for the 
DBP trait. 
Based on the    metric, for larger SNP set sizes, the BLUP approach would therefore be 
preferable. However, under this approach, it does not seem necessary to carry out SNP selection 
apriori. When the full genome was included in the PS (that is, the EBV was computed), the obtained 
   (and    ) was essentially identical to that for         and         . In other words, under 
BLUP, including all SNPs (and thus correlated) versus only independent SNPs did not impact the 
results. This is not surprising due to the way BLUP estimates the SNP effects. In fact, in BLUP, the 
effects are spread over all SNPs which results in very small effects for a single SNP. (Meuwissen, 
2009) 
On the other hand, when only the two independent SNPs with strong effects from the MAP4 
gene were included, the    was much higher than that of any of the SNP set sizes under SM and was 
also higher for the smaller SNP sets under BLUP (     and   ). In other words, under SM, 
including few SNPs with strong effects appears to predict at least as well or better than including 
thousands of small to moderate effect sizes. This comes at a price, however, because the     was 
much higher but more so under BLUP than under SM. 
In conclusion, we come back once again to the underlying genetic architecture of the trait. Our 
results seem to suggest that if few SNPs exert a strong effect and a large number exert small or 
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moderate effects on the trait, there is little benefit in terms of predictive performance in including the 
SNPs with small or moderate effect sizes in the PS using SM-derived estimates as weights. On the 
other hand, if the SNP sets sizes are allowed to include many SNPs, the BLUP-derived estimates are 
better suited as weights, and for that matter, also without the necessity to apply any apriori SNP 
selection criterion. 
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5 CONCLUSION 
 
While the hype of genetic association studies is slowly winding down, that of prediction studies is just 
starting to pick up. What have we learned about MS in this era of genetic discoveries and of what 
utility have these findings been in the understanding and treatment of this debilitating disease? 
5.1 What have we learned? 
When trying to answer this question, it is necessary to distinguish between the susceptibility of the 
disease and response to its treatment as our knowledge and understanding of these two areas have not 
evolved in a similar fashion. It is of interest to note that genetic association studies for alternative 
phenotypes related to MS have also been conducted such as a GWAS of disease severity 
(International Multiple Sclerosis Genetics Consortium, 2011) and a GWAS of brain lesion distribution 
(Gourraud et al., 2013). 
5.1.1 Susceptibility to Multiple Sclerosis 
While genetic variation appears to be an important determinant of susceptibility to MS, as we 
discussed in the introduction, estimates of its heritability vary widely between 25% and 76%. (Hawkes 
and Macgregor, 2009) Despite that many genetic variants have been associated with susceptibility to 
MS through GWASs, as with other complex diseases, a large portion of its heritability still remains 
unexplained. Alternative methods to GWAS have been explored with the aim of explaining this 
missing heritability. 
The successful application of polygenic score analyses in explaining the missing heritability in 
susceptibility to schizophrenia (Purcell et al., 2009) motivated a similar study in susceptibility to MS 
(Bush et al., 2010). The investigators found that, through polygenic score analyses, which relax 
significantly the SNP inclusion significance threshold from the typically imposed genome-wide 
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significance thresholds, they were able to explain approximately 3% of the variance in MS risk in 
another independent MS GWAS dataset. Another study using a multi-step logistic regression approach 
provided consistent evidence supporting a polygenic model of inheritance for MS risk (Wang et al., 
2011). 
To date, several studies to predict susceptibility to MS by incorporating a handful of known 
genetic risk variants have been carried out. For instance, De Jager et al. (2009) constructed a 
polygenic score based on 16 known MS susceptibility genes and evaluated the AUC for various 
models including the score with and without taking into consideration additional environmental 
factors. The obtained AUC for the purely genetic model was 0.70 and improved to 0.74 when gender 
was added (1340 cases / 1109 controls). In a second validation cohort (143 cases / 281 controls), the 
investigators obtained an AUC of 0.64 which improved to 0.68 after adding information on smoking 
and exposure to Epstein-Barr virus. The higher achieved AUC in the first validation cohort could be 
due to the much larger sample size. Nevertheless, in both validation cohorts, the models incorporating 
environmental factors improved the prediction accuracy. 
Jafari et al. (2011) also used a polygenic score approach including a varying number of 
identified SNPs by GWASs without considering any environmental factors. The AUC increased as 
more SNPs were included ranging from 0.64 (six SNPs) to 0.69 (53 SNPs). The investigators also 
conducted a simulation study illustrating that many more common variants (at least 50) with weak 
effect sizes would be needed to achieve AUC of 0.85. This led the authors to conclude that even if new 
MS susceptibility variants are continuously being identified they will have limited utility in the clinical 
setting. 
5.1.2 Response to Multiple Sclerosis Therapies 
In the introductory chapter of this thesis (see Section 1.9), we reviewed the current state of the art for 
genetic association studies of response in MS. First and foremost, in contrast to MS susceptibility 
studies, mostly candidate gene studies have been conducted for treatment response in MS. Second, 
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sample sizes were orders of magnitude smaller. For instance, the two GWASs on interferon response 
were carried out in 200-300 patients (discovery and replication combined). Third, the treatment 
response definition is extremely complex and is subjectively chosen by the investigator as no 
standardized response definition exists. 
Fourth, a total of eight drugs have been approved for MS treatment based on five different 
acting mechanisms the most widely studied being interferon-β. Despite the many studies conducted, 
however, the genetic basis for interferon response is yet to be fully determined. Our study on 
interferon response (Section 3.6.1) and a polymorphism in the OAS1 gene awaits finalization but, 
based on the results we obtained so far, if an association is detected, it is unlikely that it will be a 
strong one and will need replication in an independent dataset. To our knowledge, no genetic 
association studies have been carried out for natalizumab or fingolimod. The candidate gene 
association study we conducted (Section 3.6.2) did not show any evidence that ITGA4 polymorphisms 
were associated with natalizumab response. 
Fifth, the environmental factors influencing MS susceptibility have been widely studied. In the 
case of response to therapy in MS, not only the genetic associations are weak but also no non-genetic 
factors are known to date to be influencing response. Some studies have suggested that response in 
interferon is gender-specific but this remains to be fully investigated. Apart from a recent study that 
found the number of relapses to be a good predictor of natalizumab response (Sargento-Freitas et al., 
2013), little is known on the influence of non-genetic variables on response. The results from our 
prediction study of natalizumab response based on non-genetic factors also did not lead to any definite 
conclusions (Section 4.3.1). 
Finally, all studies on treatment response discussed so far were association studies. To our 
knowledge, no genetic prediction study has been reported. 
In summary, the need for personalized treatment in MS is widely acknowledged. (Sormani 
and De Stefano, 2013) Nevertheless, many challenges need to be overcome before we consider this 
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approach plausible in the context of MS and further studies in this area are clearly needed to achieve 
that. Such is the goal of a study designed as part of this dissertation work and which we discuss next.  
5.2 Future Directions 
The BIONAT cohort consists of roughly 1200 French MS patients with clinical, biological and 
radiological information. (Outteryck et al., 2013) The data management for this cohort requires a 
substantial effort to which I have also contributed. 
A GWAS of natalizumab response is planned on this cohort. The GWAS data are being 
generated at the time of writing this manuscript. (The GWAS was scheduled for earlier throughout my 
thesis but there were unexpected delays in generating the genotype data). 
Using this vast dataset, the main objective is to investigate the relationship between the 
different variables and response to natalizumab and to build a model predicting response by combining 
genetic with clinical, biological and radiological variables. 
The model may include the top genetic variants identified through the GWAS (restricted to 
low dimensional setting) or include the whole genome (high-dimensional setting) similarly to the 
study by Vazquez et al. (2012) discussed in the previous chapter (see Section 4.2.2). Contrary to the 
model in the low-dimensional setting, with this approach it is not necessary to identify top SNPs 
apriori. On the other hand, however, the study by Vazquez et al. (2012) was conducted on more than 
5100 subjects genotyped at 41 000 SNPs across the genome. From the BIONAT cohort, there may be 
at best 1200 subjects (not all patients may have sufficiently complete information to be included in the 
model) with at least half a million SNPs each. Thus, with these resources, the high-dimensional 
approach also has serious limitations. 
It is unlikely that the derived prediction model would achieve the desirable properties to be 
directly useful in a clinical setting. In the best case scenario, any leading findings would have to await 
replication in a completely independent dataset and perhaps in subjects of different origin (non-
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French). Such datasets are rare, expensive and take years to compile. Nevertheless, as Kitsios and Kent 
(2012) argue, “we still lack even a basic framework that permits the multiple patient attributes that 
influence the effect of treatment (be they clinical, genetic, biological, or environmental) to be 
meaningfully integrated to support personalized decision making”. Therefore, this work could make 
an important contribution in constructing such a framework to develop integrated tools for 
personalized medicine in MS. 
Finally, it is important to recognize that it is not only study limitations that influence the 
successful transition of scientific findings into medical practice. Many other factors are at play and, 
although not exhaustively, we try to address them as well. 
5.3 Other Considerations of Pharmacogenomic Studies 
So far we have been focused on methodological aspects of pharmacogenomic studies. We devote the 
remaining pages to important ethical, social, economic and legal considerations relevant to these 
studies. 
Personal genetic testing is on the rise. There are already several companies to choose from 
which offer direct-to-consumer (DTC) genetic testing such as 23andme®, Navigenics®, Knome® and 
deCodeme® to name a few. Anyone who wishes to know their genetic risk of MS (and of numerous 
other traits or diseases) can simply mail in a sample of their saliva and, shortly after, will receive a 
report of their estimated risks. This report is based on the sort of risk-SNP association findings that we 
discussed in the third chapter of this thesis and that have been extensively compiled from the scientific 
literature by these companies. While recognizing that genetic testing can be a “valuable tool to aid in 
diagnostic and therapeutic decisions”, the American Medical Association (AMA) warned against 
DTC genetic testing arguing that “patients may spend money on direct-to-consumer genetic tests 
needlessly or misinterpret the results of the tests, causing them to make unnecessary or unhealthy 
lifestyle changes.” (Todd and Craine, 2011) 
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The truth is that, as Elton (2009) put it, “personal genomics is a wildly unregulated and 
woefully immature field.” It took US legislature 13 years to approve the Genetic Information 
Nondiscrimination Act (GINA) in 2008. While previous protections existed before GINA, this was the 
first piece of law at the nationwide level to protect against genetic discrimination in health insurance 
and employment. GINA is far from perfect, however, as it does not address for instance other 
insurance policies such as life or disability insurance. It is clear that the substantial investment in 
genetic science that we have seen to date needs to be matched by innovation in regulation. (Hudson et 
al., 2008) The regulatory framework in Europe is as much, if not more, complex and challenging. 
(Borry et al., 2012) 
In fact, such regulations would only foster collaboration from the public. Individuals might be 
more willing to participate in medical research that involves genetic testing and participate in projects 
such as the Personal Genome Project (PersonalGenomes.org, 2013) as they would no longer fear 
genetic discrimination. 
Of course, protecting the information once it has been made available is one issue. The debate 
continues on whether genetic testing should be carried out only under the supervision of a medical 
professional trained to interpret genetic test results. France, for instance, does not allow the provision 
of DTC genetic tests, while Belgium does. (Borry et al., 2012) Moreover, how much of the genetic test 
results should be disclosed to the individual? If the test was carried out for one purpose in mind but 
substantial risk was noted for another condition, a so called “incidental finding”, should the individual 
be made aware of it especially if no measures can be taken to prevent it? 
The overall attitude towards genetic testing to optimize therapy decisions is somehow different 
from that to evaluate disease risk. An increasing number of FDA-approved drugs recommend genetic 
testing in their labels while, to date, genetic tests are required for three drugs (Cohen et al., 2013). The 
observed benefits so far of pharmacogenomics studies in patient stratification (for example, breast 
cancer and trastuzumab), in predicting adverse events (for example, HIV/AIDS and abacavir) and in 
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determining optimal dose (for example, blood clotting and warfarin) have perhaps contributed to this 
more positive outlook. However, we must be cautiously optimistic. 
Translating scientific findings into the clinical practice is a slow process. Kitsios and Kent 
(2012) described the process as comprising of the following three clinical translation phases: (1) basic 
biomedical research; (2) clinical research; and (3) clinical application. While warfarin, the most 
popular success case of pharmacogenomic studies, has passed phases (1) and (2), it has had very 
limited impact in phase (3). Despite recommended genetic testing by the FDA, Centers for Medicare 
and Medicaid Services (CMS) has refused to routinely pay for these tests arguing that “the available 
evidence does not demonstrate that pharmacogenomic testing of CYP2C9 or VKORC1 alleles to 
predict warfarin responsiveness improves health outcomes in Medicare beneficiaries.” (Centers for 
Medicare and Medicaid Services, 2013) That is, despite mounting scientific evidence of the benefit of 
incorporating genetic information into warfarin dose prediction, for the purposes of health insurance 
policies this evidence may still fail to be sufficiently convincing. 
Drug therapy remains suboptimal for a significant proportion of individuals (Wolpe, 2009). 
One of the promises of pharamacogenomics is that it will reduce health care costs by optimizing 
treatment options. Many are skeptical. It is true that the cost of genetic testing is quickly reaching 
affordable levels. However, the drug development process was complex, long and expensive even 
prior to the genomics era. Thus, it is not clear that incorporating genetic information into this process 
would make it more efficient. In fact, drugs with pharmacogenomics tests may be even more 
expensive targeting smaller populations and their cost-effectiveness would be far from certain. 
In fact, personalized medicine reflects a fundamental shift in the conceptual basis of drug 
development moving away from blockbuster drugs to targeted therapies. (Olivier et al., 2008) One 
serious repercussion of this is that drug companies would be driven by “profitable genotypes” focusing 
research and development of drugs for the most prevalent genotypes. (Wolpe, 2009) Entire sections of 
a population and/or ethnic and racial groups may be left out in this process. 
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In conclusion, as we continue to improve our understanding of the genetic information we 
carry and develop the necessary technologies and methodologies to analyze it appropriately, we 
believe that it is only a matter of time before the clinical utility of genetic testing in improving the 
effectiveness and efficiency of preventive interventions for many conditions is attained. Nevertheless, 
as has been already suggested, measuring only the clinical utility of genetic testing is somewhat a 
restrictive concept of the overall benefit that it may lead to. (Grosse and Khoury, 2006) Economical, 
ethical, social and legal issues, of which we have only scratched the surface here, need to be 
considered in evaluating the net balance between benefit and harm of genetic testing, whether 
treatment optimization or risk prediction is the goal. 
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I. APPENDIX I: Gene Names for Genes Cited Throughout the Thesis 
GENE SYMBOL GENE NAME 
ABC ATP-binding cassette 
ADAR adenosine deaminase, RNA-specific 
BST1 bone marrow stromal cell antigen 1 
CAST calpastatin 
CD86 T-lymphocyte activation antigen CD86 
CFTR cystic fibrosis transmembrane conductance regulator 
CIT citron (rho-interacting, serine/threonine kinase 21) 
COL25A1 collagen, type XXV, alpha 1 
CTSS cathepsin S 
CYP2C9 cytochrome P450, family 2, subfamily C, polypeptide 9 
FAS Fas (TNF receptor superfamily member 6) 
GPC5 glypican 5 
GRIA3 glutamate receptor, ionotropic, AMPA 3 
HAPLN1 hyaluronan and proteoglycan link protein 1 
HLA Class II major histocompatibility complex, class II 
HTT huntingtin 
IFNAR1 interferon (alpha and beta) receptor 1 
IFNAR1 interferon (alpha and beta) receptor 1 
IFNAR2 interferon (alpha, beta and omega) receptor 2 
IFNG interferon gamma 
IL12RB2 interleukin 12 receptor, beta 2 
IL1R1 interleukin 1 receptor, type I 
IL28B interleukin 28B (interferon, lambda 3) 
IL2RA interleukin 2 receptor, alpha 
IL7RA interleukin 7 receptor 
ITGA4 integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 
LMP7 large multifunctional protease 7 
LRRK2 leucine-rich repeat kinase 2 
MAP4 microtubule-associated protein 4 
MAPT microtubule-associated protein tau 
MBP myelin basic protein 
MxA myxovirus (influenza) resistance A 
NPAS3 neuronal PAS domain protein 3 
OAS1 2'-5'-oligoadenylate synthetase 1 
SNCA synuclein, alpha (non A4 component of amyloid precursor) 
STARD13 StAR-related lipid transfer (START) domain containing 13 
TRAIL tumor necrosis factor (TNF) related apoptosis inducing ligand 
TRAILR-1 TRAIL receptor 1 
TRAILR-2 TRAIL receptor 2 
TRAILR-3 TRAIL receptor 3 
TRAILR-4 TRAIL receptor 4 
VKORC1 vitamin K epoxide reductase complex, subunit 1 
ZFAT zinc finger and AT hook domain containing 
ZFHX4 zinc finger homeobox 4 
ZZEF1 zinc finger, ZZ-type with EF-hand domain 1 
Table I.1: Gene symbols and corresponding names. (Source: http://www.ncbi.nlm.nih.gov/gene/) 
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II. APPENDIX II: Clinical Characteristics of the Cohorts Included in the 
OAS1 Study 
France 
 
Table II.1: Clinical characteristics of the French cohort in the OAS1 study. 
  
P-value
1
Responders Non-Responders
164 (49%) 168 (51%)
Gender 0.26
NA - -
Female n (%) 127 (51%) 120 (49%)
Male n (%) 37 (44%) 48 (56%)
Age (years)
At disease onset 0.009
NA 1 1
mean (sd) 30.24 (8.65) 27.87 (8.59)
median (range) 30.00 (13.00, 52.00) 27.00 (12.00, 51.00)
At treatment onset 0.01046
NA 8 8
mean (sd) 35.51 (9.31) 32.72 (9.16)
median (range) 36.00 (15.00, 58.00) 33.00 (15.00, 55.00)
Disease Severity
EDSS at treatment onset 0.27
NA - -
mean (sd) 2.07 (1.24) 2.17 (1.33)
median (range) 2.00 (0.00, 6.00) 2.00 (0.00, 5.00)
Relapses 2-year prior treatment onset 0.05885
NA 1 2
mean (sd) 2.29 (1.01) 2.52 (1.20)
median (range) 2.00 (0.00, 5.00) 2.00 (7.00)
Type of Interferon- β 0.71
NA 1 -
Avonex n (%) 84 (50%) 85 (50%)
Betaferon n (%) 45 (52%) 42 (48%)
Rebif n (%) 34 (45%) 41 (55%)
France
1
 Chi-square test used for categorical variables (Gender, Type of Interferon-β) and Mann-Whitney test used for the 
remaining variables.
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Germany 
 
Table II.2: Clinical characteristics of the German cohort in the OAS1 study. 
  
P-value1
Responders Non-Responders
123 (60%) 83 (40%)
Gender 0.0614
NA - -
Female n (%) 87 (56%) 69 (44%)
Male n (%) 36 (72%) 14 (28%)
Age (years)
At disease onset 0.19
NA 93 73
mean (sd) 28.6 (8.74) 24.80 (6.46)
median (range) 28.00 (13.00, 51.00) 23.50 (16.00, 37.00)
At treatment onset 0.57
NA - -
mean (sd) 36.15 (9.09) 35.27 (10.58)
median (range) 36.00 (19.00, 57.00) 36.00 (16.00, 63.00)
Disease Severity
EDSS at treatment onset 0.001
NA - -
mean (sd) 1.71 (1.21) 2.16 (1.22)
median (range) 1.50 (0.00, 6.00) 2.00 (0.00, 6.00)
Relapses 2-year prior treatment onset 0.62
NA 94 74
mean (sd) 1.64 (0.94) 1.78 (0.83)
median (range) 1.50 (0.00, 5.00) 2.00 (1.00, 3.00)
Type of Interferon- β 0.74
NA 1 -
Avonex n (%) 20 (57%) 15 (43%)
Betaferon n (%) 73 (58%) 52 (42%)
Rebif n (%) 29 (64%) 16 (36%)
Germany
1 Chi-square test used for categorical variables (Gender, Type of Interferon-β) and Mann-Whitney test used for the 
remaining variables.
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Italy 
 
Table II.3: Clinical characteristics of the Italian cohort in the OAS1 study. 
  
P-value
1
Responders Non-Responders
252 (79%) 68 (21%)
Gender 0.06077
NA
Female n (%) 168 (86%) 54 (14%)
Male n (%) 84 (76%) 14 (24%)
Age (years)
At disease onset 8.53E-04
NA - -
mean (sd) 29.78 (9.09) 25.63 (7.59)
median (range) 28.70 (13.80, 60.00) 23.80 (10.90, 45.30)
At treatment onset 0.001972
NA - -
mean (sd) 34.53 (9.31) 30.58 (8.51)
median (range) 34.05 (15.60, 63.80) 29.25 (17.10, 59.30)
Disease Severity
EDSS at treatment onset 0.96
NA - -
mean (sd) 1.66 (0.66) 1.70 (0.78)
median (range) 1.50 (0.00, 4.50) 1.50 (0.00, 4.00)
Relapses 2-year prior treatment onset 0.01166
NA - -
mean (sd) 1.80 (0.95) 2.24 (1.24)
median (range) 2.00 (0.00, 5.00) 2.00 (0.00, 7.00)
Type of Interferon- β 0.67
NA - -
Avonex n (%) 81 (82%) 18 (18%)
Betaferon n (%) 13 (76%) 4 (24%)
Rebif n (%) 158 (77%) 46 (23%)
Italy
1
 Chi-square test used for categorical variables (Gender, Type of Interferon-β) and Mann-Whitney test used for the 
remaining variables.
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Spain 
 
Table II.4: Clinical characteristics of the Spanish cohort in the OAS1 study. 
  
P-value1
Responders Non-Responders
144 (56%) 113 (44%)
Gender 0.92
NA
Female n (%) 95 (56%) 73 (44%)
Male n (%) 49 (55%) 40 (45%)
Age (years)
At disease onset 0.82
NA 7 -
mean (sd) 26.26 (7.51) 26.16 (7.14)
median (range) 26.00 (10.00, 47.00) 24.00 (13.00,  45.00)
At treatment onset 0.62
NA - -
mean (sd) 32.01 (8.10) 31.50 (8.47)
median (range) 31.00 (15.00, 55.00) 31.00 (16.00, 51.00)
Disease Severity
EDSS at treatment onset 6.36E-04
NA - -
mean (sd) 1.97 (1.07) 2.34 (1.02)
median (range) 2.00 (0.00, 5.50) 2.00 (0.00, 5.50)
Relapses 2-year prior treatment onset 0.17
NA - -
mean (sd) 2.54 (1.04) 2.88 (1.71)
median (range) 2.00 (0.00, 5.00) 3.00 (0.00, 15.00)
Type of Interferon- β 0.74
NA - -
Avonex n (%) 39 (53%) 35 (47%)
Betaferon n (%) 70 (58%) 50 (42%)
Rebif n (%) 35 (56%) 28 (44%)
Spain
1 Chi-square test used for categorical variables (Gender, Type of Interferon-β) and Mann-Whitney test used 
for the remaining variables.
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All Patients (France/Non-France) 
 
Table II.5: Clinical characteristics of the France/Non-France cohorts in the OAS1 study. 
  
P-value
1
France Non-France
332 (30%) 783 (70%)
Gender 0.1337
NA - -
Female n (%) 247 (31%) 546 (69%)
Male n (%) 85 (26%) 237 (74%)
Age (years)
At disease onset 0.0163
NA 2 173
mean (sd) 29.04 (8.37) 27.72 (8.69)
median (range) 29.00 (12.00, 52.00) 26.65 (10.00, 60.00)
At treatment onset 0.3152
NA 16 -
mean (sd) 34.10 (9.32) 33.62 (9.19)
median (range) 34.00 (15.00, 58.00) 33.00 (15.00, 63.80)
Disease Severity
EDSS at treatment onset 5.36E-04
NA - -
mean (sd) 2.12 (1.00) 1.88 (1.29)
median (range) 2.00 (0.00, 6.00) 1.50 (0.00, 6.00)
Relapses 2-year prior treatment onset 2.68E-03
NA 3 168
mean (sd) 2.41 (1.11) 2.21 (1.25)
median (range) 2.00 (0.00, 7.00) 2 (0.00, 15.00)
Type of Interferon- β 8.42E-15
NA 1 1
Avonex n (%) 169 (45%) 208 (55%)
Betaferon n (%) 87 (25%) 262 (75%)
Rebif n (%) 75 (19%) 312 (81%)
All Patients
1 Chi-square test used for categorical variables (Gender, Type of Interferon-β) and Mann-Whitney test used 
for the remaining variables.
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III. APPENDIX III: Baseline Characteristics of the Patients Included in the 
Prediction Study on Natalizumab Response (Section 4.3.1) 
Clinical Characteristics 
 
Table III.1: Clinical characteristics of a subset of patients from the BIONAT cohort (database version 
November 2013) included in the prediction study on natalizumab response (Section 4.3.1.2). 
  
All Patients Responders Non-Responders
531 331 (62%) 200 (38%)
Gender 0.73
NA - - -
female n (%) 396 249 (63%) 147 (37%)
male n (%) 135 82 (61%) 53 (39%)
EDSS at treatment onset 0.78
NA - - -
mean (sd) 3.36 (1.66) 3.37 (1.64) 3.33 (1.68)
median (range) 3.50 (0.00, 7.50) 3.00 (0.00, 7.50) 3.50 (0.00, 7.00)
Relapses 1-year prior treatment onset 0.15
NA - - -
mean (sd) 2.10 (1.11) 2.04 (1.06) 2.19 (1.17)
median (range) 2.00 (0.00, 8.00) 2.00 (0.00, 6.00) 2.00 (0.00, 8.00)
Disease duration (years) 0.27
NA - - -
mean (sd) 8.94 (7.00) 9.08 (6.84) 8.71 (7.26)
median (range) 8.00 (0.00, 42.00) 8.00 (0.00, 41.00) 7.00 (0.00, 42.00)
Previous immuno-suppressant use 0.95
NA - - -
yes n (%) 111 70 (63%) 41 (37%)
no n (%) 420 261 (62%) 159 (38%)
Previous immuno-modulatory use 0.86
NA - - -
yes n (%) 475 295 (62%) 180 (38%)
no n (%) 56 36 (64%) 20 (36%)
1 Chi-square test used for categorical variables, Mann-Whitney test used for numeric variables. NA: Not available.
CLINICAL CHARACTERISTICS P-value
1
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Biological Characteristics 
 
Table III.2: Biological characteristics of a subset of patients from the BIONAT cohort (database 
version November 2013) included in the prediction study on natalizumab response (Section 4.3.1.2). 
  
All Patients Responders Non-Responders
531 331 (62%) 200 (38%)
IgG at treatment onset 0.039
NA 64 39 25
mean (sd) 9.94 (2.54) 10.07 (2.51) 9.72 (2.58)
median (range) 9.80 (0.90, 19.70) 10.00 (0.90, 17.20) 9.35 (3.00, 19.70)
IgA at treatment onset 0.10
NA 64 39 25
mean (sd) 2.00 (0.80) 2.04 (0.81) 1.94 (0.77)
median (range) 1.92 (0.20, 5.52) 1.98 (0.20, 5.52) 1.84 (0.31, 5.04)
IgM at treatment onset 0.53
NA 66 40 26
mean (sd) 1.38 (1.10) 1.39 (1.16) 1.37 (0.98)
median (range) 1.19 (0.21, 18.00) 1.21 (0.21, 18.00) 1.17 (0.24, 10.94)
Lymphocytes at treatment onset 0.28
NA 59 41 18
mean (sd) 2.38 (3.15) 2.42 (3.50) 2.30 (2.52)
median (range) 1.80 (0.19, 33.80) 1.80 (0.59, 33.80) 1.85 (0.19, 27.20)
CD3 count at treatment onset 0.12
NA 255 149 106
mean (sd) 1402 (530.91) 1364 (529.78) 1475 (528.29)
median (range) 1326 (372, 4970) 1298 (372, 4970) 1373 (594, 2919)
CD4 count at treatment onset 0.09
NA 51 35 16
mean (sd) 965 (418.06) 947.40 (436.08) 993.20 (386.75)
median (range) 897 (237, 4596) 862 (237, 4596) 938 (252, 2250)
CD8 count at treatment onset 0.04291
NA 53 36 17
mean (sd) 441.30 (211.97) 432.60 (223.56) 455.40 (191.55)
median (range) 395 (43, 1850) 379 (106, 1850) 408 (43, 1162)
CD19 count at treatment onset 0.73
NA 124 83 41
mean (sd) 298.20 (264.00) 284.60 (148.13) 319.60 (379.93)
median (range) 249.50 (33.00, 4442.00) 252 (44, 990) 240 (33, 4442)
JC virus at treatment onset 0.27
NA 70 35 35
detected n (%) 268 166 (62%) 102 (38%)
not detected n (%) 193 130 (67%) 63 (33%)
1 Chi-square test used for categorical variables, Mann-Whitney test used for numeric variables. NA: Not available.
BIOLOGICAL CHARACTERISTICS P-value1
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Radiological Characteristics 
 
Table III.3: Radiological characteristics of a subset of patients from the BIONAT cohort (database 
version November 2013) included in the prediction study on natalizumab response (Section 4.3.1.2). 
  
All Patients Responders Non-Responders
531 331 (62%) 200 (38%)
GD+ enhancing lesions at treatment onset 0.02323
NA - - -
yes n (%) 308 205 (67%) 103 (33%)
no n (%) 223 126 (56%) 97 (44%)
T2 superior to 9 at treatment onset 0.54
NA 3 3 -
yes n (%) 482 297 (62%) 185 (38%)
no n (%) 46 31 (67%) 15 (33%)
T2 confluent lesions at treatment onset 0.29
NA - - -
yes n (%) 36 19 (53%) 17 (47%)
no n (%) 495 312 (63%) 183 (37%)
Black holes at treatment onset 0.91
NA 181 109 72
yes n (%) 112 71 (63%) 41 (37%)
no n (%) 238 151 (63%) 87 (37%)
1 Chi-square test used for categorical variables. NA: Not available.
RADIOLOGICAL CHARACTERISTICS P-value1
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